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By Syed Golam Mohiuddin 
 
This thesis describes the role of mathematical modelling in the evaluation of an 
innovative automated system of wearable and environmental sensors to monitor the 
activity patterns of patients with Bipolar Disorder (BD). BD is a chronic and 
recurrent mental disorder associated with severe episodes of mania and depression, 
interspersed with periods of remission. Early detection of transitions between the 
normal, manic and depressed stages is crucial for effective self-management and 
treatment. Personalised Ambient Monitoring (PAM) is an EPSRC-funded 
multidisciplinary project involving biomedical engineers, computer scientists and 
operational researchers. The broad aim of PAM is to build and test a network of 
sensors (chosen by the patient) to collect and analyse daily activity data in order to 
identify an ‘activity signature’ for that individual in various health states. The 
hypothesis is that small but potentially significant changes in this activity pattern can 
then be automatically detected and the patient alerted, enabling him/her to take 
appropriate action. 
 
  The research presented in this thesis involves the development and use of a Monte 
Carlo simulation model to evaluate the potential of PAM without the need for a costly 
and time-consuming clinical trial. A unique and novel disease state transition model 
for bipolar disorder is developed, using data from the clinical literature. This model is 
then used stochastically to test many different scenarios, for example the removal or 
technical failure of a sensor, or the limited availability of various types of data, for 
various simulated patient types and a wide range of assumptions and conditions.  The 
feasibility of obtaining sufficient information to derive clinically useful information 
from a limited set of sensors is analysed statistically. The minimum best set of 
sensors suitable to detect both aspects of the disorder is identified, and the 
performance of the PAM system evaluated for a range of personalised choices of 
sensors.  
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This chapter presents a general introduction to the thesis and describes the motivation 
for this study, the importance of the topic, the methodology used and the research 
contributions. The research described in this thesis concerns the role and contribution 
of Operational Research (OR) modelling in the Personalised Ambient Monitoring 
(PAM) project. 
 
1.1  The PAM project 
PAM is a multidisciplinary project involving the School of Management and the 
Institute for Sound and Vibration Research at the University of Southampton, the 
School of Electrical and Electronic Engineering at the University of Nottingham and 
the Department of Computing Science and Mathematics at the University of Stirling. 
The project was funded by the Engineering and Physical Sciences Research Council. 
The aims of this project were to develop a system of unobtrusive sensors that monitor 
the behaviour patterns of mental health patients, and hopefully detect changes in these 
behaviour patterns that may signal the early onset of an acute episode of illness. By 
then issuing an alert to the patient, such an episode could potentially be averted. The 
fundamental research questions underpinning the whole PAM project were: 
•  Is it possible to obtain, in an automatic, ambient and unobtrusive manner, 
‘activity signatures’ from mental health patients that provide information 
about the trajectory of their health status? 
•  If this is so, can this information be used to assist their healthcare? 
 
1.2 Mental  illness 
Worldwide, mental illness is a major social and economic problem. One in four of the 
UK population suffer from a mental health problem at some stage in their lifetime   -2-
(Singleton et al, 2001), while one in ten are likely to suffer for a disabling mental 
health problem at some point in their lives (James et al, 2008).  91 million working 
days are lost every year in the UK because of mental health problems (Gray, 1999). 
The cost of mental ill health to the UK in 2000 was estimated by the Mental Health 
Foundation as £32 billion, of which £12 billion is lost employment and productivity 
(BOHRF, 2005). Mentally ill people can find it difficult to form personal 
relationships, and thus often fail to progress at work and can experience breakdowns 
in personal relationships (Coryell et al, 1993; Calabrese et al, 2003). 
 
1.3 Bipolar  disorder 
Bipolar disorder (BD) was selected for our study. BD is a severe form of mental 
illness linked with two types of serious episode, mania and depression, both of which 
drastically affect quality of life (Vojta et al, 2001; Michalak et al, 2007). Although 
mania is the defining trait of BD, depression is the major source of severe distress for 
patients themselves, and patients usually spend much more time in the depressed state 
than in the manic one (Judd et al, 2002; 2003). The World Health Organization 
(WHO) estimated depression and depression-allied illnesses to be the greatest cause 
of ailing health by the year 2020 (WHO, 2001). The prevalence of BD is increasing, 
and the age of onset is decreasing (Dienes et al, 2006). The prognosis for this disorder 
remains bleak, with repeated severe episodes interspersed with mild but significant 
symptomatic periods (Solomon et al, 1995). 
Bipolar disorder can lead to significant psychological, functional, occupational 
and cognitive impairments, including higher rates of unemployment (Tse and Walsh, 
2001), lower productivity and annual income (Goetzel et al, 2003), higher work 
absenteeism (Simon, 2003; Goetzel et al, 2003), episodic antisocial behaviour (APA, 
2000), reduction in life expectancy (Goodwin and Jamison, 1990), suicidality (Judd 
and Akiskal, 2003), and changes in attention, planning and working memory (Ferrier 
and Thompson, 2002; Ågren and Backlund, 2007). Furthermore, despite the existence 
of pharmacological treatment, about 30-60% of BD patients fail to regain full social   -3-
and occupational functionality between episodes (Calabrese et al, 2003; MacQueen 
and Young, 2001).  
In 1990 the WHO ranked bipolar disorder as 22nd among all diseases in terms 
of worldwide burden of illness. The disorder was also ranked as the 6th leading 
disabling illness worldwide (WHO, 2001). BD is associated with high costs for social 
and health care. Higher dependence on public assistance (Judd and Akiskal, 2003) 
and increased healthcare use and costs (Judd and Akiskal, 2003; Simon, 2003) have 
been shown to be closely associated with this disorder. In 2002, the annual cost of 
managing bipolar disorder in the UK NHS was estimated to be £199 million, of 
which £70 million was spent on hospital admissions (Gupta and Guest, 2002). 
However, despite its severely disabling nature, BD can be managed effectively 
through self-monitoring (AstraZeneca, 2010). Many bipolar patients are reportedly 
keen to monitor their condition regularly in order to minimise the severity of their 
episodes. 
 
1.4  Relapses in bipolar disorder 
Bipolar disorder is a chronic and recurrent illness associated with great morbidity and 
mortality (Müller-Oerlinghausen et al, 2002). Sadly, the mortality rate in BD is two to 
three times higher in comparison with the general population (Müller-Oerlinghausen 
et al, 2002; Belmaker, 2004). The risk of relapse for a bipolar patient increases over 
time, and can differ from a few weeks to many months. The need to prevent bipolar 
relapses was shown in a prospective naturalistic study by Tohen et al (1990), where 
the risk of relapse was found to be 90% within five years. In the survival analysis by 
Gitlin et al (1995), the risk of relapse was shown as 73% within five years, and two-
thirds of those who relapsed suffered multiple relapses. 
Bipolar patients require lifetime maintenance therapy (Müller-Oerlinghausen, 
2002). It is easier to treat milder symptoms in the early stage of a relapse than more 
severe symptoms later in the relapse (Morriss et al, 2004). The importance of 
analysing the early warning signs (i.e. prodromes) of relapse is therefore clear: if BD   -4-
patients can identify prodromes early enough, actions can be taken to avert the 
progress of a full-blown episode. Equally, prodromes of relapse are useful indicators 
to patients themselves, family members or clinicians, given that extra support may be 
required to stop prodromes progressing into a full-blown episode. Each episode 
usually begins with a similar pattern of symptoms that is distinctive for each 
individual; as such, it is often possible to detect unexpected mood changes leading to 
an imminent episode. 
Common prodromes of mania include decreased need for sleep, increased 
activity, elevated mood and racing thoughts and speech, while prodromes of 
depression include interrupted sleep, decreased activity, empty mood and loss of 
interest (Lam et al, 2001). Bipolar patients are known to be able to detect prodromes 
about two to four weeks before a full manic or depressive relapse (Lam and Wong, 
1997; Altman et al, 1992). They are also known to be able to report prodromes 
reliably (Molnar et al, 1988; Lam et al, 2001). Generally, BD patients are well-
informed about their illness and keen to manage their condition themselves. This self-
consciousness can be used as a significant factor in managing the condition, since 
early detection of prodromes is of explicit importance. It is, thus, possible for BD 
patients to learn how to identify specific personal “stressors” or triggers associated 
with manic and depressive relapses, and to develop strategies for minimising the risk 
of these triggers progressing into full-blown episodes. 
 
1.5  Human suffering associated with BD 
The condition itself is highly distressing and disruptive; both for the patient and their 
family, and the medication required for BD treatment is powerful and has many 
unpleasant side-effects. However, this is not all that BD patients have to suffer. There 
may be delays in diagnosis and timely treatment, problems with the delivery of care, 
a complex system to be navigated when seeking further information and 
communicating with caregivers, and of course there is a stigma related with all 
mental disorders. About 25% of bipolar patients were found to have never sought 
help from health services in a community survey (ten Have et al, 2002). Health   -5-
Minister Rosie Winterton declared in 2006 that the UK Government “will help people 
with long-term conditions such as cancer, or mental health problems, to stay 
independent and take control of their illness” by prescribing information alongside 
medicines, to allow people taking control of their own illness (James et al., 2008). 
 
1.6  Pharmacological and psychological treatments 
Several drugs such as lithium, olanzapine, valproate, lamotrigine and imipramine are 
available for the treatment of bipolar disorder, but (in addition to the unpleasant side-
effects of these drugs) patients commonly experience multiple relapses and frequent 
oscillations in symptom severity, despite ongoing maintenance therapy (Tohen et al, 
2005). Pharmacological treatments cannot control issues such as medication 
adherence, early detection of prodromes, alertness of the disorder and improving 
coping skills. Since drug treatment is only partially successful, psychosocial 
interventions are often combined with maintenance pharmacotherapy in order to 
target all aspects of the disorder and thus improve overall treatment outcome. Surveys 
have shown that many bipolar patients are very keen to use psychosocial therapy and 
self-management approaches in addition to pharmacological treatment (Lish et al, 
1994; Hill et al, 1996). 
Lithium has been commonly used, both in the acute phases of the illness and 
as maintenance therapy, for more than 30 years. However, about 20-40% of patients 
did not respond to lithium prophylaxis compared with the normal control subjects in 
Lam et al’s (2000) study. Moreover, around 75% of patients on lithium report 
unwanted side-effects such as irritability and mental distress (Fava et al, 1984, 1987; 
Johnson and Leahy, 2004). Despite the increased use of lithium, rising admission 
rates to British hospitals for mania were reported by Dickson and Kendell (1986) and 
Symonds and Williams (1981). Antidepressants may actually trigger an aggravated 
episode of bipolar illness (Ågren and Backlund, 2007). The possibility of inducing 
mania has been reported for almost all antidepressants (Kukopulos et al, 1980; Wehr 
and Goodwin, 1987; Kupfer et al, 1988; Himmelhoch et al, 1991; Peet, 1994; 
Altshuler et al, 1995; Joffe et al, 2002), although the reported rates vary.   -6-
As part of psychosocial therapy, bipolar patients are encouraged to detect and 
manage prodromes of an imminent episode. Patients who are able to detect and take 
action to cope with their prodromes early enough are better able to prevent the 
prodromes developing into a full-blown episode (Russell and Browne, 2005). Early 
detection and treatment also help prevent suicidal behaviour (APA, 2002). Self-
reporting of daily sleep and mood fluctuations is an established clinical tool for the 
clinician to comprehensively assess frequency and pattern of bipolar disorder (Bauer 
et al, 1991; Leverich and Post, 1996). 
The American Psychiatric Association has recommended psychosocial 
intervention as a “cornerstone” of treatment for bipolar disorder (APA, 2002). 
Teaching patients how to recognise prodromes and to act upon them is a significant 
element of psychosocial therapy (Lam et al, 2001).  In particular, teaching patients to 
identify the early symptoms of the onset of mania can provide a significant positive 
impact in patients’ lives (Perry et al, 1999). Lam and Wong (1997) state that teaching 
patients to monitor their moods can contribute significantly to their level of social 
functioning. 
 
1.7  Self-monitoring in BD 
Self-management therapy to identify prodromes is very common today, but in clinical 
practice most implementations are still paper-based (Baldassano, 2005). In healthcare 
and clinical research, computer-based data collection has been shown to be more 
accurate than paper-based data collection by minimising errors in data entry 
(Whybrow et al, 2003; Lane et al, 2006). Electronic methods for data collection have 
been reported to be better than paper-based data collection for many reasons, 
including increased motivation, privacy and secrecy, and reduced time, effort and cost 
required (Whybrow et al, 2003, Bauer et al (2004). 
Although both paper-based and computer-based self-monitoring processes 
have been shown to benefit patients and their caregivers, this is only to a limited 
extent. Over time, the usefulness of both systems can be reduced owing to various   -7-
“behavioural” factors; e.g. patients may simply forget to write the diary, or may be 
too depressed (or manic) to do so; alternatively, they may become complacent about 
the whole process and feel it is unnecessary, while others may feel embarrassed by 
the effort required to do the self-monitoring (Morriss, 2004).  Patients have also been 
known to fabricate diary entries immediately before a hospital visit, and obviously 
under such circumstances their recall of events may be incorrect and biased (Kobak et 
al, 2001). 
Of course, the accuracy of both paper-based and computer-based self-
monitoring mood and activity diaries is questionable, due to their reliance on patients’ 
commitment, openness and honesty when describing their thoughts and feelings. For 
instance, especially during the early phases of mania, many patients deny anything is 
wrong and avoid seeking treatment, even though other people can easily see 
something unusual is beginning to happen. The longer treatment is delayed in a manic 
episode, the worse the eventual outcome. Reliance on a paper-based or computer-
based tool can lead to delay in initiating the necessary treatment for such an episode. 
An automated monitoring system would avoid this problem and would facilitate the 
delivery of timely bipolar healthcare treatment. Hence, the PAM project has involved 
the development of an unobtrusive network of small wearable and environmental 
sensors, mobile phones and computers. The PAM system supports the automated self-
monitoring of a range of personal activity information to help detect any imminent 
bipolar transitions. Chapter 3 provides a detailed discussion of the PAM project and 
how the system works. 
 
1.8  Research questions in this thesis 
We differentiate between the research questions addressed by the PAM project as a 
whole, and those addressed by this thesis. The main aim of the Operational Research 
modelling in the PAM project was to address the following issue: can OR modelling 
approaches help in the design of a system to monitor ‘activity signatures’ for BD 
patients? This broad objective was then subdivided into the following research 
questions, which are addressed in this thesis:   -8-
•  Can a “natural history” model be developed for BD, using clinical data from 
the medical literature? 
•  What type of modelling approach is best suited for such a model? 
•  Is adequate clinical data available, and if not, can expert opinion be used 
instead? 
•  Can simulation be combined with this natural history model to capture the 
inherent variability and uncertainty in the real-world system? 
•  Can this model then be used to compare and evaluate different sets of indicator 
responses, from different configurations of sensors, in order to describe an 
individual’s ‘activity signature’? 
•  Can the model assist the design of PAM by minimising the number of sensors 
required, for a given individual? 
 
1.8.1  Rationale of research questions 
PAM is clearly a highly complex healthcare monitoring system, in which many 
decisions have to be made concerning the choice and configuration of sensors. There 
are also issues concerning algorithm choice and the technical reliability of the PAM 
system itself.  In addition to the acceptability issues already mentioned, there are 
various constraints on PAM. These include energy limitations and the need to prolong 
the network lifetime, the characteristics and lifestyles of the selected patient group 
and obviously, economic considerations. Therefore, the number of active sensors 
should be kept to a minimum.  However, if there are too few sensors, the information 
they provide may be of insufficient value to be useful. In some cases, if a patient is 
unwilling to accept a particular type of sensor, then PAM may not be effective for 
that person. OR can help to resolve this conflict through the use of models designed 
to evaluate different sensor configurations for different patients. OR modelling, 
which is typified by the use of mathematical and computer based models to practical   -9-
problems, has played a vital role in helping PAM to test which configurations of 
PAM sensors could potentially be useful in practice. 
“Natural history” of a recurrent and chronic disease like bipolar disorder is 
significant for clinical implications. To improve the understanding for clinical 
practices, it was vitally important to acquire the knowledge of a description of the 
continuous progression of bipolar disorder in patients from earliest pathological 
change until recovery over time.  Knowledge of sequence of developments of the 
disorder was fundamental to check if the PAM technology is good enough for 
effective relapse detection.  We had little empirical evidence and no clear data. 
Without the use of OR simulation, it would have been hugely costly and 
impracticable to put the human efforts to do this in reality. The costs and benefits of 
applying simulation modelling have been shown to be far less than trying out the 
reality (Gordon, 2001; Componation et al, 2003). 
The first step was to develop a mathematical model of the “natural history” of 
bipolar disorder in which some kinds of evidence or observations can be used to 
calculate the probability that a hypothesis may be true. However, modelling any 
chronic disease process presents various challenges. The model must be stochastic, 
since the occurrence of a relapse in a chronic disease like BD is a random event. 
Moreover, the length of an acute episode varies from patient to patient, due to the 
inherent variability of the disease process. The progression of patients through the 
natural history of BD is no different to this. Bipolar disorder is a serious problem and 
that real-world clinical decisions are to be made in the face of uncertainty, so any 
models which can reduce risk and uncertainty are a good device. It was imperative to 
rely on a stochastic process in order to reach conclusions about future events. 
Integrating patient specific data within an OR model of a healthcare process 
can be beneficial to capture resource utilisation. With this in mind, we required to 
know how to develop a framework in which we can combine the BD disease state 
transition model with simulation of the longitudinal outcomes of interventions. This 
framework was then used to test a whole range of different PAM sensor   -10-
configurations for different (simulated) patients. The model parameters were derived 
from the clinical literature. Model parameters were then varied stochastically for each 
individual, to capture patient-to-patient individuality in terms of dwelling times and 
pathways. The effects of the possible problems of missing or unreliable data within 
the system were also explored in the model. 
The PAM project as a whole was essentially a feasibility study. There was not 
enough time to undertake a full clinical trial, although a technical trial of the 
equipment was performed by the PAM team themselves and a small-scale trial on one 
patient was carried out (see Section 3.8). Therefore, a significant contribution of this 
simulation model was to perform an “artificial” clinical trial on simulated patients. 
 
1.9  Modelling in the PAM project 
Bipolar episodes can become severely disabling and repeated if effective treatment is 
missing. To improve treatment outcomes, close analysis of episodes and functioning 
over time is vital. Longitudinal profiles of bipolar patients are diverse and complex, 
and these pose a challenge to find a model that best explains the longitudinal patterns 
of bipolar affected people. The longitudinal course and outcomes of bipolar disorder 
have largely been studied using descriptive statistics, logistic regression and survival 
analysis (Marneros and Brieger, 2002).  However, it is important to build models for 
better understanding and analysis of bipolar disorder since a modelling approach may 
help clarify the dynamic process inherent with the disorder. 
How to build a model that understands and analyses the dynamic behaviour of 
bipolar patients?  It is well-known that models of dynamic behaviour may often be 
best described by a cycle of events that change with respect to time, where the events 
are the transitions among the states. This is typically called a state-based modelling 
approach in which the set of valid states of a dynamic process and probabilistic 
transitions among the states are defined. For bipolar disorder, we clearly needed to 
use a dynamic approach since the disorder evolves over time. However, the challenge 
was to define the clinical states required for an OR simulation model. Another   -11-
challenge was to construct a model of how the PAM system works and then 
experiment different policies or decisions using the model to observe what works. 
 
Whether we use a Markov or a discrete-event simulation model, it is 
impossible for a model to predict any outcome with a hundred percent accuracy. 
However, it is certainly possible to acquire a high enough prediction through an 
appropriate method.  Pidd (2010) emphasises that “models are approximations, built 
with some intended use(s) in mind and that they are the product of human thought 
and ingenuity”.  What is the use of a model if the outputs of the model are 
approximations?  “Essentially, all models are wrong, but some are useful” (Box and 
Draper, 1987). 
The dynamic “natural history” of bipolar disorder is unpredictable, not just for 
an individual person, but also from one person to another, so no two people will 
experience similar patterns of disorder. This makes bipolar disorder modelling 
stochastic and so difficult. On the one hand, bipolar disorder is known to be complex 
in nature, and on the other hand, keeping a model simple is argued to be at the centre 
of good modelling practice. Due to the diversity and distinctive attitudes of the 
participants involved, selecting the most appropriate method to describe the bipolar 
disease progression was not simple. However, a Markov model, based on the natural 
history of bipolar disorder, was developed in Excel. This model was then combined 
with Monte Carlo simulation to provide information on the clinical value of the 
information that PAM could deliver for a range of different assumptions, including 
sensor failure for technical reasons, deliberate removal of a sensor, flexible 
monitoring, or the limited availability of various types of data. 
The literature (Sonnenberg et al, 1994; Barton et al 2004) suggests that 
Markov modelling and Monte Carlo simulation might be a fruitful line to pursue 
since interaction between patients is irrelevant, a long time period needs to be 
modelled and events in the model are recurrent. Furthermore, this approach helps 
construct a less complex model that would be more advantageous in term of   -12-
flexibility, data requirement, speed and interpreting the outcomes.  Mental illnesses 
are usually unpredictable in nature, and Monte Carlo simulation is a familiar 
approach to deal with uncertainties. The use of Monte Carlo simulation enabled us to 
explore the uncertainties around the actual performance and effectiveness of the PAM 
system in practice, but with artificial, simulated patients. The model issues alerts to 
these simulated patients by comparing their current behaviour with their “normal” 
behaviour, using a set of decision rules and threshold levels. The aim of the model 
was to evaluate this automated routine decision making without human intervention. 
We estimated the model parameters at the individual level in our Monte Carlo 
trial.  It was fast to run, and was also advantageous to carry out “what-if” 
experimentation.  The Monte Carlo experimentation revealed that the Markov model 
is able to capture the true dynamic behaviour and detect a patient’s true health state 
over time. The computational demand of our multi-state model was met using the 
Microsoft Excel (VBA coding) and “@Risk” software. 
 
1.9.1  Challenges for modelling bipolar disorder 
To construct the OR simulation model, we had to deal with the following challenges: 
•  The bipolar illness manifests itself in various forms 
•  The difficulty of developing the “natural history” model due to the illness’s 
characteristics, e.g. a patient can have a mixed (mania with depression) state 
•  We did not come across any OR modelling approach of longitudinal 
monitoring of bipolar disorder in the literature, although OR modelling has 
been applied to unipolar major depression, e.g. Patten and Lee (2005) used a 
Markov model to describe the longitudinal course of major depression 
•  No universally accepted staging models for bipolar disorder were found in the 
medical literature, compared with physical diseases such as cancer   -13-
•  Lack of easily measurable criteria: diagnosis is a very individual process, 
based on self-reports by patients on their moods or behaviour, and the 
observation and judgment of the psychiatrist. 
 
1.10   Scientific contribution 
As in Section 1.8, it is vital to differentiate between the scientific contribution of the 
PAM project as a whole, and the contribution of this thesis. Therefore, in the 
following, “PAM” is used to denote the project as a whole and “thesis” denotes the 
specific contribution of the modelling research in this thesis:  
•  The application of multidisciplinary approaches to develop an innovative, 
acceptable and (hopefully) effective approach to managing BD (PAM) 
•  The use of sensor technology, computer networks and biomedical engineering 
tools to automatically detect and analyse human activity  patterns (PAM) 
•  Developing a model for the natural history of BD, capable of capturing 
individual variability yet consistent with the clinical literature (thesis)   
•  Using this model to evaluate a technology to provide automatic alerts to BD 
patients, by designing and testing different prodrome detection algorithms for 
different simulated patients (thesis). 
 
1.11 Research  paradigm 
PAM is a knowledge generating system in which the activity patterns of bipolar 
patients are studied. The aim of the research is to acquire scientific knowledge in 
order to improve patient care. The OR modelling aspect of PAM is mainly concerned 
with the collection and analysis of secondary data, and the subsequent development 
and use of a quantitative OR model to conduct experiments to test the hypothetical 
PAM system (see Figure 1.1). Therefore, the research paradigm of this thesis is a 
conventional positivistic scientific paradigm. 
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Figure   1.1   The research process in this thesis 
 
1.12    Structure of the thesis  
The remainder of this thesis is organised as follows: 
•  Chapter 2 describes the epidemiology of bipolar disorder   -15-
•  Chapter 3 describes the PAM project in more detail and clarifies the role of 
OR modelling within the overall project 
•  Chapter 4 discusses various diagnostic tests and scoring systems for bipolar 
disorder. It also compares the sensitivity and specificity of different BD 
diagnostic scoring systems 
•  Chapter 5 briefly reviews applications of modelling and simulation in 
healthcare. It concludes by summarising the essential aspects of developing 
OR simulation models 
•  Chapter 6 concentrates on mental illness and mental health, and discusses the 
(limited) use of OR modelling in mental healthcare 
•  Chapter 7 explains the structure, data requirements and other components of 
the simulation model, and explains the assumptions that were made 
•  Chapter 8 presents the model results, discusses their accuracy and includes a 
sensitivity analysis of the key model parameters 
•  Chapter 9 contains an overall discussion of the study findings and its 
limitations.  It concludes with a summary of the motivations, goals and 
findings of this research and provides suggestions for future work.   -16-
   -17-
 
 
2. Bipolar  Disorder 
This chapter provides an overview of bipolar disorder (BD), previously known as 
manic-depression. As described in Sections 1.3 – 1.5 of Chapter 1, BD is a major 
problem worldwide both in terms of human suffering and of economic costs.  
 
2.1 Introduction 
Bipolar disorder is a mental illness that causes atypical swings in a person’s mood, 
energy and ability to function. Manic behaviour is one extreme of this disorder where 
the patient feels excessively euphoric and elated, and depression is the other extreme 
where the patient feels extremely low and even suicidal. The name bipolar disorder 
officially replaced the older term “manic-depression” in 1980, although Leonhard 
(1957) first used the term “bipolar” to describe patients who exhibited both mania and 
depression. Angst and Perris separately showed the distinction between unipolar 
depression and bipolar disorder in 1966. The symptoms of bipolar disorder are far 
more acute than the natural “ups and downs” that everyone undergoes in daily life. 
It is often difficult for bipolar patients to recognise the degree of impairment 
they suffer. Some bipolar patients even deny the fact that they are suffering from a 
mental illness at all, and this flawed awareness of their own illness makes it difficult 
for them to accept treatment. The deep mood swings of bipolar disorder may last for 
weeks or even months, and cause great inconvenience in the lives of spouses, family 
members, friends, colleagues and employers. According to the National Institute of 
Mental Health (NIMH, 2010), BD patients frequently experience personal, social and 
job-related problems. Life expectancy has also been shown to be reduced by this 
disorder (AstraZeneca, 2010). 
BD usually starts in the teenage years or early adulthood and carries on 
throughout life. Some people experience their first symptoms in childhood, and some 
late in life. BD can start in childhood but may not be diagnosed until the person is   -18-
much older. The median age of onset is 25 years (Kessler et al, 2005). The average 
age at onset ranged from 17.1 to 29.0 years in a general review of six epidemiological 
surveys (Weissman et al, 1996). Due to its episodic nature, BD is often not identified 
as a psychological problem, explaining why some patients may suffer unnecessarily 
for years without proper treatment.  
Bipolar disorder is a long-term condition similar to diabetes or heart disease, 
which must be carefully controlled throughout a person’s life. However, BD is 
treatable, and patients can lead healthy and productive lives. Without treatment, 
however, the condition normally deteriorates, and can even lead to suicide in addition 
to other serious symptoms. However, most bipolar patients do not regard their manic 
episodes (at least in the early stages) as needing treatment, and are reluctant to seek it. 
BD patients experience very pleasurable feelings during the onset of a manic episode, 
and understandably they do not want this sense of euphoria to end. Due to this serious 
judgment problem, patients lose insight into their own condition to the point at which 
it becomes too late and negative behavioural aspects appear as the manic episode 
advances. Unfortunately, the National Collaborating Centre for Mental Health 
(NCCMH, 2006) states that “affective or functional changes occurring prior to the 
development of bipolar disorder have not been studied systematically”. 
 
2.2   The symptoms of mania 
The signs and symptoms of mania include (NIMH, 2009; Lam et al, 2001; Morriss, 
2004): 
•  increased energy and activity 
•  feeling very high (euphoric) 
•  increased talkativeness – talking very fast and loud 
•  racing thoughts and ideas, reduced concentration span 
•  decreased need for sleep 
•  creative and strong feeling of omnipotence 
•  increased risk-taking behaviours   -19-
•  stronger interest in sex 
•  poor judgment and lack of inhibitions 
•  spending money more freely (to the point of running up debt) 
•  provocative, disturbing or aggressive behaviour 
•  abuse of alcohol and drugs such as cocaine and sleeping medications 
•  denial that there is any problem. 
Good coping strategies with the early signs of mania include deliberately 
keeping control of one’s actions, performing relaxing activities, prioritising and 
reducing the number of everyday jobs, taking medication as prescribed, delaying 
impulsive actions, talking to someone to bring reality to one’s thoughts, taking time 
off work,  reducing alcohol intake and stopping taking street drugs (Morriss, 2004). 
 
2.3  The symptoms of depression 
The signs and symptoms of depression include (NIMH, 2009; Lam et al, 2001; 
Morriss, 2004): 
•  persistent sad, apprehensive or empty mood 
•  fatigue or loss of energy 
•  loss of interest or pleasure in usual activities such as people, sex and food 
•  pessimistic feelings that the person is useless and worthless 
•  less talkative than usual, slow speech  
•  ideas slow down 
•  difficulty remembering, concentrating and making decisions 
•  sleeping too much 
•  change in appetite 
•  unwanted weight loss or gain 
•  recurrent thoughts of death or suicide 
•  heavy drinking of alcohol. 
Good coping strategies for depressive signs include keeping active, meeting 
people, getting organised, getting the support of family or friends, recognising   -20-
impractical thoughts, avoiding negative thoughts, taking medication as prescribed by 
the doctor, stop worrying and reduce alcohol intake (Morriss, 2004). 
 
2.4  The episodic nature of bipolar disorder 
According to the American Psychiatric Association (APA, 2010), a manic episode is 
characterised by a distinct period of unusually and persistently elevated, expansive or 
irritable mood, lasting for at least one week. A hypomanic episode is characterised by 
a distinct period consisting of at least four days during which there is a persistently 
elevated, expansive or irritable mood, clearly dissimilar from a person’s usual mood. 
On the other hand, a major depressive episode is characterised by a period of time 
where a depressed mood or a loss of interest or pleasure in daily activities lasts 
unusually and consistently for at least two weeks. A mixed episode is characterised 
by meeting the diagnostic criteria (except for time period) for both a manic episode 
and a major depressive episode nearly every day for at least a week. 
The differentiable feature of bipolar disorder is the occurrence of at least one 
manic episode compared with other mood disorders. In addition, BD is a chronic 
condition because patients who have one manic episode will almost always have 
further episodes. A person with this condition can experience any number of episodes 
throughout their life. Without preventive treatment, the NIMH (2009) statistics 
suggest that a patient may on average undergo four episodes in ten years. The actual 
length of each episode does not normally vary much over time, but episodes may start 
suddenly. 
Women usually start with a depressive episode, whereas men are more likely 
to start with a manic episode (AstraZeneca, 2010). Furthermore, women are likely to 
have more depressive episodes than men. However, for both sexes the length of the 
remission periods between episodes tends to decrease with time (Goodwin and 
Jamison, 1990). The pattern of mood cycles differs from one patient to another, but it 
is usually predictable once identified. BD patients who start with depression can 
expect more depressive episodes over the course of their illness than those with a   -21-
manic onset (Perlis et al, 2005; Turvey et al, 1999). In Perugi et al’s (2000) study, 
about half of BD patients began with depression and half with mania. 
 
2.5  The prevalence of bipolar disorder 
People of all races, ethnic groups and socio-economic backgrounds may be affected 
by this disorder. NIMH has stated that more than two-thirds of bipolar sufferers have 
at least one close relative either with BD or unipolar major depression. According to 
Burgess (2006), approximately 2% - 7% of US citizens suffer from BD. Burgess 
(2006) also estimated that 10 million US people will be affected by this disorder 
sometimes throughout their lives; and of these, about half will never receive accurate 
diagnosis or treatment. Also, according to Burgess (2006), there are approximately 
723,250 bipolar affected people in the UK, while in each of India and China there are 
approximately between 12 and 15 million affected people. 
The prevalence of BD within European countries has been estimated to be 6% 
(Pini et al, 2005). A prevalence rate of about 11% was reported by Swiss researchers 
in a 20-year prospective study of young adults with BD (Angst et al, 2003). Lifetime 
prevalence rates in Australia vary from 0.45 to 5.5% (Morgan et al, 2005, Goldney et 
al, 2005). The proportion of the people with BD seems to be increasing, while the age 
of onset is falling (Dienes et al, 2006). 
 
2.6  Types of bipolar disorder 
Bipolar disorder symptoms are characterised by emotional highs and lows whose 
intensity can be mild, moderate or severe. Mood swings can be frequent or 
infrequent. Depending upon the symptoms, there are several types of bipolar disorder, 
as discussed below. 
 
2.6.1  Bipolar type I disorder 
People with bipolar type I disorder experience episodes of severe mood swings 
between mania (at least one manic episode) and depression (with or without a 
previous episode of depression). This is the most common type of bipolar disorder.   -22-
Judd et al (2002) found that patients with bipolar type I spend less time manic than 
depressed (see Figure 2.1 below). About the same number of men and women are 
known to be affected by this type (Lloyd et al, 2005). The lifetime prevalence rates of 
bipolar type I in Europe range from 0.1 to 2.4% (Faravelli et al, 1990; Szadoczky et 
al, 1998; ten Have et al, 2002; Regeer et al, 2004; Pini et al, 2005). Rates reported in 
non-European countries range (from 0.3 to 1.5%) less widely than European countries 
(Weissman et al, 1996). In Australia, a lifetime prevalence rate of 2.5% was reported 











Figure 2.1   Symptoms during bipolar type I disorder.  Source: Judd et al (2002) 
 
2.6.2  Bipolar type II disorder 
People with bipolar type II disorder experience episodes of severe depression 
alternating with milder episodes of mania, i.e. hypomania. Bipolar type II disorder 
became an officially recognised diagnosis by the APA following the introduction of 
the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV, 
1994). This is a milder type of bipolar disorder than bipolar type I. However, bipolar 
type II can also be debilitating. Judd et al (2003) found that patients with bipolar type 
II spend considerably more time in the depressive phase of the illness than the manic 
phase (see Figure 2.2).   -23-
Women (29.0%) were more commonly shown to be affected than men 
(15.3%) (Baldassano et al, 2005). In contrast, Szadoczky et al (1998) found no gender 
difference in the prevalence of bipolar type II disorder. However, prevalence rates of 
bipolar type II reported in European studies vary between 0.2 and 2.0% (Faravelli et 
al, 1990; Szadoczky et al, 1998). Estimates of the lifetime prevalence of bipolar type 
II disorder reported in the US vary (from 5.5 to 10.9%) more widely than European 












Figure 2.2   Symptoms during bipolar type II disorder.  Source: Judd et al (2003) 
 
2.6.3 Cyclothymic  disorder 
The mood swings during cyclothymia are less severe than those in bipolar types I and 
II. Symptomatically, this is a mild form of bipolar II disorder consisting of episodes 
of mood swings between hypomania and a mild form of depression. The prevalence 
of cyclothymic disorder is roughly the same for men and women. Diagnosing 
cyclothymia can be difficult since cyclothymic mood swings may appear within the 
normal range of ups and downs. Cyclothymic disorder episodes tend to last longer 
than other forms of bipolar disorder, and this may eventually lead to severe mood 
episodes (Akiskal et al, 1979). 
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2.6.4  Mixed bipolar disorder 
In the context of a mixed state bipolar disorder, symptoms of both mania and 
depression take place simultaneously. People with any type of bipolar disorder may 
found themselves in mixed states. Mixed bipolar disorder can often be found in 
children and adolescents. Around 30 to 40% of bipolar I patients are reported to go 
through mixed episodes (Swann, 1995; Akiskal et al, 2000), while the figure is 
around 49% for bipolar II patients (Benazzi, 2000). The risk of mixed bipolar 
disorder is higher for patients whose immediate family members also suffer from 
bipolar disorder. Moreover, this is the most unstable state for risk of suicide, because 
stimulation and agitation of mania are combined with irritable depressive symptoms. 
 
2.6.5  Rapid cycling bipolar disorder 
Rapid cycling, which can occur in both bipolar I and II, is the occurrence of four or 
more mood swings within a year, as defined in DSM-IV. However, this may occur 
later in the course of illness and increases the risk of severe depression and suicide 
attempts. Women are more likely than men to experience rapid cycling (Schneck et 
al, 2004). Akiskal et al (2000) reported a 20% prevalence of rapid cycling in bipolar 
patients. Papadimitriou et al (2005) state that patients with bipolar type II suffer 
comparatively more frequently from rapid cycling. 
 
2.6.6  Bipolar disorder Not Otherwise Specified (NOS) 
There are occasions when a person evidently appears to be suffering from bipolar 
disorder, but does not fit the diagnostic criteria for any of the categories discussed 
above. In a case like this, the person is diagnosed as suffering from bipolar disorder 
NOS. For example, recurring hypomanic episodes with depressive symptoms in 
between can be classified under this category. 
 
2.7  Patient descriptions of mood states 
The various mood states of bipolar disorder can be thought as a spectrum. Severe 
mania is at one end, then hypomania, then euthymia (i.e. normal mood), then mild to   -25-
moderate depression and then severe depression (see Figure 2.3). There may also be 
mixed bipolar states, when symptoms of mania and depression occur together. To 




Figure 2.3   The range of moods from severe mania to severe depression. Source: NIMH (2010) 
 
The NIMH US website also provided the following descriptions (by bipolar 
affected people themselves), which offer important insights into the various mood 
states associated with the disorder: 
 
Mania: 
The fast ideas become too fast and there are far too many...overwhelming confusion 
replaces clarity...you stop keeping up with it--memory goes. Infectious humor ceases 
to amuse. Your friends become frightened...everything is now against the grain...you 
are irritable, angry, frightened, uncontrollable, and trapped. 
 
Hypomania: 
At first when I'm high, it's tremendous...ideas are fast...like shooting stars you follow 
until brighter ones appear...all shyness disappears, the right words and gestures are 
suddenly there...uninteresting people, things, become intensely interesting. Sensuality 
is pervasive, the desire to seduce and be seduced is irresistible. Your marrow is 
infused with unbelievable feelings of ease, power, well-being, omnipotence, 
euphoria...you can do anything...but, somewhere this changes. 
 
Depression: 
I doubt completely my ability to do anything well. It seems as though my mind has 
slowed down and burned out to the point of being virtually useless....[I am]   -26-
haunt[ed]...with the total, the desperate hopelessness of it all... Others say, "It's only 
temporary, it will pass, you will get over it," but of course they haven't any idea of 
how I feel, although they are certain they do. If I can't feel, move, think, or care, then 
what on earth is the point? 
 
2.8  Depressive symptoms in bipolar disorder 
Although mania (or hypomania) is the defining feature of bipolar disorder, depressive 
symptoms are more common in the longitudinal course of illness than manic or 
hypomanic symptoms. According to the outcome of a 12.8-year prospective 
longitudinal study consisting of 146 patients with bipolar I disorder completing 
weekly mood ratings (Judd et al, 2002), patients spent about 53% of the time 
asymptomatic, 32% depressed, 9% manic and 6% in cycling/mixed states (see Figure 
2.5). Depression was reported to be over three times more common than mania, and 
patients were symptomatic about 47% of the time. 
 
Figure 2.4   The amount of time spent in various states.  Source: Judd et al (2002) 
In another prospective longitudinal study (13.4-year) consisting of 86 patients 
with bipolar type II disorder completing weekly mood ratings (Judd et al, 2003), 
patients spent 46.1% of their time asymptomatic, 50.3% depressed, 1.3% manic and 









53.9% of the time. Depression was reported to be about thirty-eight times more 
frequent than mania, but this is probably due to the fact that bipolar II patients do not 
encounter a severe form of mania. In a yearlong separate prospective study consisting 
of 258 bipolar patients using the NIMH life chart method (Post et al, 2003), 
participants spent on average three times more of their time being depressed (33.2%) 
then being manic (10.8%). The proportion of depressed time did not vary from 
bipolar I patients to bipolar II, but 76% of the participants were with bipolar I 
disorder. 
Most patients with bipolar disorder are free of symptoms between episodes, but 
some experience various residual symptoms. Despite treatment, a small number of 
people sadly encounter continuous symptoms (Hyman and Rudorfer, 2000). 
However, the natural course of bipolar disorder tends to get worse without treatment. 
A bipolar patient may undergo more frequent and more severe manic and depressive 
episodes over time than when the disease first emerged (Goodwin and Jamison, 
1990). Effective treatment may help bipolar patients alleviate the regularity and 
severity of episodes and maintain good quality of life. 
 
2.9  The causes of bipolar disorder 
The causes of BD are currently unknown. There appears to be no single cause, but 
rather a combination of biochemical, genetic and environmental factors which act 
together to activate the illness. Brain-imaging techniques such as magnetic resonance 
imaging, positron emission tomography and functional magnetic resonance imaging 
suggest that the brains of individuals with BD may vary from the brains of normal 
individuals, although the significance of this is still unclear (Soares and Mann, 1997). 
The “chemical messenger system” (i.e. the neurotransmitter system) that affects 
mood may also play a part in causing bipolar disorder, as may hormonal imbalances. 
There appears to be a strong genetic influence in bipolar disorder: it is more 
likely to occur in individuals whose biological relatives also have the condition.  
Some studies have also shown links between bipolar disorder and schizophrenia, 
indicating a combined genetic cause (NIMH Genetics Workgroup, 1998). The more   -28-
genes a person has in common with a BD sufferer, the more likely that person is to 
develop BD themselves. However, studies of identical twins suggest that other factors 
are involved in causing BD (NIMHGW, 1998). If the cause were solely genetic, then 
if one twin has BD then the other twin would always develop it also, but this is not 
the case. However, if one twin has BD then the identical twin is more likely to 
develop it (40 to 80% chance) than a non-identical twin (15 to 20% chance) or any 
other siblings (5 to 10%) (APA, 2010).  Furthermore, a single gene is not the cause of 
bipolar disorder (Hyman, 1999). It requires several genes operating collectively in 
combination with other factors to produce the illness.   
The environment may be one such factor. “Environmental causes may include 
problems with self-esteem, significant loss or high stress” (Mayo Clinic, 2010). 
Another factor is stress, which is often the main psychological cause leading to the 
onset of BD. Difficult life events such as the death of a loved one or losing one’s job 
are a significant reason of stress. The illness can be activated in women due to 
childbirth or the menopause. Stressful circumstances may trigger an episode of mania 
or depression in individuals with BD, but once again, of course stress is not the single 
fundamental reason. 
 
2.10    Bipolar disorder and suicide 
A person with bipolar disorder may commit suicide either by careful planning or as 
an impulsive act. The lifetime risk for suicide is six times higher for individuals with 
depression than the general population (Hyman, 2000). Suicide is more common in 
bipolar depression than in unipolar major depression (Burgess, 2006). Most suicide 
attempts and most completed suicides occur during the depressive course of the 
illness (Baldessarini and Tondo, 2003). However, suicidality was reported to be 
markedly common among patients with mixed mania than patients with pure mania, 
and non-remission from mixed manic episodes may result multiple suicide attempts 
(Goldberg et al, 1998).   -29-
About 30% of bipolar sufferers attempt suicide at some point during their 
lives, and of these, about 20% succeed (Burgess, 2006). The standardised mortality 
ratio for suicide in bipolar disorder is approximately 22.4 for women and 15 for men 
(Osby et al, 2001). Furthermore, the risk of suicide is greater earlier in the course of 
the illness. Therefore, early detection of the illness and understanding how best to 
manage it may significantly reduce the risk of suicidal death. Suicidal feelings and 
actions can be overcome with proper treatment. Bipolar patients who are more 
severely affected show noticeably lower suicide rates because of underlying long-
term treatment than those who are less severely affected but without proper treatment. 
Suicidal signs and symptoms include (CR, 2008): 
•  talking about wanting to die  
•  feeling hopeless and helpless 
•  talking about being a burden to others  
•  misusing alcohol and/or drugs 
•  writing a suicide note. 
 
2.11    Alcohol, drugs and bipolar disorder 
It is very common for bipolar people to abuse alcohol and drugs. Substance abuse has 
negative impacts on the illness, increases the recovery time, triggers early relapse and 
makes it difficult to distinguish mania (NIMH, 2010). According to the Mental Illness 
Fellowship of Australia (MIFA, 2008), BD patients are 11 times more likely to abuse 
alcohol or drugs than healthy people. Also according to MIFA (2008), substance 
misuse is the single most common predictor of poor outcomes. Cocaine and 
amphetamines are key factors in triggering manic episodes, followed by 
hallucinogens and marijuana. In the case of depression, it is alcohol which is the 
major precipitating factor. Substance abuse problems emerge due to many factors 
such as mood symptoms, self-medication of symptoms and risk factors; these may 
activate the occurrence of both bipolar disorder and substance use disorders 
(Strakowski and DelBello, 2000). 
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2.12    Life events and the course of bipolar disorder 
The effects of life events are associated with the course of bipolar disorder. For 
example, a person with bipolar disorder could be at high risk for depression when a 
negative life event unfolds. To this end, studies such as Kessler et al (1997) and Agid 
et al (1999) reported an association between early parental death and occurrence of 
bipolar disorder in later life. Mortensen et al (2003) showed an increased risk for 
bipolar disorder among children who experienced early suicidal parental death. 
Ellicot et al (1990) reported a fourfold increased risk of relapse for bipolar patients 
due to acute negative life events. Furthermore, negative life events increase a time for 
recovery by threefold (Johnson and Miller, 1997). 
In contrast, no independent severe negative life events were shown to predict 
an increase in manic symptoms in the longitudinal studies carried out by Alloy et al 
(1999), Johnson et al (2000) and Johnson et al (2004). However, as evidenced by 
Leibenluft et al (1996), sleep disruption may cause manic symptoms. About 10% of 
patients with bipolar depression were shown to develop manic symptoms due to sleep 
disruption (Colombo et al, 1999). People tend to remember major life events for up to 
a year (Paykel, 1997), while a large percentage of minor events are usually forgotten 
more quickly (Brown and Harris, 1982). A major life event that is involved in the 
course of bipolar disorder could be rated in terms of its severity, if it unfolds, by 
assigning a fixed number of points to assess the patient’s condition (Johnson, 2005). 
 
2.13    Incidence of bipolar disorder in UK cities 
Lloyd et al (2005) conducted a study to assess the incidence rates of bipolar disorder 
in three UK cities, including south-east London, Nottingham and Bristol. The overall 
incidence rates per 100,000 per year in these three cities were found to be 6.2, 3.0 and 
1.7 respectively. The study observed no significant gender difference in the incidence 
of bipolar disorder. The incidence of bipolar disorder was reported significantly lower 
among White groups than among Black and minority ethnic groups in all three cities. 
The reported increased incidence rates in Black and minority ethnic groups are in line   -31-
with previous similar findings from the UK (Leff et al, 1976; Bebbington et al, 1981; 
Der and Bebbington, 1987; Van Os et al, 1996). 
 
2.14    Treatment of bipolar disorder 
Regardless of the severity of disease, proper treatment can help stabilise mood swings 
and alleviate the associated symptoms of BD (Sachs et al, 2000). A combination of 
medication and psychosocial treatment is thought to manage the illness best. Bipolar 
disorder can affect many areas of life; thus a patient’s care plan may involve a 
psychiatrist, psychologist, family and friends in treating the condition effectively. 
Usually, a psychiatrist supervises the medication aspects, a psychologist monitors the 
psychosocial aspects and the others provide encouragement and support in seeking 
treatment or continuing with the prescribed treatment plan. 
It can take some time, and some changes of medication, before a suitable 
treatment plan is settled. Bipolar patients are usually advised to record their daily 
activity information even during the normal periods so as to ensure treatment efficacy 
and delay a future manic or depressive relapse. Bipolar patients those who 
communicate closely and openly, with their caregivers about their care plans, are 
likely to be treated most effectively. Medications branded as mood stabilisers are 
normally prescribed for treatment and prevention purposes. There exist different 
types of mood stabilisers—a good mood stabiliser can help reduce both manic and 
depressive episodes. 
Lithium, the first mood stabiliser, has been widely used to help manage 
bipolar disorder. However, Silverstone et al (1998) state that the benefits of lithium 
are often less in practice than the clinical trial results would suggest, mainly because 
of poor compliance. Anticonvulsant medications such as carbamazepine or valproate 
have also been shown to provide mood-stabilising effects. Anticonvulsant 
medications may also be combined with lithium for maximum effect. However, 
valproate is not recommended for women of child-bearing age (BPS, 2010). All these 
drugs are powerful and have unpleasant side-effects. Moreover, Gitlin et al (1995)   -32-
state that even aggressive drug treatment can be ineffective in a significant number of 
cases. 
Other medications such as antidepressants are used during depressive episodes 
in bipolar disorder, but use of antidepressants is controversial since this may trigger 
manic episodes at times. It often becomes difficult for bipolar patients to cope with 
medications because of unpleasant side effects. Some patients may also be tempted to 
discontinue medication during the periods when they feel better. Furthermore, the 
illness itself may lead a patient to refuse treatment, and the patient may be 
hospitalised as a result. 
In addition to medication, psychosocial interventions such as cognitive 
behavioural therapy, psycho-education and family therapy are useful in offering help, 
instruction and direction to bipolar patients and their families. Through cognitive 
behavioural therapy, bipolar patients learn how to control negative or unjustifiable 
thought patterns and behaviours. Through psycho-education, bipolar patients learn 
how to detect early warning signs and thus seek early interventions. Family therapy is 
a form of psychotherapy that involves the family of a bipolar patient in therapeutic 
sessions so that the level of distress caused by the patient within the family gets 
reduced. 
 
2.15    Impact of BD on family caregivers 
Family members play a significant role in the care plans of bipolar affected people. 
Bipolar patients find it easier to manage the illness with support and encouragement 
from their family. However, family members or other caregivers may often have to 
deal with the patient’s difficult behaviour, such as aggressiveness and wild spending 
habits during mania or heavy drinking, and excessive withdrawal from others during 
depression. Both male and female bipolar patients can become hostile and aggressive, 
especially during mania, and may even commit criminal acts. This is a particular 
worry for many family caregivers.   -33-
Like all serious illnesses, bipolar disorder affects the whole family as well as 
the patient. A study conducted by Dore and Romans (2001) highlights the notable 
problems faced by family caregivers in their relationships with patients during 
periods of illness, with considerable impact on their own employment and financial 
status, childcare duties and ordinary social relationships. In most cases, family 
caregivers show considerable tolerance towards the difficulties posed by bipolar 
patients. Sadly, though, there are cases when family members are unable to cope and 
withdraw from their caregiving roles. 
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3.  The PAM Project 
This chapter starts by explaining the motivation for the PAM (Personalised Ambient 
Monitoring) project. It then describes what the PAM system involves and how it 
operates. It also highlights the distinctive contribution of OR modelling to the project. 
 
3.1 Introduction 
We have seen in Chapter 2 that bipolar disorder is a serious mental illness which 
cannot be controlled by drugs alone. Bipolar patients who are trained to use self-help 
treatments can benefit from greater control over their care and life decisions and can 
detect early warning signs of serious illness (Morris et al, 2004). To date, self-help 
interventions have been either manual or computer-based, and are ineffective at 
identifying the onset of depression (Perry et al, 1999).  Although computer-based data 
entry may be more accurate than manual data entry, both systems still rely on human 
input and are thus prone to errors. Moreover, manual or computer-based systems do 
not routinely report physiological and patient context information. Automated data 
collection through the use of modern technology may overcome these drawbacks. 
 
3.2  Technological interventions in bipolar disorder 
The need for innovative approaches that improve the efficiency of homecare is 
growing, as healthcare services move out of the hospital into the home setting.  
Examples of such telecare projects include the Bath Institute of Medical Engineering 
(BIME, 2010) project for dementia sufferers and the Mobilising Advanced 
Technologies for Care at Home (MATCH, 2009) project for ageing people. Other 
initiatives include Extending QUAlity of Life of older and disabled people (EQUAL, 
2004) and Strategic Promotion of Ageing Research Capacity (SPARC, 2007), Smart 
and Aware Pervasive Healthcare Environment (SAPHE, 2006) and Ubiquitous 
Computing for Healthcare in the Community (UbiCare, 2003).   -36-
In July 1992, the British Government published its future vision and 
legislation in the policy manuscript The Health of the Nation (DoH, 1992), which was 
subsequently endorsed by the policy manuscript Our Healthier Nation (DoH, 1999).  
Both manuscripts identified the problem of mental illness as one of the key areas for 
action and targeted mental illness together with coronary heart disease, cancer and 
strokes for health improvement. Since then further frameworks for action have been 
developed, most notably the Health of the Nation Mental Illness Key Area Handbook 
(DoH, 1994) and the National Service Framework for Mental Health (DoH, 1999). 
Research studies such as Malan et al (2004), Van Laerhoven et al (2004), 
Chakravorty (2006) and Wood et al (2006) propose sensory networks for therapeutic 
monitoring. Sensory networks can also be used to observe the physiological and 
environmental information of patients to provide robust monitoring (Blum and 
Magill, 2008). Sensory data could be combined with self-reported data for the 
detection of prodromes with the aim of describing the mental health state, thus 
identifying and minimising both manic and depressive episodes. 
However, recording the behaviour patterns of mental health patients using 
sensory networks to issue automatic alerts in a flexible and accurate manner is a 
significant research challenge. According to the National Institute of Mental Heath 
(NIMH) US, bipolar patients are strongly advised to continue self-monitoring even 
during the normal periods to delay a future relapse and thus to ensure ongoing 
treatment effectiveness. Besides, bipolar patients may suffer cognitive difficulties not 
only during a depressive or manic episode, but also during a normal period 
(Martinez-Arán, 2004). Therefore, without the use of technology, ongoing daily self-
monitoring can be unmanageable for many patients. 
 
3.3  The PAM team 
PAM (www.pam-research.org) is a collaborative research venture between three UK 
universities:  Southampton, Nottingham and Stirling. The project was funded by the 
UK Engineering and Physical Sciences Research Council and began at the beginning   -37-
of October 2007. The funding for PAM was awarded following a “sandpit” on 
telecare in the autumn of 2006, entitled “Taking Care to the Patient”, where the four 
academic investigators met for the first time. The PI of PAM was Professor 
Christopher James, who at the time was based in the Institute of Sound and Vibration 
Research (ISVR) at Southampton, but is now at the University of Warwick.  
The PAM team involves academic researchers from the fields of electronic 
engineering (Professor John Crowe, Nottingham), biomedical signal processing 
(Professor Christopher James, ISVR), computer science (Professor Evan Magill, 
Stirling) and OR (Professor Sally Brailsford, School of Management, Southampton). 
Each had a PhD student funded on the PAM project. This mix was essential to the 
overall success of the project, and provided an interesting and distinctive 
interdisciplinary grouping. Figure 3.1 shows the PAM research team and their 
research fields. Each investigator had one PhD student on the project. The project’s 
progress was driven by a Steering Group consisting of clinicians, patients and non-
academic researchers. Appendix A1 details the people (academics, PhD students and 
Steering Group) involved in the PAM project. Members of the PAM team explored 
the potential of technology to enrich healthcare direction, motivation, independence, 
confidentiality, effectiveness and well-being within a specific area of mental health. 
 
 






















The first objective of the PAM project was to test whether distinct behavioural 
patterns (i.e. ‘activity signatures’) could be identified in healthy individuals. If so, 
then the second aim was to determine whether these activity signatures could be used 
to support self-management in bipolar disorder, by providing early warning signs of a 
change in behaviour which could potentially signal a decline in the patient’s health. 
 
3.4  The PAM system 
In the PAM project, we were specifically concerned with the management of bipolar 
disorder. The objectives of managing bipolar disorder usually involve resolving 
manic and depressive symptoms, preventing ongoing relapse, and achieving well-
being (see Figure 3.2): 
 
 
Figure 3.2   Bipolar relapse prevention  
 
The technological aspects of the PAM project involved the development of a 
system for automated activity monitoring in BD, using a personalised unobtrusive set 
of small environmental and wearable devices to monitor patients’ activity patterns. 
These devices were built by the Nottingham group. Figure 3.3 below shows how the 
PAM system collects ambient data through wearable and static environmental sensors 
from ambulatory and home settings. Examples of these include accelerometers to 
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Figure 3.3   Ambient data collection. Source (modified): Prociow and Crowe (2009) 
 
The system includes both wired and wireless communication links between 
the patient and the monitoring network. Bluetooth transmits the wearable sensor 
readings to a mobile phone and the environmental sensors readings to a PC. The data 
is summarised locally using feature extraction algorithms devised by the ISVR group, 
and then transmitted onwards via the internet to a central server, where algorithms 
(devised by the Stirling group) are used to detect whether the person’s behaviour 
pattern was within some tolerance of “normal” or whether a significant change may 
have occurred. 
A major concern was the acceptability of the PAM system to patients and their 
families. Fahrenberg (2006) states that user acceptance issues are at the heart of a 
successful monitoring system. However, we were reasonably optimistic that BD 
patients were likely to accept such monitoring, provided they understood its potential 
benefit.  In a study of the ChronoRecord, a computer-based system used to enter daily 
recordings, Whybrow et al (2003) reported that 83% of the BD patients in their study 
had no problem accepting the technology. Today, technology is becoming a part of 
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recognised as valuable to the UK’s future by the Council for Science and Technology 
(CST, 2010). 
The sensor set had to be customisable to the individual needs and preferences 
of each patient. The P in PAM stands for Personalised and is a key aspect of the 
system. The PAM system allows patients and their caregivers to select whatever 
monitoring devices they find acceptable. Patients should be unaware of the sensor 
devices and they do not need to carry out any special actions. They can simply get on 
with what they normally do.  
 
3.4.1  Types of sensor 
Based on the need to identify changes in key behaviours known to be affected during 
the course of bipolar disorder, and following discussions with the Steering Group, the 
full range of potential choices of sensors was chosen. The sensor configuration 
comprises two main sets: wearable and environmental. The first set includes small 
devices to be worn or carried by the patients, for example on a mobile phone, while 
the second includes ambient sensing devices to be set up in their home environment. 
Table 3.1 below provides the associations made between specific sensors and 
bipolar episode prodromes. The sensors are not designed to be completely hidden 
from sight, but they are also not obtrusive. Tapia et al (2004) suggest that people 
usually forget about the installation of devices in the home environment within a few 
days. Rather than adopt a conventional approach of using different sensors each 
tailored to a particular monitoring task, the PAM system includes a wireless camera 
within the PAM system to capture images of various areas of interest within a 
complex environment (e.g. a kitchen) for monitoring different activities within the 
scene. These images are not identifiable as people or objects but as “blobs” – areas of 
black and white – simply indicating the presence or absence of movement. Amor and 
James (2008) provided further details on this matter. 
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Cupboard/Fridge/Microwave/Cooker doors sensors 
Table 3.1   Sensors for specific bipolar episode prodromes 
 
3.4.2  The PAM data processing platform 
The PAM system uses a mobile phone to upload its data on a PC via Bluetooth for 
further processing. All of these aspects were developed and managed by the Stirling 
team. The ambient sensors also interface with the PC, which is a centre for long-term 
storage and data fusion. The PAM system then uploads this processed data from the 
PC to an external server to observe captured behavioural patterns. “Roaming 
gateway” software transfers operating procedures to the devices and synchronises 
sensor and network data collection. Middleware fitted on the devices supports 
multiple tasks such as device registration, task assignment and secure data transfer.  
3.4.3  PAM data processing architecture 
As shown in Figure 3.4 below, the PAM system uses a three level architecture: the 
node level, the semantic level and the fusion level, in order to process large volumes 
of data generated from the sensors. The node level performs feature extraction and 
converts the raw data into a meaningful form before transmitting to further up the 
processing chain for more advance manipulation. The semantic level then extracts 
essential connotation from the features transmitted to it from the node level for data 
fusion. These two levels were both designed by the ISVR team.  The fusion level 
(developed by Stirling) finally fabricates the semantic features passed on to it in order 
to impart prognostic competences of the system via particular pattern matching   -42-
algorithms to recognise recurring patterns. The data is then fed into the model to 
monitor variations in a patient’s behaviour and produce appropriate alerts. 
 
 
Figure 3.4   Three-level data processing architecture.  Source: Amor and James (2008) 
 
3.5  PAM and OR modelling 
The PAM team has built an automated unobtrusive system of daily monitoring of 
bipolar patients’. This was no doubt a challenge, which has been dealt through a 
multidisciplinary approach. We, the OR researchers, played a key distinguishing role 
to provide the modelling basis of the work. PAM does not require patients to enter 
data manually in any format, to reduce the bias of subjective recall from patients. The 
advantages of ambulatory monitoring, assessment and frequent measures are well 
documented. With unique features such as the OR modelling basis, and the emphasis 
on the roaming gateway and dynamic programmability, the PAM system is meant to 
be seen as an integrated function that provides a unified and coherent care 
management at home for a better insight into bipolar patients’ true behaviours. The 
system essentially offers personalised monitoring to allow a patient choice of sensors 
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The other members of the PAM team provided skills and experience across 
sensors, medical signal processing, communications and software services, while we 
dealt with OR simulation modelling. The need of this mix was essential to the success 
of the project. Within PAM, our role as the operational researchers was to formulate 
our own model in which to perform the various analyses. Building models for bipolar 
disorder is very difficult, but we have attempted to build a multi-state transition 
model that is combined with computer simulation. We used our model to check if 
daily monitoring can be adjusted and personalised, and may offer as a direct 
motivator for behavioural change in patients. The model was revised by relevant 
literature reviews to verify the intervention usefulness. 
We assisted the other members of the PAM team to design the PAM system 
and to direct the analytical conducts within the framework of the system. This role 
provided us with a chance to augment our involvement to the solution of the problem. 
The OR simulation model provided insight into the required modalities and sensors. 
We employed a prognostic modelling analytical concept that used a mathematical 
equation, computer logic and related tools to estimate the outcomes of specific 
decision options within the computations of the model rather than actually 
implementing them, e.g. to produce the preferred outcomes. We opted to use Monte 
Carlo simulation to provide a more affluent structure to reach at realistic and 
acceptable decisions. Our model was represented in Microsoft Excel in which we 
methodically searched for the multitude of decision alternatives to perceive the 
preferable steps forward. 
OR modelling, managed parametrically, allowed us to examine various 
decision choices within a short time and evaluate their effects to develop an ideal 
option for our program. In this way, cost was limited and outcomes were faster in a 
risk-free setting without directly affecting patients before implementation. However, 
it required us to discover a better mathematical tool to tackle the various issues. We 
tried to balance all the relevant considerations in developing and disseminating the 
model that is capable of informing the PAM system. Our model provided good 
tractability or simplicity for analysis, and yielded useful conclusions within the time   -44-
available for decision making. We often communicated with the members of the Pam 
team, to get maximum benefits of modelling so as to make shared decision making. 
Figure 3.5 shows the application of the simulation model to the PAM system: 
 
 
Figure 3.5   The role of simulation to evaluate outcome measures 
 
3.6  Potential benefits through PAM 
The PAM team define the potential patient benefits as: 
•  improved self-management, patient management pathways and patient care 
•  improved early detection of bipolar prodromes 
•  better patient confidentiality 
•  enhanced quality of care and quality of life 
•  increased productivity of caregivers  
•  improved applications of drugs and reduced need of hospital admissions 
•  sustainable support for health services research 
•  support for potential developments in healthcare technology and management 
•  improved health, independence and wellbeing status for bipolar patient group 
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Further to the above benefits, the clinician can quickly be provided with extra 
useful information through the PAM system. Technological monitoring can surely 
provide an early warning of any imminent episode; thereby stop patients escalating 
into a severe state and requiring unnecessary hospital admissions, and help steady the 
lifestyle of patients. The potential PAM technological benefits are: 
•  improved evaluation of ambient monitoring in a mental healthcare context 
•  enhanced the ability to simply plug in and turn on a sensor 
•  better identification of behavioural signatures from disparate and sparse data 
•  enhanced intermittent connectivity to sensors 
•  enhanced the concept of the remote monitoring of bipolar patients  
•  enhanced the use of OR modelling to guide a technology 
•  enhanced the use of low-cost sensors at home. 
 
3.7 Acceptability  of  PAM 
One may question about the acceptability of PAM from the perspective of both 
patient and caregivers. The members of the PAM team have shown through the trials 
that the system works technically and generates detectable repeated daily activity 
patterns from different sensors, but will bipolar sufferers actually accept it? 
Technologies are a part of everyday living at present. Whybrow et al (2003) reported 
that 4 out of 5 bipolar patients accepted the ChronoRecord, which is a computer-
based system to enter daily recordings. Moreover, the concept of the remote 
monitoring of patients has already been tested, e.g. the Bath Institute of Medical 
Engineering (BIME) and UbiCare (Ubiquitous Computing for Healthcare in the 
Community), mentioned earlier in Section 3.2.  In any case, the PAM team involved 
the user community from the start to reflect the patients’ ambitions and concerns in 
the design of the PAM system. The experimental PAM design crucially provides 
bipolar patients the opportunity to withdraw at any time without compromising the 
final outcomes. 
   -46-
3.8  Testing the PAM system on real patients 
Originally we had planned to carry out a small trial on four patients, but delays in 
obtaining ethical permission and recruitment difficulties meant that in the end, we 
were only able to recruit one patient, who participated in the study for about three 
months. Healthcare ethics is about protecting the human participants in a research 
study from any kind of physical or psychological harm. Ethics was clearly a major 
issue for PAM. We obtained NHS ethical approval (see Appendix A7) to run the 
PAM study. 
The participant was given some brief training about the PAM system. She was 
clearly informed about all aspects of the monitoring system, including how data 
would be collected, stored and processed. She had to give consent to every aspect of 
the monitoring system in order to participate in the study, and had the right to 
withdraw from any part of the monitoring at any point without the need to give a 
reason. During the study, she was encouraged to report any part of the system that 
was troublesome. She was also asked to record her own activity in a diary during the 
study with the purpose of matching the self-recorded data with the automatically 
logged data obtained from the PAM system, although unfortunately this did not 
happen. 
At the beginning and end of the trial, a member of the PAM team conducted a 
semi-structured interview with the participant. The main purpose of the interview was 
to document the participant’s opinions regarding the acceptability of individual 
sensors, the obtrusiveness of sensors and acceptability of the PAM set-up as a whole, 
any user compliance issues for devices and suggested changes to improve 
compliance, any issues about data access and privacy, and reasons for not wearing or 
disabling devices. In addition, she was asked how she felt about the effects of self-
monitoring, and was asked to describe her thoughts and feelings about external 
monitoring. At the end, she was asked about her thoughts and feelings about how life 
changed via the use of the technology, and for any improvements that could be made 
to improve compliance.   -47-
 
 
4.  Diagnosis of Bipolar Disorder 
The first stage in developing a mathematical model of any disease is to understand its 
clinical aspects, and to study the medical literature for any pre-existing (and 
preferably commonly used) staging and diagnostic criteria. This is particularly 
challenging in a psychiatric condition such as bipolar disorder, because of the 
qualitative and behavioural nature of the symptoms of this disorder. A few diagnostic 
tests and scoring systems are available, but most diagnoses are made by a psychiatrist 
essentially on the basis of a conversation with the patient and a discussion of the 




Chapter 2 discussed the symptoms of BD, which vary from patient to patient. 
Monitoring symptoms and the frequency and duration of episodes are key for an 
accurate diagnosis. Without accurate diagnosis, it is difficult to initiate effective 
intervention. To make matters worse, many bipolar patients avoid treatment, and this 
usually leads to severe long lasting consequences. Delay in treatment can prevent 30 
to 60% of bipolar patients from regaining full functional capabilities (MacQueen and 
Young, 2001; Calabrese et al, 2003). 
 
4.2  Diagnosis delay and the benefits of screening 
The bipolar spectrum, a key area of recent research, includes bipolar I, bipolar II, 
cyclothymia and bipolar Not Otherwise Specified (NOS), all of which were discussed 
in Chapter 2.  Regrettably, bipolar spectrum disorders frequently go unidentified with 
common hold-ups of 8 years or more before accurate diagnosis (Lish et al, 1994). 
This ensues a considerable delay in diagnosis and proper treatment (Hirschfeld et al, 
2000), the consequences of which can be severe and may even lead to suicide   -48-
(Dunner, 2003). The cost to the NHS of undiagnosed cases of BD may be even higher 
than the costs of identified cases (Li et al, 2002; McCombs et al, 2007), estimated at 
£200m in the UK by Gupta and Guest (2002). 
However, the early identification of any illness can be improved through 
screening. There are several screening tools for psychiatric disorders, but only a few 
specifically for bipolar spectrum disorders. The Diagnostic and Statistical Manual, 
Fourth Edition, Text Revision (DSM-IV-TR, 2000), by the American Psychiatric 
Association, is one of the key sources for psychiatric diagnosis. The DSM-IV-TR 
diagnostic criteria for bipolar disorder are based on the detection of various mood 
episodes, which must have a distinct onset and end point.  
 
4.3  Structured and semi-structured interviews 
The Structured Clinical Interview for DSM-IV (SCID) is the most extensively used 
clinical evaluation device for the diagnosis of bipolar spectrum disorders (First et al, 
1997). A patient’s underlying episode type can be determined via a SCID interview 
(Hilty et al, 1999). It usually takes between one to two hours to accomplish a SCID 
interview, depending on the patient and who (a clinician or a trained mental health 
professional) conducts the interview. The SCID interview is split into six separate 
components covering mood episodes, psychotic symptoms, psychotic disorders, 
mood disorders, substance use disorders, anxiety, and adjustment and other disorders. 
These can be conducted one after another to describe a patient’s present psychiatric 
state. The SCID interview has been validated in many diverse populations and its 
reliability has frequently been shown to be high. 
However, the SCID interview may be more reliable in detecting the severe 
form of BD rather than a milder form (i.e. hypomania). Baldassano (2005) states that 
the diagnosis of hypomania may require a more delicate approach than the SCID. A 
semi-structured interview may be more fitting for the diagnosis of bipolar spectrum 
disorders (Benazzi, 2003), because it permits the clinician to bring up new questions   -49-
during the interview and to explore a framework of themes combined with clinical 
experience and judgment. 
 
4.4  Underdiagnosis or misdiagnosis 
Diagnosis and treatment of bipolar disorder are clearly challenging. Burgess (2006) 
reported that nearly 70% of bipolar patients were found to be misdiagnosed over three 
times prior to the correct diagnosis. Bipolar II and bipolar NOS types pose a 
particular challenge, and both types are often misdiagnosed as unipolar major 
depressive disorder and thus receive improper treatment (Bowden, 2001). One reason 
for the misdiagnosis of bipolar patients is that they usually spend substantially more 
time in the depressive phase of the illness than in the manic or hypomanic phase 
(Judd et al, 2002; Judd et al, 2003). 
On the other hand, underdiagnoses can be caused by the patients’ lack of 
insight into mania and failure to involve a caregiver in the diagnostic process, 
together with the clinicians’ failure to agree on the boundaries of the bipolar spectrum 
(Ghaemi et al, 2002). All bipolar patients go through periods of depression (Goodwin 
and Jamison, 1990), and especially this primary appearance of bipolar depression 
may subsequently trigger misdiagnosis as unipolar depression. Depressive patients, 
who lack understanding of hypomania as pathological, fail to express it to the 
clinicians spontaneously (Scott, 2002). As such, the clinicians often fail to put 
forward appropriate direct questions (Angst and Gamma, 2002). One statistic shows 
that the prevalence of bipolar disorder in patients being treated for unipolar 
depression in a private psychiatric clinic in northern Italy was 49% (Benazzi, 1997). 
Other diagnostic problems include presence of more than one health condition, 
poor understanding of the classification systems and overlapping symptomatology 
with a range of type I and type II disorders (Vieta et al, 2000). Anxiety and substance 
abuse disorders are very common among patients with bipolar disorder. McElroy et al 
(2001) found anxiety disorders in 40% of bipolar patients and substances abuse in 
60% of bipolar patients.   -50-
To screen and diagnose bipolar disease in both psychiatric and general 
practices, clinicians commonly use the operational diagnostic criteria such as DSM-
IV and the International Classification of Diseases (ICD-10, 1993). There is some 
variability between these two major diagnostic classification systems. The DSM-IV 
criteria for a diagnosis of BD require a single episode of mania or hypomania 
together with a single depressive episode. In contrast, the ICD-10 criteria require two 
separate mood episodes including at least one episode of mania for a bipolar 
diagnosis. Both DSM-IV and ICD-10 may be less consistent and logical than 
previously thought in the detection of hypomania, which may entail more delicate 
inquiry than described in SCID and the Composite International Diagnostic Interview 
(CIDI) (Angst et al, 2005).  
It has been reported that about 40% bipolar sufferers are primarily 
misdiagnosed (Ghaemi et al, 2002), which hinders prompt active intervention. Thus, 
the true prevalence of bipolar disorder may well be greater than is currently believed 
(Ghaemi et al, 1999). However, the diagnosis and treatment of bipolar spectrum 
disorders as well as the subset of depressed patients actually with bipolar disorder 
may be improved through self-report screening measures (Hirschfeld et al, 2000; 
Hirschfeld et al, 2005). 
 
4.5  Self-report screening measures 
The chance of detecting treatable illness where an intervention may enhance outcome 
of the illness can be increased through screening. This should be simple to run and 
acceptable to patients, and able to detect most of the true cases (Wilson and Junger, 
1968). The lack of classification systems for the diagnosis of bipolar spectrum and 
the subsequent rise in prevalence present a clear need for a broader screening 
approach that may enable a large number of bipolar patients to benefit from effective 
intervention. It has been reported that bipolar patients’ ratings of their own symptoms 
may differ from their clinicians’ opinions (Laje et al, 2002).  This may be because the 
self-report survey is designed for the whole BD spectrum. Another reason for this is   -51-
that as mentioned previously, patients have impaired insight into mania (Ghaemi et 
al, 2002). 
Self-report measures are widely used to detect depression, but they have not 
generally been used for identifying bipolar disorder (Passik et al, 2001). Today, self-
report measures have dependably been used to assess manic symptoms (Truman et al, 
2002). Furthermore, Benazzi (2002) used evidence derived from a self-report measure 
as a diagnostic tool for bipolar spectrum disorders. Meyer and Hautzinger (2003) and 
Angst et al (2005) respectively conducted validation studies of two screening tools, 
the Hypomanic Personality Scale and the HCL-32, both of which have been 
developed specifically for identifying hypomania. Hirschfeld et al (2000) developed 
and later validated the Mood Disorder Questionnaire, which is now one of the most 
widely used self-assessment screening tools for identifying bipolar spectrum 
disorders. 
Dr Ronald Pies developed the Bipolar Spectrum Diagnostic Scale, which was 
later validated by Ghaemi et al (2005). There are other self-assessment methods such 
as the Self-Report Inventory for Mania (Shugar et al, 1992), the Symptom Checklist 
90 for a broad range of psychological problems (Hunter et al, 2000) and the Brief 
Bipolar Disorder Scale (Dennehy et al, 2004), but these are predominantly to assess 
symptoms and have not been advocated as screening tools (Angst et al, 2005). 
 
4.6  Diagnostic and screening tests in psychiatry 
The use of symptom clusters, rather than disease cause or pathology, has been 
common in the diagnosis of psychiatric disorders for a long time (Warner, 2004). A 
disease screening test ideally provides information on chronic disease progression at a 
stage at which an intervention can be useful. However, a screening test is never 
without difficulty. Screening tests must be safe, cost-effective and acceptable since 
such tests are carried out within a healthy population. Screening tests are intended to 
detect the likelihood of having a disease and to indicate the need for further 
examination for a patient who screens positive. On the other hand, diagnostic tests   -52-
should offer more certainty whether an individual has a specific disease. Diagnostic 
and screening tests in psychiatry are common today. Examples include screening for 
bipolar disorder (Hirschfeld et al, 2000) and neuropsychological testing to diagnose 
dementia (De Jager et al, 2003). An overall understanding of the use of tests is vital 
whether to infer results of clinical trials or for the point of routine clinical practices. 
However, the over interpretation of a diagnostic or screening test may lead to 
incorrect diagnosis; thus the correct evaluation and interpretation of sensitivity, 
specificity and predictive values are necessary. Sensitivity and specificity indicate 
how precise a test is, and this information is particularly important to clinicians than 
patients. However, patients are usually more concerned to know about the likelihood 
of having a disease (i.e. positive predictive value) or not having a disease (i.e. 
negative predictive value). These calculations are used in the simulation model to 
evaluate the effectiveness of the PAM system to detect changes in a person’s mental 
health state. 
 
4.6.1  The sensitivity of a test 
The sensitivity of a test measures the proportion of individuals who are correctly 
identified as having a specific disease. The formula for sensitivity is: 
Sensitivity  =  TP / (TP + FN), 
where TP is the number of true positives (people with the disease who test positive),  
FN is the number of false negatives (people with the disease who test negative) and 
(TP + FN) is the total number of patients who have the disease. 
 
4.6.2  The specificity of a test 
The specificity of a test measures the proportion of individuals who are accurately 
identified as not having a specific disease. The formula for specificity is: 
Specificity  =  TN / (TN + FP),   -53-
where TN is the number of true negatives (healthy people who test negative), FP is 
the number of false positives (healthy people who test positive) and (TN + FP) is the 
total number of healthy people. 
 
4.6.3  The Positive Predictive Value (PPV) 
The PPV of a test measures the proportion of individuals with positive test results 
who are correctly diagnosed. The formula for PPV is: 
PPV  =  TP / (TP + FP), 
where TP is the number of true positives,  FP is the number of false  positives  and 
(TP + FP) is the total number of patients who test positive. 
 
4.6.4  The Negative Predictive Value (NPV) 
The NPV of a test measures the proportion of individuals with negative test results 
who are correctly diagnosed. The formula for NPV is: 
NPV  =  TN / (TN + FN), 
where TN is the number of true negatives, FN is the number of false negatives and 
(TN + FN) is the number of patients who test negative. 
 
4.7  The Mood Disorder Questionnaire (MDQ) 
The MDQ is a short self-report form, designed to be easy to complete by patients and 
their caregivers. It is a screening tool to find out the best possible symptom threshold 
for recognising bipolar disorder. The MDQ form consists of three main questions 
(MDQ, 2000). Question 1 has 13 brief ‘yes’ or ‘no’ items, which are derived from 
both DSM-IV criteria and clinical experience. In Question 2, patients are asked a 
further ‘yes’ or ‘no’ question to check if any symptoms have occurred within the 
same time period. Finally, in Question 3, a 4-point scale is used to assess the level of 
functional impairment.   -54-
The MDQ was first validated against the SCID in a sample including 198 
patients from five psychiatric outpatient clinics (Hirschfeld et al, 2000). The 
sensitivity was 0.73 and the specificity was 0.9, confirming the MDQ as a good 
functional screening tool for bipolar disorder in the community. In a follow up study, 
Hirschfeld et al (2003) again validated the MDQ against an abbreviated version of 
SCID within a selected sample consisting of 695 participants from a nationwide 
epidemiological general US population. The MDQ was shown to have a sensitivity of 
0.28 and a specificity of 0.97.  According to the authors, the low sensitivity observed 
in the general population may have been due to the low sensitivity of the abbreviated 
version of SCID in this population. However, the high specificity of MDQ in this 
study screened out nearly all the true negatives. 
The MDQ has since been validated in various US settings by Miller C et al 
(2004), Hirschfeld et al (2005), Graves et al (2007) and Kemp et al (2008), and in 
other countries by Hardoy et al (2005), Weber et al (2005), Konuk et al (2007), Vieta 
et al (2007) and Twiss et al (2008). Unsurprisingly, the psychometric properties of the 
MDQ were shown to differ slightly according to the sample population studied.  
More recently, the MDQ was verified for a UK population. In this study, Twiss et al 
(2008) measured the sensitivity and specificity of the MDQ for a sample of 127 
patients, of whom 54 had BD and 73 had unipolar depression. The overall sensitivity 
of the MDQ was 0.76 and the specificity was 0.86.  
Table 4.1 summarises the performance of the MDQ screening tool in four 
different studies, all of which are based on using the initial scoring criteria described 
above: 
 
Study  Population  Sensitivity  Specificity 
Twiss et al (2008)  Psychiatric population  0.76  0.86 
Miller C et al (2004)  Psychiatric population  0.58  0.67 
Hirschfeld et al (2003)  General population  0.28  0.97 
Hirschfeld et al (2000)  Psychiatric population  0.73  0.90 
Table 4.1   Sensitivity and specificity of the MDQ in four different studies   -55-
4.8  The Bipolar Spectrum Diagnostic Scale (BSDS) 
The BSDS is another short self-report questionnaire used to screen for bipolar 
spectrum disorders. This story-based scale is scored using an algorithm requiring 
endorsement of 19 mood items by one of the following four statements:  i) “fits me 
very well”,  ii) “fits me fairly well”,  iii) “fits me to some degree”  and  iv) “does not 
really describe me at all” (BSDS, 2002a; 2002b). A score between 0 and 25 is then 
assigned, depending on the strength of the response. 
Ghaemi et al (2005) first investigated the BSDS screening tool for entire 
bipolar spectrum in two psychiatric clinics. A total of 95 patients took part in this 
study, 68 with BD (44 type I and 24 type II or NOS) and 27 with unipolar major 
depressive disorder. The performance of the BSDS was validated in its original 
version against the SCID interviews conducted by psychiatrists. The scale showed a 
high overall sensitivity of 0.76 (with 0.75 for bipolar type I and 0.79 for bipolar type 
II) and specificity of 0.85. Miller C et al (2004) had shown that the MDQ was not 
sensitive enough to detect milder form of BD, but Ghaemi et al (2005) showed that 
the BSDS is equally sensitive in detecting both severe (type I) and milder (type II) 
forms of BD. However, the MDQ was more recently shown to perform highly for 
entire bipolar spectrum disorders by Twiss et al (2008) in distinction; thus making it 
also helpful in identifying milder form of the illness. Ghaemi et al (2005) suggested 
using self-report questionnaires such as the BSDS as a complement to the MDQ and a 
supplement to clinical interviews in screening for bipolar spectrum disorders.  
 
4.9  The CIDI-based bipolar disorder screening scale 
The CIDI (Composite International Diagnostic Interview) is another screening tool 
for detecting bipolar spectrum disorders. This scale starts with asking individuals two 
“stem questions”: a “euphoria” stem question and an “irritability” stem question 
(CIDI, 2001). If the respondent answers yes to one of these stem questions, s/he then 
proceeds to the “criterion B screening” question. If the answer is again yes, s/he 
moves to the 8 or 9 further “criterion B symptom” questions.   -56-
Kessler et al (2006) validated this scale among the US household population. 
The scale was shown to have the ability to identify a high percentage of true cases 
while minimising the number of false positives. The sensitivity was between 67% and 
96%, which is comparable with the MDQ (Twiss et al, 2008) and the BSDS (Ghaemi 
et al, 2005). However, the two stem questions are not phrased in a simple manner; 
thus some bipolar patients may respond to these stem questions inappropriately. 
Hence, a genuine case may be missed simply because of the participant’s failure to 
answer correctly one of the two stem questions to start with, and this is a serious 
limitation. Furthermore, patients with poor insight may not be able to complete this 
screening questionnaire without assistance. 
 
4.10    The Hypomanic Personality Scale (HPS) 
The HPS is an instrument that could possibly be used to screen for bipolar affective 
disorders. Eckblad and Chapman (1986) initially developed this scale as a 48-item 
self-report questionnaire to assess stable hypomanic characteristics. It was shown that 
participants scoring highly on this scale undergo episodes of mood disorders. This 
scale was validated in a large sample of adolescents (Klein et al, 1996; Meyer et al, 
1998). In a 3-year follow-up study, Meyer et al (1998) found that this scale predicted 
depressive symptoms but not anxiety. Klein et al (1996) found similar results. Over a 
13-year follow-up study, Kwapil et al (2000) reported the scale to be prognostic for 
bipolar spectrum disorders with a prevalence of 25% for the risk group compared 
with none of the patients who were part of the control group. Recently, Meyer and 
Hautzinger (2003) conducted a study to verify this scale in a sample of 212 German 
university students. Meyer and Hautzinger (2003) replicated the findings of Eckblad 
and Chapman (1986) that participants with high scores experienced more manic or 
hypomanic episodes than participants with low scores.  
One of the downsides of HPS to its use in general practice settings is the time 
required to complete a 48-item self-report questionnaire. This scale was developed to 
target personality traits. Also, the episodic nature of hypomania was not investigated.   -57-
The HPS may be more appropriate in the psychiatric setting rather than in general 
practice. 
 
4.11    The Hypomania Checklist (HCL-32) 
The HCL-32 is a self-report questionnaire that includes 32 ‘yes’ or ‘no’ questions. 
This tool has mainly been developed to detect bipolar disorder patients who are being 
misdiagnosed as having major depressive disorder. Recently, Angst et al (2005) 
tested the performance of the scale in a sample of 426 adult psychiatric patients (266 
with bipolar disorder and 160 with major depressive disorder). The factor structure of 
HCL-32 (“active/elated” hypomania and “risk-taking/irritable” hypomania) was fairly 
similar in both samples. A score of 14 or more yielded the optimal cut-off for 
sensitivity (0.80) and specificity (0.51) to differentiate between bipolar disorder and 
major depressive disorder. The HCL-32 was shown to be sensitive enough for 
hypomanic symptoms, but did not distinguish between type I and type II BD. 
Although the sensitivity of the HCL-32 is fairly similar to that of the MDQ, its 
specificity is much lower. Besides, the HCL-32 is not as quick and easy to administer 
as the MDQ. 
 
4.12    Use of scales to rate disease severity 
The Young Mania Rating Scale (Young et al, 1978), the Altman Self-Rating Mania 
Scale (Altman et al, 1997), the Internal State Scale (Bauer et al, 2000) and the Bipolar 
Affective Disorder Dimensional Scale (Craddock et al, 2004) are some of the rating 
scales that have been used to measure the severity of symptoms of patients with 
bipolar disorder. All of these scales must be administered by trained clinicians. 
Such scales or staging criteria are of great potential value in developing 
disease state transition models, as they provide a quantitative measurement for 
representing the disease state. Thus, they are of particular interest to the OR modeller, 
especially if any particular scale turns out to be universally accepted, such as are 
common in cancer staging. 
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4.12.1   The Bipolar Affective Disorder Dimensional Scale (BADDS) 
Craddock et al (2004) proposed the BADDS in order to overcome the drawbacks of 
simple classification and diagnostic scoring systems, which assign BD patients to one 
of a small number of distinct categories. BADDS is a numerical rating system, 
building upon the existing categorical classifications, which can be used in addition to 
traditional diagnostic procedures. BADDS has four dimensions: Mania, Depression, 
Psychosis and Incongruence. Each dimension uses integers in the range 0 to 100. The 
dimensional ratings are formulated using all available clinical data, including 
psychiatric case notes and semi-structured psychiatric interviews. The criteria used to 
make bipolar spectrum diagnoses follow DSM-IV and ICD-10. The BADDS has been 
tested for psychiatric assessment in family-genetic studies of bipolar disorder, 
unipolar depression and puerperal psychosis. Each of 20 patients was rated by two 
psychiatrists and seven psychologists using the BADDS dimensions to reach a 
consensus. Inter-rater reliability of this scale was found to be excellent, but sample 
limitations are clear. BADDS has been used in clinical samples, but it requires further 
validation study in a bigger sample in non-specialist and community based settings. 
The idea of dimensional classifications may provide a better structured approach than 
a conventional categorical approach, but it is clearly labour-intensive in practice and 
its interpretation in terms of care management may not be easy.  
 
4.13    Long-term self-monitoring of bipolar patients 
Some bipolar patients may experience different signs, symptoms, forms and features 
of the illness over their lifetime (Whybrow et al, 2003). It is difficult to set up 
medication programmes for such patients unless the early warning signs and the 
number and length of episodes can be identified (Leverich and Post, 2003). 
Therefore, long-term monitoring of the illness can be beneficial for patients, 
caregivers and clinicians to improve effective treatment plans (Leverich and Post, 
2003). 
To assess the effectiveness of maintenance treatment for bipolar disorder, a 
patient’s course of illness need to be monitored in a systematic and accurate manner.   -59-
Driven by this need, self-monitoring tools such as the National Institute of Mental 
Health Life Chart Method and the Clinical Monitoring Form have been developed to 
be used by both patients and clinicians to achieve a depiction of the patterns of the 
illness in a clinically useful layout (Baldassano, 2005). 
 
4.13.1   The Life Chart Method (LCM) 
The LCM is the most widely used graphical method among those currently available. 
It allows a daily assessment of mood status to be documented, based on the level of 
mood related functional impairment (Denicoff et al, 2000; Leverich and Post, 2003).  
Hence, an imminent manic or depressive episode can be recognised early on. Life 
charting provides a retrospective viewpoint on the illness and allows clinicians and 
patients to recognise features that may cause episodes. An electronic version of the 
LCM form has recently been developed for use on a handheld device (Scherer, 2002). 
The LCM was initially developed for use in the research setting by professionals, but 
patients can also use the forms nowadays (Denicoff et al, 2000). Many interested 
bipolar patients have been trained to complete both versions of the LCM forms as 
part of their treatment plan.  
 
4.13.2   The Clinical Monitoring Form (CMF) 
The CMF is another method designed to monitor regularly the mood status of bipolar 
patients. The CMF has been validated against formal rating scales by Sachs et al 
(2002), and shown to be useful to the clinician to describe a patient’s disease 
progression. The CMF is based on the compilation of factors that may trigger an 
episode. A computerised version of the form is presently under development. 
 
4.14    Drawbacks of self-monitoring systems 
Whether electronic-based or paper-based, a self-monitoring system may suffer from 
the following problems: 
•  it may be too time consuming, given the amount of data entry involved   -60-
•  it suffers from its inbuilt dependence on the accuracy, completeness and 
honesty of patient-reported data 
•  use of routine self-report monitoring for clinical purposes may be expensive 
•  it requires a great deal of energy from patients 
•  it may not provide a sense of control over a patient’s life 
•  regular monitoring requires motivation which some patients may lack 
•  intentionally or unintentionally, patients may forget to record the exact details 
later on (Whybrow et al, 2003) 
•  existence of other illnesses may prevent patients from recording data on time 
•  overall data quality may be negatively impacted by data entry errors 
•  it does not allow patients to document their physiological and contextual 
details that could be helpful for treatment purposes (Blum and McGill, 2008) 
•  self-monitoring has been shown to have fallen short of reducing depressive 
relapses (Perry et al, 1999) 
•  the National Collaborating Centre for Mental Health state that “most self-
report scales are not very specific and are less sensitive to detecting problems 
with cognition and functional impairment” (NCCMH, 2006). 
However, Blum and McGill (2008) state that monitoring via a set of sensors 
may free patients from the above drawbacks. They also advocated that mood status 
related data could well be reported via sensor networks as well as self-reporting in 
order to provide details about the course of a patient mental health, because this may 
help set up even better therapeutic association between patients and caregivers. 
 
4.15    Performance comparison of bipolar screening tools 
Most of the self-appraisal screening tools discussed in this chapter are clinically 
useful and timesaving. In particular, the BSDS and the MDQ are both sensitive   -61-
enough to be used to identify bipolar spectrum disorders in psychiatric practice 
(Ghaemi et al, 2005; Twiss et al, 2008). Both of these scales can be used as a 
complement of each other (Ghaemi et al, 2005). Although the MDQ has been 
validated in psychiatric settings across different countries (Hirschfeld et al 2000; 
Miller C et al, 2004; Weber et al, 2005; Konuk et al, 2007; Vieta et al, 2007; Twiss et 
al, 2008), the BSDS still requires further validation. In most cases, evaluation of the 
sensitivity and specificity of the MDQ met the desired requirement in identifying a 
high ratio of true positives while minimising the number of true negatives. 
An ideal screening instrument for common use in clinical practice should be 
short and simple to complete. The MDQ tool is slightly shorter than the BSDS (13 as 
opposed to 19 questions). The MDQ has been successfully validated in a UK 
psychiatric practice (Twiss et al, 2008), whereas the BSDS has not yet been validated 
in any UK setting. However, both tools allow fast and simple processing. Table 4.2 
shows the performance comparison of these two screening tools: 
 
  MDQ  BSDS 
Study conducted by  Twiss et al (2008)  Ghaemi et al (2005) 
Population  Clinical  Clinical 
Sample size  127  95 
Validated against  SCID interviews  SCID interviews 
Overall sensitivity  0.76  0.76 
Overall specificity  0.86  0.85 
Sensitivity for bipolar I  0.83  0.75 
Sensitivity for bipolar II  0.67  0.79 
Table 4.2   Comparative performance of the MDQ and the BSDS 
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5.  OR Modelling in Healthcare 
Mathematical Operational Research (OR) modelling approaches have been widely 
applied within healthcare for many decades and there is a massive literature on this 
topic. One aspect of this literature deals with the application of modelling techniques 
to deal with organisational and process issues such as resource allocation and service 
redesign. Examples of organisational modelling include scheduling outpatient clinics, 
staffing hospital Emergency Departments and scheduling surgical lists. However, the 
literature related to this thesis concerns the use of OR approaches to increase medical 
understanding of diseases, to evaluate treatment interventions and improve clinical 
decision-making. This chapter focuses on two issues: why healthcare is complex and 
how this complexity can be overcome.  
 
5.1 Introduction 
OR modelling and simulation are well-known scientific methods that have been 
widely used and proven in manufacturing, logistics, airlines and defence. The use of 
OR in healthcare began in 1952 (Flagle, 2002) and has been increasing ever since 
(Eldabi et al, 2008; Naseer et al, 2008; Jahangirian et al 2010, Lagergren, 1998). In 
the UK, healthcare is regarded as one of the key growth areas for OR (Royston, 
2009). As in other industrial sectors, a variety of strategic and operational decisions 
have to be made within healthcare. The “production process” in healthcare usually 
consists of a clinical process (i.e. clinicians’ decision-making behaviour) and 
operational processes (i.e. the delivery of a care service, along with the resources 
required to provide it). The clinical process is the core process in which a patient’s 
health problem is diagnosed and treated through a set of linked decisions and tasks. 
On the other hand, operational processes involve the resources that support the 
clinical process. Lessons can be learned in healthcare from the application of   -64-
modelling and simulation in other industries. Taylor and Robinson (2006) identify the 
use of modelling and simulation in healthcare as a research priority. 
Few would disagree with the statement that the complexity of any healthcare 
system is overwhelming. Pressure on healthcare providers is increasing worldwide, 
for many reasons: quality, safety and performance management, constant 
organisational restructuring, the need to provide a wide range of services, increased 
public expectation, demographic changes and the ageing population, government 
policies, clinical and pharmaceutical advances (and associated costs), and so on.  
Healthcare is an enormous business in the UK, where the National Health 
Service (NHS), the third largest employer in the world, spends more than £70 billion 
annually that approximates to £8m hourly (DoH, 2006). In the USA, healthcare is 
regarded as the main domestic industry (Carter, 2002). Healthcare spending has risen 
rapidly over the last decade and this trend is unlikely to change. Royston (2005) 
reported over 7% annual growth in NHS spending. The pressures to control costs and 
to provide various healthcare services and facilities are increasing all the time. 
Royston (2005) noted four important performance challenges in healthcare, 
including i) better quality and safety, ii) better access, iii) better personalisation and 
more participation and iv) better value for money. Healthcare systems require 
effective and sustainable decision making tools to help clinicians and administrators 
make better decisions. Decision-making is even more difficult when it involves a 
group of stakeholders with different perspectives, as is often the case in health. For 
example, patient benefits and provider costs often conflict when designing services. 
However, quantitative models can aid decision-making in health and expert 
opinions can easily be incorporated. Quantitative modelling enables health service 
managers to decide in a reasonable and impartial way whether to invest in specific 
treatment or prevention policies (Cooper et al, 2007). To this end, one may analyse 
complex design issues and treatment pathways through modelling in a risk-free 
setting without having to wait years to prove an improvement (Rawlins and   -65-
Littlejohns, 2004). It has been argued by Eldabi et al (2007) that modelling and 
healthcare systems should gain benefits from each other in a “symbiotic” manner. 
 
5.2  Modelling in healthcare 
A model represents a simplified form of a real world process. Modelling, as an 
investigational method, can reduce cost, risk and interruption. Pidd (2010) defines a 
model as “an external and explicit representation of part of reality as seen by the 
people who wish to use that model to understand, to change, to manage and to 
control that part of reality”. OR modelling is about using common sense, but it may 
also require using a fair bit of mathematics (Crane, 2007). Figure 5.1 shows a simple 
idea of OR modelling: 
 
 
Figure 5.1   The basic principles of modelling 
 
Our main focus in this thesis is on disease models. OR models can be used not 
only for the more traditional organisational issues described above but also for 
representing disease processes. Today, disease management is an effective way to 
control healthcare costs and to improve
 quality of care for patients who especially 
suffer from chronic diseases. The natural history of chronic diseases such as cancer, 
HIV/AIDS and depression is important for clinical reasons. It is, therefore, important 
to quantify a patient’s progression through different stages of chronic disease for 
early detection, prevention and treatment purposes (Shih et al, 2007). The progression 
of a chronic disease can be modelled and studied through a multi-state model (Chan 
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Generally, building a disease model requires knowledge about the disease 
itself, together with the care required and the treatments available in each stage of 
illness. Modelling requires detailed knowledge of the range of outcomes of any 
treatment, including any side-effects. It requires a good understanding of the clinical 
conditions that cause distress, dysfunction or difficulty to the person afflicted. A 
disease model can also incorporate other features, such as biological or physiological 
markers, psychological or sociological aspects. OR modelling can help understand 
disease processes better and form knowledgeable preferences of medical actions. The 
healthcare community has become increasingly more willing to apply modelling 
techniques as a common means to reach well-informed clinical, policy and treatment 
decisions in real world settings (Lagergren, 1998). 
Despite this, and despite the large academic literature on this topic, the impact 
of OR simulation models has been somewhat limited in healthcare settings (Lowery 
et al 1994, Brailsford 2005 and Proudlove et al 2007). Many reasons have been put 
forward for this disappointing impact of OR simulation models in healthcare.  
Authors such as Butler (1995), Robinson and Pidd (1998), Harper and Pitt (2004), 
Brailsford (2005), Proudlove et al (2007) and Eldabi (2009) all tried to shed light on 
this issue. Some of the reasons are listed below: 
•  conflict of interests between modellers and stakeholders 
•  low levels of mathematical skill within health service professionals 
•  overcomplicated models published in OR academic journals 
•  lack of OR papers specifically aimed at healthcare professionals 
•  lack of awareness with the process and jargon of OR 
•  lack of in-house OR capability 
•  engaging external OR consultants is costly 
•  translating theory into practice is never easy   -67-
•  cultural unwillingness to embrace computer-based models of patient care 
processes 
•  natural complexity and multiple interactions in healthcare environment 
•  rapidly changing national policies 
•  lack of involvement of stakeholders in the modelling process and difficulty 
keeping stakeholders on board continually. 
 
In the view of Jun et al (2009), the role of OR modelling in healthcare would 
have been even more extensive had the healthcare community not lacked knowledge 
of a wide variety of approaches. However, Jun et al (2009) argue that clear guidelines 
can help the healthcare community to use various efficient modelling approaches 
acceptably and fruitfully, even though people may find an approach unfamiliar to 
start with. Lowery et al (1994) and Brailsford (2005) provide excellent discussions on 
the barriers (e.g. methodological suitability, stakeholder issues and data problems) of 
putting OR simulation models into practice in healthcare, and proposed a number of 
potential ways that the healthcare community can generate more uptake. 
Nevertheless, disease modelling has been used very successfully in healthcare 
to evaluate treatments, screening and other interventions (Davies and Davies, 1994; 
Russell et al, 1996; Mauskopf, 1998). Such models permit experimentation with 
different policies, which may be too expensive, too time-consuming (or even 
unethical!)  to test in reality with a randomised controlled clinical trial. The aim of the 
model is to act as a risk-free environment in which to compare options and gain 
deeper understanding. A typical structure for such a model is depicted in Figure 5.2 
below. The boxes represent system states, which may, as in this case, simply be 
disease states. Depending on the modelling approach chosen, the objects in the 
system (i.e. patients) move individually or as a group from state to state through time. 
Different patients may spend different times in each state or follow different 
pathways through the system.    -68-
 
Figure 5.2   Transitions between different states in a disease model 
 
5.2.1    OR models in chronic disease management 
A chronic disease is a long-lasting, persistent or recurrent disease state. Examples 
include diseases such as diabetes, heart disease, asthma and (of course) mental 
disorders. Chronic diseases can be preventable and are often manageable by the 
patient themselves, although they tend to be very costly due to their long term and 
recurrent nature. Most chronic disease management models are concerned with cost-
effectiveness analysis. Only a smaller body of work is dedicated to operational 
processes to improve patient flow. 
 
5.2.2   Types of model in healthcare 
The healthcare modelling literature contains examples of an extraordinarily wide 
range of mathematical OR approaches such as statistical analysis, simulation 
modelling, queuing theory, linear programming and integer programming. These 
methods are mainly used either to locate the optimal or a near optimal solution. In an 
extensive systematic review, Brailsford et al (2009) discovered a wide range of 
methods that are being used for healthcare modelling. They found statistical analysis 
as the most widely used method for healthcare modelling, while the second most 
widely used method was simulation modelling. Lagergren (1998) provided a broad 
range of bibliographic examples of operational applications of modelling, covering 
diseases such as HIV/AIDS, diabetes, cancer, heart disease and dementia. Fone et al 
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of a wide range of OR modelling techniques that are applied to devise improved 
resource allocation decisions and healthcare planning. 
 
5.3  Decision tree models in healthcare 
Decision trees are widely used in disease models where clinical decisions have to be 
made and the long-term implications analysed. Decision trees are a family of analytic 
methods that include Chi-square Automatic Interaction Detector and Classification 
and Regression Trees. In principle, a decision tree can be used to represent any 
decision problem that complies with the assumption that all patients behave 
independently and do not compete for resources or interact with each other in any 
way (Barton et al, 2004). Decision trees or Markov models are often used to represent 
the flows of patients through various disease states. Many experts agree that decision 
tree models are inappropriate for modelling long-term health interventions and 
situations where events take place more than once (Sonnenberg et al, 1994; Karnon 
and Brown, 1998). 
 
5.4  Markov models in healthcare 
Markov models are used to represent a patient’s stochastic progression through 
different health states over time. In a Markov model, a patient is assumed to be in one 
of a finite number of discrete health states (Sonnenberg and Beck, 1993). A Markov 
model is one of the most useful tools available to healthcare researchers to evaluate 
disease progression (Karnon, 2003). This approach offers exact, analytical outcomes 
for both time dependent progression and the steady state of the system. At each step, 
a patient may remain in his/her present state, go back to a previous state or move to 
totally a new state with a known probability distribution or rate of transition from one 
health state to another. The changes in state are called transitions, and during a time 
step or cycle, only a single state transition is allowed. The transitions between 
Markov states can be shown in a diagram involving all clinically significant events 
(see Figure 5.3): 
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Figure 5.3   Example of state transitions within a Markov model 
 
Markov states can be structured in a state transition matrix, which facilitates 
numerical evaluations. A state transition matrix is a square matrix that represents the 
probabilities of moving from one state to another. Each row of a transition matrix 
sums to one, since each row contains the probabilities of all possible transitions from 
the current state. It is more convenient to model prognosis for chronic conditions by 
means of Markov models (Sonnenberg and Beck, 1993). However, using a Markov 
model, it may not be easy to follow a patient’s disease history accurately, due to the 
Markov “memoryless” property, which can formally be written as: 
                        () ( ),   Pr Pr 1 1 1 1 1 1 t t t t t t t t x X x X x x X X x X = = = = = + + + + K K              (5.1) 
where the state of the system at time (t + 1) depends only on the state of the system at 
time (t). This is not an issue when disease progression is independent of a patient’s 
past medical history. However, this can be a limiting assumption since past medical 
history evidently plays a role in the progression of many diseases. This problem can 
be overcome by incorporating multiple health states, to capture small changes so that 
the disease pathway to a particular state is considered (Karnon and Brown, 1998; Lay 
et al, 2006). However, the use of too many health states in a Markov model may lead 
to a combinatorial “explosion” – known as the curse of dimensionality – making it 
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this, simulation techniques can efficiently be used to model large Markov processes, 
and may often be the only practicable alternative (Klein et al, 1993). 
A Markov model can be solved as a cohort simulation (one replication with 
many patients), as a Monte Carlo simulation (many replications, each for a single 
patient), or – if the number of states is tractable – by standard matrix algebra 
(Sonnenberg and Beck, 1993). Simulation is a relatively simple and flexible way to 
solve the model. A spreadsheet package can be used to model a deterministic Markov 
process. However, to model a stochastic Markov process, the spreadsheet would 
require use of a risk analysis add-in such as @Risk (Palisade, 2008) or Crystal Ball 
(Oracle, 2010) to solve the model stochastically, using randomly chosen input 
parameters from specified probability distributions. It is easier to represent time-
dependent and recurrent events through Markov models, but they cannot model 
interactions between individuals (Barton et al, 2004). To allow interactions between 
individuals, which may occur in an infectious disease, discrete-event simulation 
models should be used instead. 
Karnon (2003) used both Markov and discrete-event simulation models to 
assess the cost-effectiveness of the treatment of early breast cancer therapies. Their 
intention was to compare the outputs so that they can recommend an appropriate 
modelling technique. The outputs obtained from both models were fairly similar, but 
the long run time of the discrete-event simulation model was a notable disadvantage 
when compared to the run time of the Markov process. Furthermore, the discrete-
event simulation model required to include more inputs. The author recommended the 
Markov process as an optimal method for their studied case study. 
 
5.5  Simulation modelling in healthcare 
A philosophy of approximation is expressed as “it is better to be approximately right, 
than precisely wrong”, which is also the philosophy of simulation modelling. 
Philippatos (1973) provides a useful definition of simulation: an artificial setting 
within which to assess the behaviour of the real-world system. Table 5.1 shows the 
use of simulation modelling in various sectors:   -72-
 
“Simulation Modelling” AND  Google Hits 
Environment 136,000 
Health  87,000 
Transport 57,000 
Agriculture  56,000 
Defence 33,000 
Table 5.1   Use of simulation modelling by sector.  Source: Royston (2005) 
 
In recent years, the use of simulation modelling for healthcare issues around 
the world has been recognised, since it is highly flexible and provides a risk-free 
setting in which to experiment. The degree to which simulation models could be 
applied in a range of healthcare areas varies from administrative or operational to 
medical or clinical issues (Pritsker, 1986). Mielczarek (2004) showed five key 
healthcare areas such as epidemiology, health care system operations, health and care 
systems design, medical decision making and crisis management, which have been 
supported by the simulation models. Lagergren (1998), in his paper, reviewed 
simulation models that have been applied to predict future incidence, prevalence and 
mortality for a wide range of diseases, as well as to plan disease intervention policies 
and assess various screening schemes. 
The use of simulation in healthcare began in the 1960s (Brailsford, 2005),  but 
the recognition of applying simulation methods for operational and clinical decision 
making has not been appreciated until recently (Fone et al, 2003). The periodic 
reviews of the use of simulations in healthcare conducted by Wilson (1981), Davies 
(1985), Lehaney and Hlupic (1995), Jun et al (1999) and Fone et al (2003) cover 
many healthcare related issues such as clinical decision-making, scheduling, resource 
allocation, screening and diseases. Jun et al’s (1999) review of simulation studies 
found 8 studies from 1973 to 1977 and 28 studies from 1993 to 1997, and this 
provides an indication of increased acceptance of the use of simulation. Using Google   -73-
Scholar, Royston (2005) showed the increased trend of the number of citations of 













Figure 5.4   Growth in use of simulation in healthcare.  Source: Royston (2005) 
 
Simulation models have been applied for out-patient scheduling appointments 
(Worthington and Brahimi, 1993), capacity planning (Ridge et al, 1998), surgical bed 
planning (Millard et al, 2000), patient flow and resource utilisation (Rotondi et al, 
1997) and waiting list management (Benneyan, 1997). Simulation has been massively 
applied within emergency departments. Brown et al (1999), Lane et al (2000), Coats 
and Michalis (2001), Eldabi et al (2002), Brailsford et al (2004) and Lattimer et al 
(2004) are amongst the many who have implemented a range of simulation 
techniques to improve aspects of healthcare within emergency departments. 
 
5.5.1  Discrete-event simulation models in healthcare 
Through the use of statistical distributions, discrete-event simulation (DES) models 
replicate the stochastic behaviour of a healthcare system over time very well. One of 
the key advantages of this method is its ability to model complex scenarios. DES can 
capture a vast amount of detail complexity. It is a flexible method which can describe 
health policy issues involving large population groups, but often specialist analytic 
knowledge is required to achieve greater flexibility (Davies et al, 2003).    -74-
Within a DES model, entities (patients) move from one event to another in 
sequential order. This type of model can capture individual attributes or 
characteristics. It is possible to assign significant risk factors to each individual, such 
as sex, age, disease history and attitude towards treatment, which may influence the 
path taken and the time between events (Davies and Davies, 1994). The pathways and 
times of patients’ future events are typically sampled from parametric or empirical 
distributions derived from clinical data (Davies et al, 2003). 
Heeg et al (2005) and Lay et al (2006) amongst many others argue that DES 
models are useful when it is necessary to consider a participant’s past history to 
observe how it affects the course of the illness over time. Furthermore, unlike a 
decision tree or a Markov model, a DES model can incorporate interaction between 
individuals. Therefore, DES models allow more complex depictions of a system than 
Markov models (Campbell et al, 2001). The flow of patients through the healthcare 
process can be captured by such a model, and DES is clearly an ideal tool to describe 
the performance of a system in terms of patient arrival time, waiting time, service 
time, length of stay and capacity within an overall treatment network. However, DES 
modelling may be very time-consuming since such an individual-based model 
requires many repetitions to obtain statistically reliable approximations of the 
outcomes. In addition, it may require expert knowledge before developing and 
verifying such models (Davies et al, 2003). 
Discrete-event simulations have been applied in a wide range of disease areas 
such as major depression (Lay et al, 2006), drug misuse (Zarkin et al, 2005), renal 
diseases (Huybrechts et al, 2005), mother-to-child HIV transmission (Rauner et al, 
2005), gastric cancer and peptic ulcer (Roderick et al, 2003), liver transplantation 
(Ratcliffe et al, 2001), coronary artery disease treatment (Cooper et al, 2002) 
emergency admissions (Bagust et al, 1999) and outpatient clinics (Harper and 
Gamlin, 2003) and early breast cancer (Brown et al, 1999). Although discrete-event 
simulation models have successfully been applied at operational levels, its use to 
improve health policy has not yet been practiced (Gunal and Pidd, 2005).   -75-
An OR analyst may need to take account of human behaviour elements of the 
people involved to provide effective treatment. For example, distinction in human 
behaviour elements such as sleeping, change in appetite and talkativeness may 
indicate a treatment plan for depression. It is possible to include parameters that 
depend on human behaviour elements into OR models, and to this end, Brailsford and 
Schmidt (2003) describes the feasibility of incorporating human behaviour elements 
in a discrete-event simulation model to provide solutions for clinical decisions. 
 
5.5.2  Monte Carlo simulation in healthcare 
We noted in section 5.4 that one of the drawbacks of both decision trees and Markov 
models is the combinatorial explosion in the state-space as more and more complex 
disease states are introduced. A common approach for dealing with this problem is to 
use Monte Carlo simulation. Such models can handle this complex structure without 
growing unmanageably large (Barton et al, 2004). Monte Carlo simulation is a 
recognised approach in the field of healthcare, but it requires the analyst to set up a 
mathematical model of the process. 
Put simply, Monte Carlo simulation uses the principle of random sampling to 
estimate outcomes of interest, which are too complex (or impossible) to be calculated 
using a mathematical formula. The values of the variables are sampled from 
probability distributions using simulation. Monte Carlo simulation methods have 
been widely applied in the construction industry, for assessing risks of infrastructural 
projects, calculating electricity options and forecasting the future contribution of 
biotechnology industry. 
Using Monte Carlo simulation, like DES, it is possible to assign attributes to 
the entities within a model, which determine how that entity will behave. Moreover, 
the model can update these attributes while it is running. It is, therefore, possible to 
track individual entities over time using the output from a random number generator. 
Typical applications include cost calculations, inventory control calculations, demand 
projections, disease progressions and analyses of life years and quality-adjusted life 
years.   -76-
Monte Carlo simulations can be conducted using spreadsheet software such as 
Microsoft Excel. The additional functionality required to run multiple repetitions 
using Monte Carlo simulations is provided by add-ins such as @RISK, which can 
analyse the effect of varying inputs or outputs of the system being modelled. Through 
a Monte Carlo simulation approach, it is possible to run a highly complex scenario 
and determine the probability of a particular outcome. Moreover, crucially, this is not 
a point estimate: the whole range of likely outcomes can also be obtained. 
Furthermore, it is easier to test and improve model assumptions to forecast risk more 
accurately. 
Economic evaluations of healthcare interventions can be performed using 
Monte Carlo disease simulations. Monte Carlo disease simulation works on an 
individual patient level, explicitly capturing the effect of variability between patients 
in both disease progression and response to treatments (Richter and Mauskopf, 1998). 
In addition, the question of risk related with individuals for whom the aggregate 
solutions produced by decision trees or Markov models are inappropriate can be 
addressed through a Monte Carlo disease simulation (Richter and Mauskopf, 1998).  
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6.  OR Models in Mental Health 
In the preceding chapter, we reviewed a range of Operational Research (OR) 
approaches that could be applied for various diseases. This chapter focuses on the use 
of OR modelling and simulation approaches in mental healthcare. We begin, 
however, by reflecting briefly on the philosophical nature of health and healthcare, 
which is of particular relevance in mental health. 
 
6.1 Introduction 
Mental health, which is a key public health issue, can be defined as “a state of 
balance between the individual and the surrounding world, a state of harmony 
between oneself and others, a coexistence between the realities of the self, that of 
other people and that of the environment” (Sartorius, 1983). Simply put, this is 
about how one thinks, feels and behaves. Shah (1982) states that mental health is “the 
most essential and inseparable component of health… An integrated component of 
public health and social welfare programmes”. 
Mental health indisputably needs fostering, promoting and protecting to ensure 
that people with mental health problems can nevertheless enjoy a good quality of life, 
productive work, and meaningful interactions with others. Mental health care needs 
can be delivered in hospital and primary care settings, social services and self-help 
groups. Mental healthcare services are not merely confined to the treatment of 
affected people, but are closely related to all other health activities. 
 
6.2  Biomedical and social models of mental health 
Traditionally, medical care is usually defined by the “biomedical” model, which sees 
health as the absence of disease. In diagnosing diseases, physicians have been using 
the biomedical model of medicine as a conceptual model of illness for many years. 
Excluding the role of social factors or individual subjectivity, the focus of the   -78-
biomedical model of a disease is simply on physical or biological factors such as the 
pathology, the biochemistry and the physiology so as to comprehend a person’s 
medical illness or disorder. The biomedical model also neglects the fact that a 
diagnosis is a result of a social mediation between doctor and patient (Annandale, 
1998). Diseases such as mental disorders, heart disease and diabetes are very much 
dependent on a person’s actions and behaviours. Therefore, it is restrictive not to take 
social factors or individual behaviour into account since, for example, it omits the 
idea of disease prevention. 
Of course, the biomedical model has been undeniably useful for reducing 
morbidity and premature mortality. In mental health services, the biomedical model 
has been the dominant model since the main purpose behind the work of medically 
trained psychiatrists is the diagnosis and treatment of mental illness or disorders. 
However, mental health is a prime example in which the biomedical model has clear 
limitations. Therefore, there is a need for a much broader model of understanding 
mental health than the biomedical one alone to influence the work of psychiatrists, 
since mental health is a complex area in which one must focus not only on the disease 
alone, also on the role of way of life in mental health. 
Psychiatrists are typically driven by the idea that medical science must 
alleviate mental diseases in order to return people to a state of health. This view 
regards health as an attribute that can be determined by the presence or absence of 
disease. The emphasis on the absence of disease is a significant indicator of good 
health, but ignores the effect of other important influences. The WHO states that 
“Health is a state of complete physical, social and mental well-being and not merely 
the absence of disease or infirmity. The enjoyment of the highest attainable standard 
of health is one of the fundamental right of every human being, without distinction of 
race, religion, political beliefs or economic and social conditions” (Constitution of 
the WHO). 
We have seen that mental illness is usually caused by a mixture of individual, 
social and environmental factors. Thus, the social model can be effective in the   -79-
prevention of mental illness since it considers wider determinants (e.g. educational, 
cultural, social, spiritual, socio-economical and environmental), which may have an 
impact on people’s health. Dalgren and Whitehead (1991) developed a model to show 
how a variety of factors influence health positively or negatively by trying to map the 
relationship between the individual, their environment and disease. The social model 
searches to educate people and allow them to recuperate control of their lives. 
Duggan et al (2002) argue that the progressive social model in mental health 
should have the following key characteristics: 
•  it should embody the intricacy of human health and well-being 
•  it should pay attention to the internal and the external worlds of individuals 
•  it should facilitate interaction between social factors and biology 
•  it should commit to the development of theory and practice 
•  it should encompass the critical evaluation of process and outcome. 
 
6.3  OR modelling for mental illness 
The main purpose of this chapter is to review the current literature in relation to the 
use of OR techniques for mental illness, specifically focusing on the application of 
simulation for bipolar disorder. The English language academic and clinical literature 
was searched for documents in which the key focus was OR modelling and 
simulation in mental healthcare. We searched the electronic databases Medline and 
Web of Science, as well as the internet search engine Google Scholar and the web 
library catalogue TDNet.  
It was clear from the literature review that the use of OR methods in mental 
healthcare is mainly limited to service system planning and cost-effectiveness 
analysis rather than disease modelling. For instance, Pagel et al (2008) applied OR 
techniques to reconfigure services with a view to improve access to a generic mental 
healthcare service. There are many reasons for this paucity of OR models to describe 
chronic psychiatric disease processes:   -80-
•  unlike most physical diseases, there are few recognised staging or 
classification systems for mental disorders which lend themselves to 
modelling. The classification of mental illnesses is a crucial issue. The 
international classification of diseases (ICD-10, 1993) and the diagnostic and 
statistical manual for mental disorders (DSM-IV-TR, 2000) are currently the 
two main recognised diagnostic classification systems used to classify mental 
healthcare. However, there is a considerable scientific debate about the 
different kinds of categorisation (Manning, 2006) and psychiatrists still make 
diagnoses mainly by talking to the patient, using subjective judgments and 
their experience 
•  there is no single cause of any mental illness: the reasons for mental health 
problems are complex, and this complexity limits the practicality of modelling 
•  fear, misunderstanding and stigma are commonly associated with mental 
illness 
•  in mental illnesses it is difficult to quantify the risk of specific outcomes or 
behaviours. For example, one study shows that mental health professionals are 
mistaken 95% of the time when predicting aggressive behaviour (Ennis, 1972) 
•  the ethical aspects of research in this field can be very challenging 
•  it is extremely difficult to identify and recruit people who are at risk for mental 
disorders for prediction or prodromal behaviour studies (Heinssen et al, 2003) 
•  it is difficult to recruit sufficiently large samples to provide adequate statistical 
power to test hypotheses concerning illness onset and progression 
•  at times, it is difficult to persuade clinicians to collect relevant data 
•  in the UK, there is no national classification of mental health interventions 
except for children and adolescents (Elphic, 2007) 
•  it is difficult for professionals to arrive at an agreed approach in psychiatry. 
Menninger, in the 1960s, argued that diagnostic classification should be 
completely discarded (Farmer, 1997)   -81-
•  lack of information technology and large databases 
•  reluctance of psychiatric patients to take part into longitudinal research studies 
(Whybrow et al, 2003) 
•  lack of research funding for mental health (“Cinderella diseases”): broadly 
speaking, mental health research is expensive 
•  lack of appreciation of the severity of mental illness 
•  many mental disorders such as depression and mania require person-specific 
assessment because different patients have different symptoms 
•  lack of uniformity in research findings and prevalence rates (Mee-Lee, 2006) 
•  it is impossible to define “abnormality” – any statistically-based definition 
would categorise people with extraordinary talents as abnormal too 
•  changing clinical processes as a result of modelling is particularly challenging 
because it requires changing clinicians’ behaviour in a less “evidence-based” 
way than for physical disease. 
 
6.4  Decision tree models for mental illness 
Although decision trees can help identify the presence or absence of psychiatric 
symptoms in patients, the tools have been very rarely employed in the area of mental 
health (Batterham et al, 2009). This is probably due to the fact that predicting mental 
risk is more complex than predicting, for example, the risk of cardiovascular disease. 
However, decision trees have been used to predict suicide attempts in major 
psychiatric disorders (Mann et al, 2008), the relationship between neuroticism and 
depression (Schmitz et al, 2003) and quality of life in multiple sclerosis (D’Alisa et 
al, 2006). 
 
6.4.1  Decision tree models to predict major depressive disorder 
In a 4-year follow-up cohort study in Australia, Batterham et al (2009) investigated 
the likely effects of a reduction of risk factors that predict the presence of major   -82-
depressive disorder over time. In doing this, they employed a decision tree approach, 
which was compared with logistic regression analysis. Each cohort was followed up 
for a total period of 20 years. The results show that earlier depressive symptoms were 
significantly predictive after four years. Using the same predictors, the decision tree 
was found to have better sensitivity and specificity than the logistic regression. Their 
method was found to be useful in distinguishing and delineating a broad range of risk 
profiles over four years across different age groups. 
The decision tree methodology was appropriate here, since it provided risk 
estimates by classifying patients into meaningful and significant categories.  
Furthermore, it demonstrated potential in assessing mental health risk. However, the 
range of risk indicators used to develop the risk model did not include the sleeping 
pattern, which is known to be a significant risk indicator in depression. A cohort 
approach reduces the possible selection bias, but validating a cohort model is not easy 
and it can be difficult to apply the results to a wider population. As such, further 
validation is required in other samples. Moreover, the study did not use a full clinical 
interview, and this may not have captured depressive episodes that may have 
occurred within a 4-year period. Over-reliance on patient reported data may also be a 
point of concern in the study. 
 
6.5  Markov modelling for mental illnesses 
Markov models divide the population into various health states, and the transitions 
between these health states occur according to assigned probabilities (Sonnenberg 
and Beck, 1993). Broadly speaking, Markov modelling is useful for providing a 
methodological framework within which to identify the presence or absence of 
psychiatric symptoms, or quantify the health benefits and healthcare cost savings. 
Mentally ill patients visit their psychiatrist at differing intervals between 
episodes of a given type. Fisher and Knesper (1983) developed a Markov model to 
predict the operation of psychiatric services for such patients. Patten and Lee (2005) 
showed how modelling offers a methodological framework for incorporating   -83-
psychiatric epidemiological data. Besides, the prospect of using the computer to link 
different levels of healthcare as patients move through a system makes Markov 
modelling a potentially attractive approach in the design of care programs. The 
following discussion shows how Markov models can be applied in various aspects of 
psychiatric healthcare research. 
 
6.5.1  Markov modelling for longitudinal data analysis 
The “natural history” of major depression can be characterised by incidence, 
recurrence and episode duration. Incidence and episode duration are both important 
variables in understanding the dynamics of episodic chronic diseases such as major 
depression, as they can be used to estimate the prevalence of such diseases in the 
general population. However, it is not easy to estimate these variables without a full 
set of detailed long-term data. Patten and Lee (2004) applied a Markov approach to 
decrease the bias embedded in estimates obtained from data sources of the National 
Population Health Survey (NPHS) in Canada to underline the effectiveness of 
Markov models for long-term data analysis. 
Patten and Lee developed a Markov model to concurrently simulate the 
associations among incidence and the incidence estimation and episode duration and 
the number of depressed weeks reported in the preceding year. A series of Monte 
Carlo simulations were applied over a 2-year time period to the Markov process, in 
order to identify the incidence and recovery probabilities resulting in the observed 
incidence estimations and numbers of depressed weeks. The annual incidence was 
calculated to be 3.1%, while episode duration was 17.1 weeks. Refined estimates 
using a Monte Carlo Markov model were found to be less subject to bias than the 
simple point estimates obtained by Kessler et al (1998) in the NPHS study for major 
depression. Therefore, Patten and Lee were able to get better estimates through 
modelling than those obtained without modelling. 
However, in their approach, the non-depressed state was chosen to be the 
starting point for all simulated subjects in order to estimate the incidence. During the 
simulation interval, some depressed subjects at baseline may possibly get better and   -84-
subsequently undergo a recurrence, and this possibility was not considered in the 
incidence estimation. A health state such as “moderately depressed” could have been 
incorporated in the model to refine the severity of the illness so as to make the model 
even more useful for public health applications. Although the estimates provided are 
of assistance for health system priority setting and planning, connecting these 
epidemiological notions to clinical concerns such as risk and prognosis could offer 
more impact on the accountability of major depression in the population as a whole. 
 
6.5.2  Markov modelling to enhance clinical decisions 
There is a clear need to integrate epidemiological prevalence data into clinical 
decision making, and a Markov model may provide a useful methodology for doing 
this. Patten (2005) applied Markov modelling to describe incidence, prevalence and 
recovery from major depressive episodes to enhance clinical decisions. This analysis 
used data from a series of Canadian survey studies. Patten amalgamated 
epidemiological data from three different sources to describe incidence and recovery 
from unipolar major depressive episodes involving two health states: depressed and 
non-depressed. Monte Carlo simulation over a series of one week time steps was 
applied to fit model parameters to the epidemiological data, using incidence-related 
transition probabilities and weekly recovery probabilities obtained from a previous 
study conducted by Patten and Lee (2004). 
A higher incidence in females confirmed the correlation of gender with major 
depression, while no evidence of correlation with educational level was reported. The 
findings from the Markov models developed by Patten (2005) are mostly consistent 
with the findings from Eaton et al (1997), who ran a follow-up study to monitor a 
similar prognosis in major depression. However, Eaton et al (1997) reported no 
significant correlation between marital status and episode duration, but Patten (2005) 
“found that an effect of unmarried status on prevalence was due to an impact of this 
variable on episode duration”. Both Patten (2005) and Eaton et al (1997) observed 
decreasing incidence of major depression with age. The recovery pattern described by   -85-
Patten (2005) was similar to that found in other related studies carried out by Melartin 
et al (2004) and Vos et al (2004). 
One source of data in Patten’s (2005) study was obtained from a cross-
sectional study (a “snapshot”). Prevalence estimates for major depression have 
commonly been assessed through a number of cross-sectional studies in recent 
decades. A cross-sectional study can be used to estimate various outcomes and risk 
factors, but it is not easy to make deductions about changes over time. The standard 
purpose of a cross-sectional study is to determine the prevalence of a particular 
condition in the chosen population at a given point of time. As such, different results 
may well be found at another point of time. A cross-sectional study is subject to the 
prevalence-incidence bias, especially in the case of a chronic disease like depression, 
because any risk factor that results in death will be under-represented among those 
with the disease. 
 
6.5.3  Markov modelling to describe a longitudinal course 
The benefits of using Markov models with epidemiological data of major depression 
to obtain a range of parameters such as incidence, episode duration and recovery have 
been discussed above. The longitudinal course of major depression can also be 
represented through a Markov model, and this was explored by Patten and Lee 
(2005). They amalgamated data from three surveys carried out by Statistics Canada in 
a Markov model to represent the long-term path of major depression. They separated 
the subjects into low, moderate and high recurrence categories. The values for the 
weekly transition probabilities in the model were 0.00028 for low risk, 0.0010 for 
moderate risk and 0.00575 for high risk to describe incidence, recurrence and 
recovery of major depression. Based on these values, they expressed the annual 
incidence of the subjects in low, moderate and high recurrence groups for major 
depression as 1.4%, 5.1% and 25.9% respectively using the following formula: 
         annual cumulative incidence = 1 - (1 - weekly transition probability)
52        (6.1) 
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To decrease random variation in the output, they used Monte Carlo simulation 
with 50,000 replications over the six years simulation time period. The simulation 
output yielded 16.8 weeks as the mean number of weeks for patients being depressed. 
The use of Markov modelling in Patten and Lee’s (2005) study to describe the 
longitudinal course of major depression enhances the possible advantage of 
modelling in characterising the condition. And their study illustrated the possibility of 
integrating several data sources in epidemiological modelling to describe a rational 
epidemiological representation. However, their model did not include mortality, 
which may have an effect on the dynamics of epidemiology. Furthermore, the results 
of their study may be subject to bias due to any minor difference between the three 
surveys. However, they have clearly shown the possibility of obtaining dependable 
descriptions of major depression through modelling. 
 
6.5.4  Markov modelling for cost-effectiveness analysis in depression 
Depression has a significant bearing on the individual and society. It may grow as a 
recurrent illness in many patients, and the higher the number of previous episodes of 
depression, the higher the risk of recurrences (Solomon et al, 2000). The illness is 
associated with a high cost for social and health care. In 2000, the annual cost of 
managing the illness in USA was found to be $83.1 billion, of which 31% for 
therapeutic costs, 7% for suicidal mortality costs and 62% for costs related to missing 
output due to the illness (Greenberg et al, 2003). In Europe, the annual prevalence of 
major depression was estimated by Paykel et al (2005) at about 5%. The prevention 
of recurrences is associated with effective treatment plans. A longitudinal outlook in 
the treatment of patients with the illness can be beneficial. 
Sobocki et al (2008) combined the results of several studies with a modified 
Markov model to examine the economic evaluation of longitudinal maintenance 
treatment with venlafaxine in recurrent unipolar major depressive patients from the 
Swedish healthcare setting. In a cost-utility study, Sobocki et al (2008) used the 
following standard “incremental cost-effectiveness ratio (ICER)”:   -87-
                                      ICER = ∆C/∆E = (C1 - C0)/(E1 - E0) ,                             (6.2) 
where ∆C and ∆E represent the difference between intervention and no intervention 
‘in total cost’ and ‘in effectiveness’ respectively. 
Their model included high risk patients with recurrent depressive episodes 
from the population studied in the clinical trial led by Keller et al (2006). Sobocki et 
al (2008) estimated a Weibull survival function based on survival data from the above 
clinical trial to calculate time to relapse comparing venlafaxine with placebo. Data on 
direct costs, quality of life and transition probabilities were drawn from several 
naturalistic long-term observational studies, while the mortality risks data were 
obtained from the literature. Stochastic analyses were executed using Monte Carlo 
simulations with 10,000 runs to describe the uncertainty of key parameters. 
Sensitivity analyses were performed to estimate the variation of underlying 
parameters used in their model. 
Their approach of using meta-analysis in a Markov model may well be less 
subject to bias. However, combining results of several studies may not reach well-
founded conclusions since there remain some qualitative differences between the 
subjects of studies. In Sobocki et al’s (2008) model, remission was chosen as the 
starting point for all simulated subjects who were at high risk of recurrent depressive 
episodes. Hence, the results may not be totally free of bias since it ignored patients 
who were in episodes at baseline. It is also unknown if their method would yield the 
same outputs, had it considered both high and low risk patients. 
Sobocki et al (2008) showed that two years’ maintenance treatment with 
venlafaxine in recurrent depression is cost-effective. They compared venlafaxine with 
placebo, but they did not discuss if venlafaxine is more cost-effective than other anti-
depressants available. “Psychotherapy, alone or combined with medication, has been 
shown to be effective in preventing further episodes of depression” (Nierenberg et al, 
2003). According to Burgess et al (2003), it is possible for a depressive patient to 
suffer high recurrence rates despite effective treatment, so treatment alone may not be 
the only solution. Lam et al (2000 and 2003) reported that depressive recurrence can   -88-
be delayed effectively through cognitive behaviour therapy. Adding both self-help 
and psychological components in addition to an anti-depressant may be even more 
cost-effective in the long run. 
 
6.6  Discrete-event simulation modelling for mental illnesses 
This approach has been rarely used for mental disease modelling. Examples of how 
discrete-event simulations can be applied in various decision-making processes are 
discussed below. 
Kuno et al (2005) described a discrete-event simulation model to convince 
decision-makers to consider exercising model-based decision support tools for health 
service system planning for individuals with serious mental disorders. Their case 
study was based on the Philadelphia health system of psychiatric care. They depicted 
the existing psychiatric health care system and the nature of client flow within that 
system. It was a good choice of modelling since the decision-makers could use the 
model to visualise different policy scenarios in order to improve the system. 
Klok et al (2007) investigated the cost-effectiveness of quetiapine, a treatment 
during acute mania in bipolar I disorder, evaluated with other substitutes such as 
lithium, olanzapine and risperidone. They developed a discrete-event simulation 
model to investigate the effectiveness of quetiapine specifically focusing on severe 
side-effects. They reported a better-quality combination of lithium with quetiapine 
than lithium with olanzapine or risperidone in terms of reduced possibility of picking 
a serious side-effect. The study was carried out in Netherlands. 
Recently, Heeg et al (2005) developed a discrete-event simulation model to 
reflect the treatment for British schizophrenia patients with multiple psychotic 
episodes. Over a 5-year time period, the model considered the dependencies among 
an extensive array of factors into the decision making process, including gender, 
disease severity, symptoms, psychiatrist visits, treatment and treatment location, 
occurrence of psychotic relapses, compliance level, quality-adjusted life-years and 
side-effects. The model was used to estimate the economic evaluation of atypical   -89-
relative against conventional antipsychotics. Their method was applicable to 
schizophrenia since it required taking patients’ histories into account. 
 
6.6.1 Discrete-event  simulation for major depression 
Assessment of episode duration is useful since increased episode duration is linked 
with various causes such as physical illness, reduced social support and severity of 
the illness (Spijker et al, 2004). There is no association of increased episode duration 
with demographic variables (Spijker et al, 2002). However, Spijker et al (2002) and a 
research study carried out by Keller et al (1992) have shown that the chance of 
recovery from a major depressive episode decreases if an episode duration increases, 
and thus epidemiological data on the prediction of episodes may have important 
implications for clinical practice. 
Patten (2006) predicted the probability of recovery during a specific time 
interval. In doing this, he first used cross-sectional Canadian psychiatric 
epidemiological data to fit a Weibull distribution to the duration of episodes. Using 
the longitudinal data from a sample from Canadian general population, Patten then 
developed a discrete-event simulation model and standardised the model by 
considering incidence and the Weibull distribution as inputs to the model. The 
resulting estimates from the model were used to calculate the probability of recovery. 
After six months, the probability of recovery during a subsequent week for an 
individual with major depression was found to be less than 1%, but the chance of 
recovery was estimated to be about 20% in the first week of illness. 
The use of discrete-event simulation was a good choice in this study since the 
calculated episode duration was time-dependent, and the choice of the Weibull model 
was also good. However, as the model depended on data reported by patients, 
recording an incident incorrectly might have led to inaccuracy in the model 
calculations. Since the model does not specify the severity of a patient’s state and 
since treatment may not be required for all major depressive episodes, it may not be 
easy for a clinician to identify an appropriate level of active treatment based only on   -90-
this model. Effects such as social changes and negative life events taking place over 
time as episodes progress may reduce the recovery rate as episodes grow longer. 
 
6.6.2 Discrete-event  simulation  to describe depression prognosis 
Lay et al (2006) developed a model in order to show the advantages of discrete-event 
simulation modelling over Markov modelling within the area of major depression. 
The model attempted to describe the prognosis of major depression. Although 
Markov modelling was adequate to model this disease progression, the authors 
believed that DES models could be even better in this regard, because of their 
flexibility in allowing patients with varying attributes to move from state to state in 
time order by taking into account attributes such as age, sex, disease history, 
treatment, suicide attempt and adverse events. 
According to the authors, the main drawback of using a Markov model is the 
Markov “memoryless” property. They claimed that incorporating multiple patient-
specific socio-demographic characteristics would only be possible by adding more 
health states. Therefore, they proposed DES modelling as a particularly useful 
technique, compared with Markov modelling techniques.  
To argue with Lay et al’s (2006) recommendation, it can be said that it takes a 
long time to develop a discrete-event simulation model owing to the need to include a 
large amount of detailed data in the model, and it is not always easy to find 
appropriate and good quality data (Davies et al, 2003). The price that must need to be 
paid to model such complex scenarios using a DES model is lengthy run times 
(Davies et al, 2003; Barton et al, 2004). Specialist software or programming skills are 
required to build DES models (Barton et al, 2004). Furthermore, discrete-event 
simulation models are complex to understand and interpreting the outcomes of such 
models require good statistical knowledge, and some may view this as a disadvantage 
(Davies et al, 2003). In general, simplicity in model buildings is beneficial (Ward, 
1989).   -91-
The need to take various attributes into account to depict disease progression 
was not fully justified by Lay et al (2006). More research is required to more fully 
clarify the effectiveness of taking a variety of factors into account and to analyse the 
empirical value. For example, Patten (2005) reported that education had no effect in 
unipolar major depressive disorder, while Eaton et al (1997) reported no effect of 
marital status for the same disorder. In addition, a range of other factors may well be 
a crude pointer in depicting the progression of major depression in the study. Lay et 
al (2006) themselves pointed out that discrete-event simulation “may induce over-
specification, whereby possible patient pathways become more complex than 
necessary, thus implying an increase in data requirements”. Probabilistic sensitivity 
analysis can offer a broader representation of any associated uncertainty in notifying 
policy decisions. 
 
6.7  Summary: OR modelling for bipolar disorder 
We have presented the current literature on the use of OR modelling for psychiatric 
disorders and have set up a theoretical framework for our research. In general, there 
are very few examples of OR models for mental healthcare in the literature. In 
particular, there are no examples in the OR literature for models of the full spectrum 
of bipolar disorder. We found models for the depressive aspects of BD, but no single 
OR model which describes both aspects of the disorder. Most statistical studies of 
unipolar major depression have estimated characteristics that are applicable for public 
health applications, but not as markedly useful for informing clinical practice. There 
is an obvious gap in the literature and a real practical need for OR models to deal with 
both aspects of bipolar disorder in a robust manner, and are therefore applicable to 
clinical practice. 
The literature suggests that the majority of mentally affected patients can be 
freed from requiring long-term or unnecessary hospitalisation if alternative home care 
and support services are obtainable. To this end, OR modelling can surely play a big 
role. Marneros and Brieger (2002) state that main features of studying the 
longitudinal course of any mental disorder are: onset of the disorder (type of onset,   -92-
age of onset), episodes (type, length, number), cycles (length, frequency) and 
outcome (end of follow-up in a defined period of time). An OR model can easily 
include these features, but it may not be possible for a model to predict any outcome 
with full precision. Having said this, a model may nevertheless be applied to make 
practicable and acceptable decisions. 
Before choosing an appropriate model, a modeller must consider many aspects 
of the approach, including methodology, treatment strategies, key features of a 
disease progress, risk factors, timing, costing and expertise. It can cautiously be said 
that both Markov and discrete-event simulation models are efficient approaches in 
psychiatric healthcare research. Although validating such a model may involve a 
major research attempt, it may be commendable as the validated model for the 
different aspects of bipolar disorder could then be applied effectively. The use of OR 
modelling techniques in providing early detection of transitions between the normal, 
manic and depressed stages of both aspects of bipolar disorder may render very good 
reasons for future research, but it would require adequate understanding of the disease 




This chapter describes the health state transition model that we have developed in 
order to help in the design of the PAM system. The modelling methodology, choice 
of approach and the model itself are all presented. The rationale for modelling 
decisions is explained. 
 
7.1 Introduction 
It is more difficult to apply OR methods to model mental diseases than physical 
diseases. Guidelines for prediction and prevention of mental diseases are plagued by 
the lack of evidence about the collective prognostic effect of identified risk factors. 
Section 6.4 of Chapter 6 provided a list of various reasons of underlying difficulties. 
To overcome these difficulties, an integrative research approach may be beneficial to 
better understand the complex procedures of mental illness. 
The literature search did not reveal a single OR modelling approach that 
combines technology and modelling to describe the dynamic behaviour of bipolar 
patients to promote efficient monitoring and healthcare networking. Building models 
for bipolar disorder is clearly difficult, but we have attempted to build a multi-state 
transition model that is combined with computer simulation. This is the first example 
of an OR model to analyse the behavioural activities of bipolar patients. The model 
parameters were derived from the literature. 
 
7.2  Choice of OR modelling approach 
We decided to employ a very simple Excel-based Markov state transition model for 
the basic disease process, combined with Monte Carlo simulation (using @Risk) for 
generating the stochastic behaviour (in terms of daily activities) of our simulated 
individuals, and the corresponding stochastic data collected by the PAM system 
under a range of different scenarios. Thus, we would be able to test the performance   -94-
of the PAM system. For bipolar disorder, we clearly need to use a dynamic approach 
since the disorder evolves over time. The first step is to study the clinical literature to 
understand the natural history of BD, and thus define the clinical states required for 
the Markov model. The next stage was to embed this in a spreadsheet model which 
represented the activity patterns of hypothetical patients, and then somehow to model 
the collection of data from different configurations of sensors and the subsequent 
analysis and interpretation of these data by the PAM algorithms. 
The literature suggests that Markov modelling and Monte Carlo simulation 
would be appropriate, since interaction between patients is irrelevant, the time 
element needs to be modelled and events in the model are recurrent. Furthermore, this 
approach allows us to keep the model fairly simple, which is advantageous in terms 
of flexibility, data requirements, run speed and interpreting the outcomes. The use of 
Monte Carlo simulation enabled us to incorporate variability and uncertainty.   
 
7.3  The natural history of bipolar disorder 
Bipolar disorder fluctuates over time in severity of symptoms, polarity of episodes 
and cyclicity (Kalbag et al, 1999). In fact, different patients show different rhythm 
(Kalbag et al, 1999; Goodwin and Jamison, 1990; Slater, 1938). Goodwin and 
Jamison (1990) suggest that bipolar patients vary from each other on severity of 
depressive, manic and mixed states, polarity and duration of episodes, cyclicity, 
instability or rapidity of state changes, and treatment responsivity. 
 
7.3.1 Episode  polarity 
Almost all bipolar patients experience both manic and depressive episodes; the 
majority experience no mixed episodes (Miller I et al, 2004; Judd et al, 2002). Bipolar 
patients who experience mixed episodes appear to be at higher risk for rapid cycling; 
and rapid cycling has usually been found to be brief in several studies (Angst and 
Sellaro, 2000). To avoid further complexity, one may classify the episode polarity as 
either depressed or manic, as proposed by Kalbag et al (1999). However, according to 
Kalbag et al (1999), it is still possible to inform if a patient experiences mixed   -95-
episode or not by using a set of relevant decision rules. Kalbag et al (1999) identified 
mixed episodes by oscillating 5-day durations of fully syndromal manic and 
depressive symptoms simultaneously or separately within the same day or week. 
 
7.3.2 Asymptomatic  and symptomatic periods 
Judd et al (2002) report that almost all bipolar patients have both asymptomatic and 
symptomatic phases. They also report that the median proportion of time that patients 
were asymptomatic in their study was 62% and symptomatic 38% (at mild, moderate 
and severe levels of severity). Similarly, Miller I et al (2004) report the median time 
as 59% for asymptomatic and 41% for symptomatic. Miller I et al (2004) also report 
that about 90% of patients experienced some time in all three of the symptom levels 
(asymptomatic, partially symptomatic or fully symptomatic). 
 
7.3.3  Duration of symptomatic episodes 
The median duration of acute episodes in bipolar illness is 3 to 6 months in clinical 
studies, and 2 to 3 months in epidemiological studies (Angst and Sellaro, 2000). The 
overall median length of episodes has been reported by Angst and Preisig (1995) as 3 
months in a follow-up study. According to the UK bipolar disorder treatment 
guidelines, the average lengths of manic and depressive episodes are 9 and 13 weeks 
respectively (NCCMH, 2006). Angst and Sellaro (2000) suggest that over the past 
120 years, the natural length of episodes has changed little.  
 
7.3.4  Intervals between episodes 
Falret (1851, 1854) and Kraepelin (1913) conceded the existence of mild fluctuations 
between episodes. Slater (1938) followed up 116 patients diagnosed with bipolar 
illness by Kraepelin, to investigate the length of intervals between episodes, and 
observed the existence of symptom-free intervals between episodes for most of these 
patients. Kalbag et al (1999) propose nine bipolar subtypes, and they marked the 
classic bipolar I pattern with periods of remission between fully syndromal manic and 
depressive episodes. In fact, most of the bipolar subtypes proposed by Kalbag et al   -96-
(1999) concede inter-episode intervals. Very recently, Fajutrao et al (2009) assumed 
that bipolar patients use euthymia as a transit before moving to an acute mood event. 
 
7.3.5  Changes in polarity 
Dunner et al (1979) reported a frequency rate of 0.54 episodes per patient per year in 
an 11.4-year follow-up of 140 bipolar I patients. They reported no association 
between episode frequency and age of onset. Similarly, Judd et al (2002) reported 0.6 
median changes per patient per year in a 13-year follow-up of 146 bipolar I patients. 
Over the 18 months cycle, Paykel et al (2006) also reported changes in polarity. 
 
7.3.6 Cycle  length 
In Zurich follow-up study, Angst and Preisig (1995) reported the median cycle length 
of 18 months. Median time to remission of bipolar I patients has been reported as 5 
months in Miller I et al’s (2004) study and 6 months in Keller et al’s study (1986). 
Since the median is a more representative statistic in this context, we have chosen an 
18-month horizon in our model for representing a segment of the disease process. 
 
7.3.7  Onset of episodes 
Depressive symptoms are more common in the longitudinal course of illness than 
manic or hypomanic symptoms (Judd et al, 2002). At least 5 out of 10 patients start 
with depression as their first episode as opposed to mania (Perugi et al, 2000). 
However, Kinkelin (1954) observed 146 patients in an extended study and reported 
that almost 86% patients started with a depressive episode. 
 
7.3.8  Ranges of manic and depressive measurement 
Based on two observer-rated scales (Young Mania Rating Scale and the Hamilton 
Depression Rating Scale), Bauer et al (2005) used the following scale to rate the 
various phases of the illness: 0-19 (moderate to severe depression), 20-39 (mild 
depression), 40-60 (euthymia), 61-80 (hypomania) and 81-100 (moderate to severe 
mania). On the other hand, Kalbag et al (1999) used the Life Chart Program
TM that is   -97-
designed as 0.0 (asymptomatic), 2.5 (mild symptoms), 5.0 (moderate symptoms), 7.5 
(severe symptoms), or 10.0 (extreme symptoms). Both of them classified the episode 
polarity as either manic or depressed. 
Having considered the above scales, one may propose mild to severe 
depression at the bottom of a scale, euthymia (i.e. normality) at the middle and mild 
to severe mania at the top. Like depression and mania, normality also ranges between 
two points due to the existence of residual symptoms. Kraepelin (1913) and many 
others (Judd et al, 1998; Paykel et al, 2006; Bauer et al, 2007) argued the existence of 
mild remaining symptoms following recovery from the manic and depressive 
episodes. The symptom levels are commonly labelled as mild, moderate and severe, 
but no one can be certain about the order in which the symptom levels change on the 
scale over time. 
 
7.4 Modelling  framework 


























Figure   7.1   Modelling framework   -98-
A conceptual description of the above modelling framework is provided below: 
•  Step 1:  At the start of each day t, the time-dependent health state value λ(t) 
was generated stochastically, based on an archetypal patient trajectory (as 
depicted in Figure 7.2) through the “gross” health states Normal – Depressed – 
Normal – Manic, but with individual minor daily fluctuations within each 
gross state sampled using Monte Carlo simulation. Thus while all patients 
follow the same broad overall pattern of illness, no two patients will have 
exactly the same λ trajectory.  
•  Step 2:  For each PAM-observable behavioural activity, for example hours of 
sleep, the actual, true value representing that activity on day t was calculated 
using Equation 7.1, which involves parameters λ(t),  N (the value for that 
activity for that person when normal), M (value when manic) and D (value 
when depressed). To account for natural individual daily variability  unrelated 
to bipolar disorder, the actual values of N, M and D for day t used in Equation 
7.1 were sampled from  probability distributions describing the range of 
possible values for that parameter. To use the example in Figure 7.4, a person 
may sleep for N = 8 hours when fully normal.  But even when completely 
healthy that person will not sleep for precisely 8 hours every night,  so some 
natural random variation is added by sampling a value for N from a pre-
determined interval representing the normal range for that individual, for 
example [7, 9].  The same is done for D and M, and then substituted in 
Equation 7.1 to yield the number of hours actually slept on day t: for example, 
7.22.   
•  Step 3:  In order to account for PAM technical reliability, the PAM-observed 
value of each activity was derived by sampling a value in a specified interval 
(small or wide, depending on the level of reliability) containing the true value.  
For the above example, if PAM is very reliable at detecting hours of sleep, the 
PAM-observed value would be sampled from within a small interval around 
7.22, say [6.82, 7.62].   -99-
•  Step 4:  The decision rules of whether or not to send alerts were applied. For 
example, if the PAM-observed value of hours of sleep was say 6.84, this could 
mean the person was in the very early stages of a manic episode, but of course 
it could just be within the normal spectrum. So should the patient be alerted, or 
not?  
•  Step 5:  The overall effectiveness of the PAM system (in terms of true/false 
positive and negative alerts) was calculated. 
 
Based on the information from the clinical literature described in Section 7.3, 
we have represented the disease progression of bipolar I disorder in terms of a single 
parameter denoted by λ.  The parameter λ can be conceptualised as a measurement of 
a person’s mental health status, similar to the Young Mania Rating Scale and the 
Hamilton Depression Rating Scale described in Section 7.3.8.  Although in reality 
this parameter is continuous, we have discretised it in the Excel model and thus we 
have a multi-state Markov model in which λ can take values between 0.00 and 1.00. 
The time-step is one day, and each day the value of λ either stays the same or is 
incremented or decremented, with a certain probability (shown in Table 7.3 below). 
The parameter λ  models the progression of individuals through the various 
disease states over a time horizon of 18 months, as described in Section 7.3.6.  The λ 
values range between 0.00 and 1.00. Following Bauer et al (2005), values of λ 
between 0.00 and 0.19 represent severe to moderate depression; values between 0.20 
and 0.39 represent mild depression; values between 0.40 and 0.60 represent normal 
health; values between 0.61 and 0.80 represent mild mania; and values between 0.81 
and 1.00 represent moderate to severe mania. We then split the ranges 0.00 to 0.19 
and 0.81 to 1.00 into a pair of two equal ranges (Kalbag et al, 1999): 0.00 to 0.09 and 
0.10 to 0.19 represent severe and moderate levels of depression, while 0.81 to 0.90 
and 0.91 to 1.00 represent moderate and severe levels of mania, respectively. These 
are summarised in Table 7.1:  
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Value of λ  Clinical state  Source 
0.00 – 0.09  Severe depression  Kalbag et al (1999) 
0.10 – 0.19  Moderate depression  Kalbag et al (1999) 
0.20 – 0.39  Mild depression  Bauer et al (2005) 
0.40 – 0.60  Normal health  Bauer et al (2005) 
0.61 – 0.80  Mild (hypo) mania  Bauer et al (2005) 
0.81 – 0.90  Moderate mania  Kalbag et al (1999) 
0.91 – 1.00  Severe mania  Kalbag et al (1999) 
Table   7.1   Values of the parameter λ and their clinical interpretation 
In reality these transitions can be very subtle and gradual. An individual may 
move almost imperceptibly from the “normal” range to the depressed or manic range. 
The time spent making this transition will of course vary from individual to 
individual, and the boundaries between the “gross” states (Depressed, Normal and 
Manic) are blurred. To test the PAM system, we required a natural history model 
which represented an entire bipolar cycle, i.e. we needed to construct a complete and 
realistic trajectory of an “archetypal” BD patient including periods of depression, 
mania and normal health. The parameters given below are all derived from the 
literature in Section 7.3.  In the Monte Carlo simulation, they are all subject to minor 
random fluctuation in order to create individual variability. Thus, although all patients 
follow the same general pattern, each individual has a slightly different trajectory. 
Following Angst and Preisig (1995) we used a cycle length of 18 months (546 
days), of which an average of 328 days (60%) are asymptomatic and an average of 
218 days (40%)  are symptomatic (Judd et al, 2002; Miller et al, 2004). Symptomatic 
periods include both depressive and manic episodes. On average, out of their total 
symptomatic time patients spend 130 days (60%) being depressed and 88 days (40%) 
being manic (Angst and Sellaro, 2000; Judd et al, 2002; NCCMH, 2006). We allowed 
symptom-free intervals between episodes (Slater, 1938; Kalbag et al, 1999), and in 
doing this so, we split the asymptomatic period in two equal halves (164 days each) 
to allow a change in polarity in the cycle length (Dunner et al, 1979; Judd et al, 2002; 
Paykel et al, 2006). It is not possible in our model to transition directly from 
depression to mania without passing through the asymptomatic state; this assumption 
was also made by Fajutrao et al (2009). Thus, we have not modelled mixed states.    -101-
Many patients start with depression as opposed to mania (Kinkelin, 1954; 
Kalbag et al, 1999; Perugi et al, 2000; Judd et al, 2002), and we have applied this in 
our model. We assigned mild, moderate and severe symptoms levels (Kalbag et al, 
1999; Judd et al, 2002; Miller I et al, 2004; Bauer et al, 2005), and assumed that the 
symptom levels change over time from mild to moderate to severe. On average, out 
of the total 130 days of depression, patients spend 39 days in a mild depressive state 
(30%), 55 days in a moderate depressive state (42%) and 36 days in severe depression 
(28%). Similarly, out of the total 88 days of mania, 23 days (26%) are mild, 43 days 
(49%) are moderate and 22 days (25%) are severe (Judd et al, 2002).  Figure 7.2 
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Figure 7.2   The archetypal values of λ and the associated disease states 
In other words, our archetypal patient has a period of depression between days 
165-294, a period of mania between days 459-546, and otherwise is normal. The 
simulation model then adds random noise within the ranges depicted in Figure 7.2 – 
as depicted in Figure 7.3 below: 
























Figure 7.3   A sample trajectory of BD defined by small fluctuations of the parameter λ 
The next step is to develop a model for a person’s daily activity pattern, based 
on this natural history model. A key assumption of this model is that an individual’s 
daily activity pattern is a function of two things: a) his/her mental health status (as 
defined by λ) and b) a random element totally unrelated to their health. A patient who 
passes from normal health into depression or mania may do so very gradually, with 
some good days and some bad days, and of course a healthy individual with no 
background of mental disorder can experience days on which their mood is either 
high or low, and their behaviour can reflect this, although they are in no way 
clinically ill. We have, therefore, constructed a function which maps λ onto a series 
of observed activities (sleeping, talking, watching TV etc) but also includes a random 
aspect – e.g. the person’s TV may be broken, so they do not bother switching it on 
even though they are not depressed at all.  
This mapping function is actually a slight simplification of the real-life PAM 
system as it omits part of the data processing that the real PAM performs. The sensors 
in PAM do not directly monitor a person’s observable behaviours, but just collect a 
vast amount of raw data, such as the sound levels in decibels in a particular room at   -103-
10-second snap-shot intervals.  By the use of intelligent “feature extraction” 
algorithms, PAM decodes this raw data into meaningful measures such as the average 
number of hours the person has slept in a 24-hour period. In our simulation model, we 
assume that this feature extraction has already occurred and that we can observe 
meaningful behaviours, which may have clinical significance in terms of bipolar 
disorder.  In other words, the model assumes that we can measure and classify actual 
behaviours over a 24-hour period, using sensor data. It also assumes that we have 
calibrated these activity levels for our patient in the normal, manic and depressed 
states. This is not a restrictive assumption: most BD patients are aware of their own 
behaviour patterns in all three states. Moreover, in a practical setting the PAM system 
would be calibrated for a patient’s normal activity before use “in earnest”. 
We have modelled this mapping function as follows. For a given individual, 
let N, D and M  be the average levels of some particular variable (e.g. light levels in 
lux in the kitchen at 4.00 am) in the normal, extremely depressed and extremely 
manic mood states, respectively. We have devised the following function of the 
parameters λ, N, D and M to calculate the value of this variable across all possible 
mood states: 
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where λ represents the multi-state-scale that ranges from 0 to 1 corresponding to the 
various mood states. When λ = 0 then the equation 7.1 yields D (the value when fully 
depressed), when λ = 0.5 we get N and when λ = 1 we get M.  Equation 7.1 is similar 
in structure and in some detail to the expression utilised by Bauer et al (2005). As 
before, in the Monte Carlo simulation Equation 7.1 is not applied deterministically 
but is subject to small random variation. 
Psychiatrists very commonly use various rating scales such as the Young 
Mania Rating Scale (Young et al, 1978), the Altman Self-Rating Mania Scale 
(Altman et al, 1997) and the Bipolar Affective Disorder Dimensional Scale 
(Craddock et al, 2004), to measure the severity of bipolar symptoms. These scales   -104-
rate the severity of mania and depression separately.  It is this idea that initially led us 
to work out two separate equations: (1 – λ)N + λM  and  (1 – λ)N + λD,  in which λ 
ranges between 0 and 1 (λ = 0 implies N  and  λ = 1 implies either M or D), for our 
intended purpose.  Our intention was to quantify the severity of mania through the 
former equation and quantify the severity of depression through the latter one. 
The idea was virtually feasible, but we required having to create a common 
interface in which to combine the two aspects of the disorder at the end, which would 
have been rather time consuming. We then started to research the feasibility of using 
a single scale to rate the both aspects of the disorder, as proposed by Bauer et al 
(2005).  Consequently, we constructed Equation 7.1 above for our simulation study 
for the purpose of quantifying the possible current activity across all possible mood 
states by assigning fully depressed state when λ = 0, normal state when λ = 0.5 and 
fully manic when λ = 1.  Clearly, an individual cannot simultaneously be fully 
depressed and normal or fully manic and normal. We had to satisfy this by allowing 
the M and D disappear from the equation 7.1 when λ = 0.5.  In the same way, we let 
M and N disappear when λ = 0, and D and N disappear when λ = 1. We also allowed 
the estimation of nonlinear effects among these interacting variables.   
To make the above idea clearer, we have used a person’s sleep pattern as a 
descriptive example. Suppose that over a 24-hour period, a person sleeps (on average) 
for 6 hours when they are in good health, for 10 hours when they are very depressed 
and for 4 hours when they are very manic. We can then use Equation 7.1 to work out 
the person’s potential actual sleep hours over time, across any possible mood states. 
Figure 7.4 shows the mapping between the mood states and sleep hours and 
highlights the purpose of the equation even further. Approximate mental state is 
depicted on the x-axis, colour coded in an obvious way: green denotes normal, blue 
depressed and red, manic. We can clearly see from Figure 7.4 that sleep hours 
decrease nonlinearly from N to M as λ increases from 0.5 to 1, while sleep hours 
increase from N to D as λ decreases from 0.5 to 0. This is evidently in line with the 


















Figure 7.4   Time spent asleep across various days 
In Figure 7.5, we have shown λ values on the x-axis and potential time spent 



















Figure 7.5   Time spent asleep across various mood states 
   -106-
Of course, observations such as disturbed sleep patterns (although a 
recognised symptom of BD) may naturally vary for reasons totally unrelated to 
mental health; thus we cannot use Equation 7.1 in a deterministic fashion. Normal 
healthy people can still find it difficult to sleep at times! In social and behavioural 
sciences, it is feasible to encompass nonlinear relations among variables 
(Moosbrugger et al, in press). We, therefore, allowed the estimation of nonlinear 
effects among interacting variables. In other words, we used N, D and M to obtain 
combined estimates. 
 
7.4.1  Summary of model assumptions   
During the first series of Steering Group meetings, we discussed the details of the 
model with a psychiatrist who is engaged with bipolar disorder. We have, thus, 
augmented the literature-based assumptions and parameters with expert opinion. 
Clearly, like any model this is an over-simplification of reality. We have had to make 
a number of assumptions and to estimate the values of some parameters. We have 
performed sensitivity analysis to test how robust the results are to these estimated 
parameters, so that areas of uncertainty are identified and the effect on the results 
noted, the level of confidence is increased and (in some cases) areas for further 
research identified. The following assumptions are taken into account in our analysis: 
•  it is clinically meaningful to use the parameter λ to represent a person’s mental 
health state 
•  all patients start in the normal, healthy state at time zero 
•  the model time horizon is 18 months, since based on clinical data on average a 
patient will experience one episode of depression and one episode of mania in 
an 18-month cycle 
•  all patients experience roughly the same “archetypal” disease trajectory, as 
illustrated in Figure 7.4. Minor variation is introduced by small random 
changes   -107-
•  direct transition from depression to mania is not allowed: all patients must 
pass (albeit briefly) through the asymptomatic state 
•  mixed states have not been modelled 
•  the average times spent in each state were derived from the literature and are 
as described in Section 7.4 
•  it is possible to devise a formula as a function of λ to represent a simulated 
person’s daily activities, for a specific limited set of behaviours relevant for 
bipolar prodromes 
•  a patient’s actual behaviours depend partly on their mental health state (i.e. on 
the parameter λ) and partly on a random factor 
•  it is possible to calibrate these activity levels for any patient in the normal, 
manic and depressed states. 
 
7.4.2  Prodromes, behavioural and technical parameters 
In addition to the disease-related parameters discussed above, the inputs to the model 
also include a selection of the most common bipolar prodromes, together with 
behavioural parameters and technical parameters relating to the choice of sensors and 
the reliability and accuracy of the PAM system. 
Self-reporting of daily sleep, activity and mood fluctuations is an established 
clinical tool for the clinician to assess the severity of bipolar disorder (Bauer et al, 
1991; Leverich and Post, 1996). The following list contains the most common bipolar 
prodromes, derived from the clinical literature (WHO, 1992; Morriss, 2004), which 
we mapped in the model to various observable behaviours: 
•  Activity levels 
•  Sleep 
•  Talkativeness 
•  Social energy 
•  Appetite   -108-
Other prodromal symptoms are described in the literature but were not 
included in PAM, either because they are hard to translate into observable activity, or 
because they are less common. These include ‘feeling in another world’ and anxiety, 
which may precede episodes of mania and depression respectively (Morriss, 2004).   
We also had to exclude another important prodrome – increased or decreased interest 
in sex – for obvious ethical and privacy reasons! 
The following list contains the 14 PAM-observable behaviours, with units of 
measurement shown in parentheses, which were mapped in the model to the above 
five prodromes (see Figure 7.6 below): 
A.  daily activity (PAL). The PAL (Physical Activity Level) is a measurement 
commonly used to express a person’s daily physical activity, and is used to 
approximate a person’s total energy expenditure (UNU, 1994). For example, 
the PAL for an office worker getting little or no exercise fluctuate between 1.4 
and 1.7 
B.  earliest time person leaves home in the morning (time of day) 
C.  latest time person gets back home in the evening (time of day) 
D.  total number of TV remote keypresses (number)   
E.  total time spent in bed in 24-hour period (hours)   
F.  average light level between 11pm and 7am (lux)   
G.  average noise level between 11pm and 7am (decibels)  
H.  total time spent talking on the telephone (minutes) 
I.  total number of daily phone calls (number) 
J.  total time spent outside the home between 5pm and 1am (hours) 
K.  cupboard doors usage (i.e. the total number of times the doors were opened)   -109-
L.  fridge doors usage (ditto) 
M. microwave door usage (ditto) 
N.  usual time person cooks the evening meal (time of day). 
 
This choice of observable behaviours was based entirely on the capability of 
the PAM sensors selected in the real system. Other observable behaviours such as 
‘talking speed’ or ‘spending habits’ could hypothetically have been considered in the 
model, but none of the PAM sensors can collect these types of information. Although 
observable behaviours such as ‘time spent talking on the phone’ and ‘number of daily 
phone calls’ can be used as proxies to indicate whether a person is talking more or 
less than usual, obviously, “talking speed” will not be captured. This hierarchy of 
clinical prodromes, observable behaviours and the sensor data is depicted in Figure 
7.6 below.  The prodromes defined by psychiatrists and cited in the literature are at 
the top level, with the observable behaviours at the next level down, and the sensor 
data at the bottom level. 
 
 
Figure 7.6   Mapping between prodromes, observable behaviours and sensors 
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Some of the observable behaviours such as ‘time spent in bed’ and ‘daily 
activity’ are generic (i.e. common to all people), while behaviours such as ‘earliest 
time leaving home in the morning’ and ‘usual time for cooking’ are variable 
depending on a patient’s lifestyle, whether they live on their own, go out to work, 
have an active social life, cook for themselves, etc. We have assumed that our 
patients live alone, are employed and cook for themselves. Following discussion with 
the Steering Group, it was felt that the main use of PAM would be for patients who 
live alone, although in our technical trials of the equipment on members of the 
research team (all of whom lived with several other people) it was found to be 
possible to identify some data by individual.  By definition, in practice the PAM 
system would be configured to suit the patient’s particular lifestyle. 
Table 7.2 depicts this mapping of prodromes indicating a possible change in 
mental health state onto observable behaviours: 
 
Prodrome  Observed behaviours 
Activity levels 
(increased or decreased) 
Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home  (C) 
TV remote keypresses (D) 
Sleep 
(increased or decreased) 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Talkativeness 
(more or less) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Social energy 
(increased or decreased) 
Latest time of getting back home (C) 
Time not at home between 5pm and 1am (J) 
Appetite 
(increased or decreased) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 
Usual time of cooking (N) 
Table   7.2   Mapping between the prodromes and observable behaviours   -111-
Different people will have different sets of prodromes that may indicate the 
onset of an acute episode. In reality, people may have very personal and specific 
warning signs of an episode, which apply only to them. For example, our trial 
participant mentioned that she always knew she was about to “go off” (i.e. have an 
episode of mania) when she realised she was spending a lot of time in her spare 
bedroom, which normally she did not use. Other patients may know from their own 
personal experience that simultaneous changes in several different behaviours can 
indicate the onset of an episode. A patient may know that changes in both ‘activity 
level’ and ‘sleep’ mean that he/she is going to have an episode. Obviously, if this 
patient is not willing to have any sensors which monitor the observable behaviours of 
‘activity level’ and ‘sleep’, then PAM will not work for him/her. 
Patients will also differ in how they make the choice. Some people may object 
to a particular sensor rather than the activity it is intended to monitor. Figure 7.6 
above shows that there are several ways in which a specific prodrome can be 
monitored. For example, sleep patterns could be monitored by a pressure mat placed 
in the bed which detects the presence or absence of a person in the bed, or by a 
pressure mat placed on the floor by the bed, or by light and/or sound levels in the 
bedroom. A patient might object to the pressure mat in the bed but be willing to have 
it on the floor. He may object to the sound level sensor but be happy about the light 
sensor (or vice versa). Another patient might object to having his sleep habits 
monitored at all. 
The model considers 25 different patient types, defined on the basis of the 
prodromes they were willing to be monitored on rather that the individual sensors 
they were willing to use. This was a pragmatic choice since the potential number of    
combinations of sensors and different locations within a person’s home is 
astronomically large. The 25 selected combinations of the selected prodromes are 
given below.  Although the prodromes used in this research were selected on the basis 
of the clinical literature, this is obviously by no means an exhaustive set. However, 
the 25 patient types listed here are more than sufficient for the purposes of our   -112-
analysis. For each patient type, a different set of sensors were required to monitor 
each choice of prodromes, as shown in Appendix A11. 
Patient type 1:  activity level + sleep 
Patient type 2:  activity level + talkativeness 
Patient type 3:  activity level + social energy 
Patient type 4:  activity level + appetite 
Patient type 5:  sleep + talkativeness 
Patient type 6:  sleep + social energy 
Patient type 7:  sleep + appetite 
Patient type 8:  talkativeness + social energy 
Patient type 9:  talkativeness + appetite 
Patient type 10: social energy + appetite 
Patient type 11:   activity level + sleep + talkativeness 
Patient type 12:   activity level + sleep + social energy 
Patient type 13:   activity level + sleep + appetite 
Patient type 14:   activity level + talkativeness + social energy 
Patient type 15:   activity level + talkativeness + appetite 
Patient type 16:   activity level + social energy + appetite 
Patient type 17:   sleep + talkativeness + social energy 
Patient type 18:   sleep + talkativeness + appetite 
Patient type 19:   talkativeness + social energy + appetite 
Patient type 20:   activity level + sleep + talkativeness + social energy 
Patient type 21:   activity level + sleep + talkativeness + appetite 
Patient type 22:   activity level + sleep + social energy + appetite 
Patient type 23:   activity level + talkativeness + social energy + appetite 
Patient type 24:   sleep + talkativeness + social energy + appetite 
Patient type 25:   activity level + sleep + talkativeness + social energy + appetite.   -113-
7.4.3  Incorporating individual variability and uncertainty 
Equation 7.1 was used to generate the person’s actual behaviours. The measurements 
are stochastic, based partly on the parameter λ and partly on the natural variability 
associated with the observed behaviours, just as in real life. The parameter λ has been 
generated randomly based on the “natural history” of the disease progression, as 
explained in Figure 7.2 above. The λ  values were generated on the basis of the 
information provided in Table 7.3: 
 
Day  Clinical state  Value of λ  Random variation 
1 to 164  Normal health  0.40 – 0.60  RAND() × (0.6 – 0.4) + 0.4 
165 to 203  Mild depression  0.20 – 0.39  RAND() × (0.39 – 0.2) + 0.2 
204 to 239  Severe depression  0.00 – 0.09  RAND() × (0.09 – 0) + 0 
240 to 294  Moderate depression  0.10 – 0.19  RAND() × (0.19 – 0.1) + 0.1 
295 to 458  Normal health  0.40 – 0.60  RAND() × (0.6 – 0.4) + 0.4 
459 to 481  Mild (hypo) mania  0.61 – 0.80  RAND() × (0.8 – 0.61) + 0.61 
482 to 503  Severe mania  0.91 – 1.00  RAND() × (1 – 0.91) + 0.91 
504 to 546  Moderate mania  0.81 – 0.90  RAND() × (0.9 – 0.81) + 0.81 
Table   7.3   The archetypal λ values at various disease states 
Thus, values of λ between 0.40 and 0.60 were generated randomly for days 1 -
164 and days 295 - 458, when the patient was in normal health. Similarly, for days 
165 to 203, when the patient was mildly depressed, values of λ were generated 
randomly between 0.20 and 0.39; and between days 204-239, when the patient was 
severely depressed, values of λ were generated randomly between 0.0 and 0.19.  
Exactly the same approach was applied for mild and severe mania.  In any of the 
“gross” states, e.g. mild depression, a person’s mood and mental health status will not 
steadily decline, improve or stay static over the whole period: there are small daily 
fluctuations, and the patient will experience better days and worse days. This is also 
true for a healthy person in real life: everyone has good days and bad days within a 
“normal” spectrum.   -114-
Therefore, the parameter λ was allowed to fluctuate subtly and randomly over 
time (but always within the broad range for that gross state) with a daily time-step to 
represent the different clinical states. This daily random variation was achieved non-
linearly through incorporating the random product RAND(), which yields real 
numbers between 0 and 1. 
The random element of each behaviour, i.e. the part not dependent on mental 
health state but simply due to daily variability, was modelled by fitting triangular 
probability distributions. Clearly we did not have any empirical data to which to fit 
these distributions, other than common sense, practical experience and some clinical 
input. The triangular distribution was chosen as it is simple to parameterise and is 
widely used as a subjective description of a population for which there is only limited 
sample data, especially in cases where the relationship between variables is known 
but data is scarce. For example, if a person in the healthy state spends time in bed on 
average 7 hours a day (N = 7 in the terminology of Equation 7.1), a suitable triangular 
distribution might have min 6, mode 7 and max 9. 
The next task then, was to specify these probability distributions for different 
simulated patients and all the behavioural observations (see Table 7.4 below for full 
set). This table is also provided in Appendix A3, which contains the list of references 
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Daily activity (PAL)  RiskTriang(1.7,1.9,2.0)  RiskTriang(1.9,2.2,2.5) RiskTriang(1.0,1.4,1.7) if AA > 2.0  OR 
AA < 1.7, then 1 
Earliest time of 
leaving home (time) 
RiskTriang(7,8,9)  RiskTriang(5,6,7)  RiskTriang(8,9,11)  if AA < 7 OR 
AA > 9, then 1 
Latest time of getting 
back home (time) 
RiskTriang(18,19,21) RiskTriang(20,23,24) RiskTriang(16,17,19) if AA > 21 OR 
AA < 18, then 1 
TV remote 
keypresses (number) 
RiskTriang(20,40,60)  RiskTriang(40,75,100)  RiskTriang(0,15,25)  if AA > 60 OR 
AA < 20, then 1 
Time spent in bed 
(hour) 
RiskTriang(6,7,9) RiskTriang(2,4,6) RiskTriang(8,12,14)  if AA < 6 OR 
AA > 9, then 1 
Light level between 
11pm to 7am (lux) 
RiskTriang(5,10,20)  RiskTriang(20,40,70)  RiskTriang(1,4,10)  if AA > 20 OR 
AA < 5, then 1 
Noise level between 
11pm to 7am (dB) 
RiskTriang(15,20,25) RiskTriang(25,30,40) RiskTriang(5,10,20)  if AA > 25 OR 
AA < 15, then 1 
Time spent talking 
on the phone (minute) 
RiskTriang(10,25,50)  RiskTriang(40,70,120)  RiskTriang(0,10,20)  if AA > 50 OR 
AA < 10, then 1 
Number of daily 
phone calls (number) 
RiskTriang(2,5,7) RiskTriang(7,10,16)  RiskTriang(0,1,3) if AA > 7 OR 
AA < 2, then 1 
Time being outside 
btwn 5pm & 1am (hour) 
RiskTriang(1,2,4)  RiskTriang(3,5,8)  RiskTriang(0,0.5,1)  if AA > 3 OR 
AA < 1, then 1 
Cupboard doors usage 
(number)  RiskTriang(8,10,14) RiskTriang(12,18,22)  RiskTriang(2,4,10)  if AA > 14 OR 
AA < 8, then 1 
Fridge doors usage 
(number)  RiskTriang(6,8,10)  RiskTriang(10,14,18)  RiskTriang(2,4,6)  if AA > 10 OR 
AA < 6, then 1 
Microwave door usage 
(number)  RiskTriang(4,6,8) RiskTriang(6,10,14)  RiskTriang(0,2,4) if AA > 8 OR 
AA < 4, then 1 
Usual time of cooking 
(time)  RiskTriang(18,19,21)  RiskTriang(20,22,24)  RiskTriang(16,18,19)  if AA > 20 OR 
AA < 18, then 1 
Table 7.4   Dataset 1 
Of course, the major source of uncertainty is the functionality of the PAM 
system itself. Indeed this was the prime motivation for the research in this thesis.  
Ambient data collection is inherently unreliable. The sensors may malfunction or 
break down completely, there may be a power loss, the patient may accidentally (or 
deliberately) switch off the PC, or simply forget to recharge the wearable device or 
the mobile phone. The patient may lose the wearable device or the mobile – our trial 
participant once accidently left the wearable in a friend’s car. The patient may 
damage, lose or switch off any of the sensors (or the whole system) either 
accidentally or deliberately. There may be software problems, local or remote, with 
the PC and the onward transmission of data. 
In these circumstances, PAM may report a change in behaviour which has not 
taken place (a false positive) or miss a change which has taken place (a false   -116-
negative). Both of these are undesirable: clearly failing to issue an alert if a genuine 
change in mental health state has occurred would render the whole PAM system 
pointless, but on the other hand if the system keeps issuing alerts when nothing is 
wrong then the patient will quickly become disillusioned with PAM and will stop 
using it. Data errors caused by technical malfunction were modelled by randomly 
modifying the relevant observed behavioural parameter upwards or downwards by an 
amount based on a combination of suggestions from the other members of the PAM 
team, and common sense, as shown in Table 7.5: 
 
Observed behavioural activity (unit)  Technical variation (±) 
Daily activity (PAL)  0.2 
Earliest time of leaving home (time of day)  0.5 
Latest time of getting back home (time of day)  0.5 
TV remote keypresses (number)  10 
Time spent in bed (hours)  0.5 
Light level between 11pm to 7am (lux)  2 
Noise level between 11pm to 7am (decibels)  2 
Time spent talking on the phone (minutes)  5 
Number of daily phone calls (number)  1 
Time being outside between 5pm and 1am (hours)  0.5 
Cupboard doors usage (ditto)  2 
Fridge doors usage (ditto)  2 
Microwave door usage (ditto)  2 
Usual time of cooking (time of day)  0.5 
Table 7.5   Modelling technical variation 
The data shown in the above table was then incorporated in the model using 
the function:  Uniform((actual activity – error), (actual activity +  error)).  To give 
an illustrative example, the sampled value of ‘Time spent in bed’ was varied 
uniformly by ±0.5 hours (i.e. ±30 minutes). Thus, if the actual daily value for ‘Time 
spent in bed’ was 6 hours, then the PAM-detected corresponding value will be a 
randomly chosen value between 5.5 and 6.5 hours. In this case, we of course do not 
know if the value 0.5 is scientifically legitimate or not, but it is plausible, given the 
huge scope for error in the real PAM system. The simulation runs incorporated these 
plausible random effects to sample the corresponding actual values. Although the 
choice of these error margins was subjective and the values illustrative, it does not 
affect the underlying credibility of the model. Of course, we may not have dealt with   -117-
this problem justifiably, but we also considered a greater range of variability in the 
PAM-detected estimates to see the effects of more serious technical malfunctions. 
 
7.4.4 Decision  rules  and threshold levels 
The next step was to define the decision rules for identifying whether a significant 
change in behaviour had occurred so that PAM would issue an alert (i.e. a text 
message) to the patient. Although there was some guidance on this in the literature, as 
in the case of the behaviours the main aim was to produce rules that were credible and 
practicable. The decision rules and threshold levels were chosen using ideas from the 
literature together with common-sense judgement, in order to address the need for 
timely and accurate evaluation of bipolar relapses. Morriss (2004) used the 
occurrence of at least four out of a total of six prodromes to define a danger level of 
relapse, with two or three as indicating a warning level. We adopted a similar 
approach, assuming that the simultaneous presence of any combination of two or 
more prodromal symptoms (e.g. ‘sleep’ + ‘talkativeness’,  ‘activity level’ + ‘appetite’, 
‘activity level’ + ‘sleep’ + ‘social energy’, or etc) may trigger an alert.  
However, we also assumed that not all the corresponding observed behaviours 
need to occur in order to indicate a prodrome. For example, when a person’s ‘activity 
level’ is identified as high, then clearly that person could be highly active at home, or 
outside the home. However, it is impossible for the person to be highly active in two 
places at once! Similarly, the time a person spends outside the home is not just 
associated with that person’s ‘activity level’, but also with ‘sleep’ and ‘social energy’.  
The existence of any two or more prodromes may be sufficient to indicate a potential 
relapse, and thus we set a certain number of observed behaviours to be occurred at a 
time to imitate its associated prodromes (see Appendix A2). 
We assigned a value of 1 (= ‘yes’) when an observed behaviour exceeded its 
specified threshold levels, and 0 (= ‘no’) otherwise. Hence, the PAM scoring system 
ranged from 0 to 14 since there are 14 observable behaviours. Hirschfeld et al (2000) 
used a similar type of scoring system in developing the Mood Disorder   -118-
Questionnaire. To be screened positive for a potential relapse, it is not mandatory to 
score the maximum 14 points. Different values were tested in the simulation.  
The question remains how long a person should persist with the prodromal 
symptoms before receiving an alert, to minimise the number of false alerts. Again we 
used information from the clinical literature to guide our choice. Keane (2010) 
reported that a manic patient hardly slept for 4 successive days. In our first set of 
tests, PAM sent an alert if the prodromal symptoms persisted for 3 out of 5 successive 
days. Table 7.6 (where A, B, …, G represent the observed behaviours) shows a 
descriptive example of how such a decision rule would work for a hypothetical 
patient who had chosen to be monitored on ‘activity level’ and ‘sleep’ patterns: 
 
Day  A  B  C  D  E  F  G  If A+B+C+D >= 2 
and E+F+G >=2 
PAM 
alert 
1 0 0 1 0 0 0 1  No no 
2  1  0  0  1  0  1  0  No  no 
3 0 1 0 1 1 0 1  Yes no 
4  1  0  1  0  1  1  0  Yes  no 
5 0 1 1 1 0 0 1  No no 
6  1  1  0  0  1  1  1  Yes  yes 
7 1 1 1 1 1 1 1  Yes yes 
Table 7.6   An example of how the decision rules work 
Of course, the form of the decision rules and the threshold levels for deciding 
whether PAM should alert a patient or his/her carer may be too sensitive or not 
sensitive enough. This was the whole reason for undertaking the simulation 
modelling, to test out values and settings for these rules in an artificial environment 
on synthetic patients. 
 
7.5  The computer model 
The model was implemented in Microsoft Excel using the risk analysis add-in 
“@Risk” software (Palisade, 2008), which offers a wide choice of input probability 
distributions to test various monitoring scenarios. Our computer model is based on 
the theoretical framework of stochastic process to predict the risk of any outcome 
arising from the underlying multi-state process with the inclusion of individual traits.    -119-
Basically the model is driven by the mental health status (as determined by the 
parameter λ) of a single patient, varying stochastically over an 18-month time 
horizon.  Each row in the spreadsheet represents one day, and each iteration of the 
model corresponds to one potential realisation of that patient’s mental health 
trajectory over 18 months.  Each day, the λ is used to generate a set of behaviours, 
and then according to the set of sensors that that person has chosen, that behaviour 
may (or may not) be observed by PAM, as described in Section 7.4.3.  Finally, the 
chosen decision rule is applied for that day and an alert issued (or not). Since the true 
value of λ is known in the model, it is thus possible to determine whether an alert (if 
issued) was a true positive or a false positive, and otherwise, if no alert was issued, 
whether this was a true negative or a false negative. 
 
7.5.1  Excel implementation 
The model was implemented in Excel and coded in Visual Basic for Applications (see 
Appendices A.6.1, A.6.2 and A.6.3), which can be viewed using the memory stick 
enclosed in Appendix A8, but the “@Risk” software is required to view and run the 
model.  It is driven by the UserInterface worksheet (see Figure 7.7), in which the 
various buttons correspond to the observed behaviours, and are used to store patient-
specific data within specific locations of the Data worksheet, i.e. the values of N, D 
and M for each behaviour, as described in Section 7.4 (see Figure 7.8 below). 
 
 
Figure 7.7   Screenshot of UserInterface worksheet   -120-
 
Figure 7.8   Screenshot of Data worksheet 
At runtime, the Actual worksheet (see Figure 7.9) reads in the data from the 
Data worksheet and (using the @Risk functionality) samples that day’s actual value 
for each behaviour from the appropriate triangular distribution. Next, @Risk is used 
to determine whether that actual activity was detected by PAM. Another column in 
the Actual worksheet is used to represent the PAM-detected behaviour. Finally, the 
model checks the decision rules and compares the person’s PAM-observed behaviour 
with his/her normal behaviour to check if the threshold levels are exceeded. The 
Scores worksheet is used to calculate the daily PAM score, which is of course based 
on the threshold levels. 
 
Figure 7.9   Screenshot of Actual worksheet   -121-
The numbers of true/false positive alerts and true/false negatives are recorded 
in the Results worksheet (see Figure 7.10), and form the primary output of the model, 
enabling the performance of the PAM system to be evaluated for that particular 
combination of patient, behaviours, sensors and decision rules. The model also 
outputs the number of days before the first depressive alert (denoted by ODE) and the 
number of days before the first manic alert (OME). Again, since the true 
(approximate date) of onset of an episode is known, we can determine how long PAM 
takes to detect this, and this was achieved through VBA coding (see Appendix A6.4). 
On average, the model took about 20 minutes to run each combination of prodromes 
on a PC with 1.18 GHz and 1.99 GB of RAM. 
 
 
Figure 7.10   Screenshot of Results worksheet   -122-  -123-
 
 
8.  Experimentation and Results 
In this chapter, we first show that our OR model is valid and suitable for its intended 
purpose. We then describe all the different scenarios that were run for various 
hypothetical patient types in terms of their various preferences for sensors and their 
‘activity signatures’. 
 
8.1 Model  validation 
We have used a continuous-time multiple state model, because it allowed us to 
illustrate the underlying process comprehensively. We estimated a large number of 
transition intensities, for which satisfactory data did not exist. We attempted to 
properly verify the computer simulation model by incorporating the comprehensive 
understanding of the actual operation to ensure that it is fit for purpose. We have 
performed a validation study in order to make sure that the model works well.  In 
conducting the analyses, we essentially concentrated on some widely applied 
validation characteristics, including accuracy, repeatability, uncertainty, nonlinearity, 
range and clinical robustness. We considered questions such as did we proceed in the 
right direction, do the results make sense and were our scenarios appropriate? 
The model plots graphs for all the observed behaviours. In order to do this, it 
was necessary to devise a quick way to measure all the PAM-observed behaviours for 
each day. Basically, we sampled the normal (N), manic (M) and depressive (D) data 
from triangular distribution for each day, and used these along with the value of λ 
into Equation 7.1 (see Page 103), which was then used to measure the actual 
behaviours during various mood states. An example of this is shown in the Excel 
function bar (see Appendix A10). Figures 8.1 to 8.4 below show the viability of using 
the modelling framework. The graphs for the ten remaining behaviours are included 
in Appendix A9.  In these diagrams, approximate mental state is colour-coded on the 
x-axis. The normal state is shown in green, the depressed state in blue and the manic   -124-
state in red. Of course, in reality the transition from one state to the other is normally 




































































































Figure   8.4   Daily no. of TV remote keypresses during various mood states 
   -126-
It can be seen that all the daily behavioural activity patterns illustrated in 
Figures 8.1 – 8.4 are in line with common sense and clinical experience. There is 
clearly daily fluctuation around an average value, but distinct changes can be seen 
correlated to mental health status in a logical way. For example, Figure 8.1 shows that 
the model has calculated the physical activity levels of bipolar individuals to be high 
during mania and to be low during depression, compared with their normal activity 
levels.  Similarly, Figures A9.4 and A9.5 both show that the model has correctly 
indicated that bipolar individuals will talk more during mania and talk less during 
depression.  These findings are in line with the clinical literature such as Lam et al 
(2001) and Morriss (2004).  It can also be seen that the evidence of subtle symptoms 
change at every stage of the illness suggests that the moods are clearly never constant 
over a period of time. 
We have shown that the model created is actually a very good representation 
of the reality. In order to model the potential technological uncertainties of the PAM 
system, random variation was added to the actual observations. An illustrative 





































Physical Activity Levels (PAL)
PAM detected PAL
 
Figure   8.5   PAM detected physical activity levels during various mood states   -127-
8.2 Model  outputs 
To assess the usefulness of PAM, two datasets were used, representing different 
patient groups (roughly) corresponding to bipolar I disorder.  Dataset 1 (see 
Appendix A3) relates to bipolar people who typically show marked ups and downs 
during mania and depression with a minimal overlap with normality, whereas Dataset 
2 (see Appendix A4) contains data that overlap noticeably with normality.  
Intuitively, one would expect PAM to work better for Dataset 1 than for Dataset 2. 
For both cases, the model was run for 1,000 iterations for each of the 25 hypothetical 
patient types, thus simulating the disease trajectories of 1,000 different patients of 
each type.  
Each patient type was defined by the combinations of prodromes they 
selected, as described in Chapter 7 (see Page 110 and 111).  Patient types 1 to 10 
chose a selection of two different prodromes, patient types 11 to 19 chose a selection 
of three different prodromes, patient types 20 to 24 chose a selection of four different 
prodromes, and patient type 25 chose all five prodromes. 
 
8.2.1  Running the simulation model with Dataset 1 
The model was first run using the decision rules that if the selected prodromes were 
observed by PAM for 3 out of 5 successive days, then an alert would be sent. These 
were called Decision rules 1. An illustrative example of these rules was previously 
provided in Table 7.5 of Chapter 7 (see Page 113). The model computed the 
following metrics, which were all averaged over 1,000 iterations: 
•  TP (true positive count): the average number of days when patients were 
unwell, i.e. had mild, moderate or severe mania/depression, and PAM 
correctly sent an alert 
•  FP (false positive count): the average number of days when patients were in  
normal good health yet PAM sent an alert 
•  FN (false negative count): the average number of days when patients were 
unwell yet PAM did nothing   -128-
•  TN (true negative count): the average number of days when patients were in 
normal health and PAM did nothing.  
In addition, the model computed the average number of days that PAM took to 
detect the onset of a depressive episode (denoted ODE) and the average number of 
days that PAM took to detect the onset of a manic episode (OME). Table 8.1 shows 
the summary outputs, while Appendix A5.1 shows more detailed outputs: 
 
Patient 
type  ODE  OME  TP  FP  FN  TN 
Type  1  30.72 15.58  143.03 0.88  74.97  327.12 
Type 2  40.26  18.67  102.87  0.18  115.13  327.82 
Type  3  41.63 19.86 97.34  0.10 120.66  327.91 
Type 4  33.23  21.14  124.08  0.86  93.93  327.14 
Type  5  37.92 11.18  116.96 0.25 101.04  327.75 
Type 6  38.40  07.53  125.90  0.32  92.10  327.68 
Type  7  26.29 14.96  144.25 0.84  73.75  327.16 
Type 8  42.61  13.31  97.64  0.05  120.36  327.95 
Type  9  41.06 19.83  101.97 0.11 116.03  327.89 
Type 10  40.62  17.86  107.89  0.22  110.11  327.78 
Type  11  18.82 06.33  165.66 1.47  52.34  326.54 
Type 12  20.83  04.81  166.60  1.47  51.40  326.53 
Type  13  10.99 05.63  171.10 2.30  46.90  325.70 
Type 14  33.35  07.15  137.02  0.67  80.98  327.33 
Type  15  21.08 09.71  153.48 1.83  64.52  326.17 
Type 16  32.84  20.85  124.88  0.81  93.12  327.19 
Type  17  27.31 04.28  157.05 1.05  60.95  326.95 
Type 18  16.73  06.54  165.20  1.39  52.80  326.62 
Type  19  33.03 07.06  140.56 1.00  77.44  327.24 
Type 20  08.10  03.12  185.77  2.79  32.23  325.21 
Type  21  08.37 04.01  182.36 3.45  35.64  324.55 
Type 22  08.17  03.54  183.47  4.26  34.53  323.74 
Type  23  15.97 04.70  168.37 3.90  49.63  324.10 
Type 24  11.14  03.43  179.93  3.02  38.07  324.98 
Type  25  05.90 02.64  190.71 6.94  27.29  321.06 
Table 8.1   Performance of PAM for all the different selections of prodromes (Dataset 1) 
 
The performance of PAM for all 25 hypothetical patient types and their 
various prodromal choices is represented graphically in Figure 8.6 below. Clearly, the 
average TP is fairly low for patients who selected different combination of two 
prodromes only (see Figures 8.6 and 8.7), but considerably higher for those patients 
who chose three or more prodromes (see Figures 8.6, 8.8 and 8.9).  As one would 
expect, as the number of prodromal choices increases, the average ODE and OME   -129-
correspondingly reduces (see Figures 8.7, 8.8 and 8.9).  However, as the number of 












































































Figure 8.7   Performance of PAM for various selections of two prodromes (Dataset 1) 





































































Figure 8.9   Performance of PAM for various selections of four/five prodromes (Dataset 1) 
 
Recall that patient type 1 selected two prodromes (‘activity level’ and ‘sleep’), 
patient type 11 selected three prodromes (‘activity level’, ‘sleep’ and ‘talkativeness’) 
and patient type 20 selected four prodromes (‘activity level’, ‘sleep’, ‘talkativeness’   -131-
and ‘social energy’), on which to be observed. These three patient types have at least 
two prodromes in common, but type 11 has one more prodrome than type 1 and type 
20 has one more prodrome than type 11. Likewise, patient types 2, 12 and 21 form 
another such subgroup. Figures 8.10, 8.11, 8.12 and 8.13 compare the values of TP, 













































































Figure 8.13   Comparison of OMEs for various choices of prodromes (Dataset 1) 
   -133-
Out of all the personalised choices of prodromes discussed above, it appears 
that the PAM system is sending reliable alerts for those individuals (patient types 11 
to 25) who had selected three or more different choices of prodromes. However, 
PAM’s performance is significantly better for individuals who were being observed 
for four/five different choices of prodromes than for those who only chose three 
prodromes. Clearly, in this case the additional prodrome provides additional 
information about the severity of illness, and in a real-life situation, this could be used 
to enable such a patient to make a better informed choice about the value of PAM. 
The patient would need to trade off the benefit of more reliable PAM performance 
against the drawback (for them) of having extra sensors to measure these additional 
prodromes: sensors which they would probably not, in an ideal world, have chosen.  
A further potential disadvantage of adding sensors can be seen from the fact 
that once again, as the number of choices of prodromes increases, so do the FPs.  
Clearly, monitoring additional behaviours helps to increase the TP rate but also 
increases the FP rate. The three highest average FPs for patients selecting three or 
more prodromes were 25 were 6.94 days (patient type 25), 4.26 days (type 22) and 
3.90 days (type 23). Nevertheless, these are not excessive out of a total of 546 days. 
Thus, the PAM system is not only capable of keeping false alarms to a reasonably 
low level, but is also capable of providing genuine alerts a high proportion of the 
time: the average true positive rates were 87.5% (type 25), 84.16% (type  22) and 
77.23% (type 23).   
However, for those individuals who had only chosen two prodromes (patient 
types 1 to 10), the results show that PAM may not be robust enough to send reliable 
alerts for all of these individuals. In particular, it can be seen from Table 8.1 and from 
Table 8.2 below that the overall performance for patient types 2, 3, 8, 9 and 10 is not 
as good as for the others. Nevertheless, the results for patient types 1, 4, 6 and 7 are 
more encouraging. The TP rates of these four particular patient types were 
respectively found to be 65.61%, 56.92%, 57.75% and 66.17%, while the FP rates are 
very low indeed: 0.27%, 0.26%, 0.10% and 0.26%.   -134-
The other performance measure was the time taken to detect the onset of 
depressive and manic episodes, i.e. the metrics ODE and OME. The model yielded 
satisfactory average ODEs and OMEs for nearly all patient types. Unsurprisingly, the 
results suggest that the more prodromes that are chosen, the better the outcomes. The 
best results were for type 25, with all five prodromes; in this case PAM would on 
average take 5.90 and 2.64 days to detect the onsets of depressive and manic 
episodes, respectively. Of those patient types who chose four prodromes, 20 to 24, the 
best results were for type 22. In this case PAM would respectively take 8.17 and 3.54 
days to detect the onsets of depressive and manic episodes. The worst case was 
patient type 23, with 15.97 and 4.70 days respectively. For the patients who chose 
three prodromes, types 11 to 19, the ODEs and OMEs are respectively 10.99 and 7.26 
days in the best case scenario (type 13), and 32.84 and 20.85 days in the worst case 
scenario (type 16).   
On the other hand, the ODEs and OMEs for individuals with two prodromes 
whose choices are earlier described as encouraging in terms of TPs and FPs are 
shown in Table 8.2 below: 
 
Patient type 










Type  1  30.72 15.58 65.61  0.27 
Type 4  33.23  21.14  56.92  0.26 
Type  6  38.40 07.53 57.75  0.10 
Type 7  26.29  14.96  66.17  0.26 
Table 8.2   Promising combinations of two prodromes (Dataset 1) 
 
It can be seen from the results that the ODE is generally longer than the OME.  
This is in line with the clinical literature and provides further evidence that the model 
is producing valid results. The average duration of a depressive episode (128 days) 
has been found to be longer, and more gradual in onset, than the average duration of a 
manic episode (90 days). However, the main reason for the difference between the 
ODE and the OME is that the characteristics of manic behaviour are more distinctive 
and thus relatively easier to recognise than those of depressive behaviour. Many   -135-
people with no mental health problems at all will experience some of the symptoms 
of mild depression from time to time, whereas even mildly manic behaviour is much 
less common in the general population. Chapter 9 contains further discussion on this 
matter. Finally, of course, the underlying structure of the decision rules may also have 
been a causal factor. The model requires a threshold to have been exceeded for three 
out of the previous five days before sending an alert. Since the symptoms of mild 
depression are subtle and intermittent in nature, we would expect to have to wait 
longer to get a consistent result of 3 out of 5 days. 
Therefore, even though the TPs and FPs appear reasonable for patient types 1, 
4, 6 and 7 (see Table 8.2 above), the reliability of the PAM system is still unclear for 
these patients, especially for detecting the onset of depressive episodes. Thus, further 
experimentation is required in order to evaluate the benefit of PAM for these four 
patients. 
 
8.2.2  Running the simulation model with Dataset 2 
To further assess the usefulness of the PAM system, we next ran the model using the 
same decision rules for 1,000 iterations with Dataset 2 for an 18-month period for 
each of the same 25 hypothetical patient choice types. Recall that Dataset 2 refers to 
patients with generally milder symptoms.  Various model outputs are shown in Table 










   -136-
Patient 
type  ODE  OME  TP  FP  FN  TN 
Type  1  34.15 22.23  128.23 0.68  89.77  327.32 
Type 2  42.04  21.17  87.22  0.09  130.78  327.91 
Type  3  46.13 25.37 49.71  0.01 168.29  327.99 
Type 4  38.45  23.46  104.23  0.40  113.77  327.60 
Type  5  40.98 20.74 96.53  0.13 121.47  327.87 
Type 6  42.00  24.69  79.00  0.06  138.99  327.94 
Type  7  36.67 23.65  119.60 0.49  98.40  327.51 
Type 8  45.66  24.82  62.17  0.01  155.83  327.99 
Type  9  43.31 23.66 81.76  0.04 138.09  327.96 
Type 10  42.82  25.06  67.29  0.01  150.71  327.98 
Type  11  25.13 12.24  153.25 1.15  64.75  326.85 
Type 12  31.12  19.21  142.72  0.90  75.28  327.10 
Type  13  20.73 15.76  156.32 1.45  61.68  326.55 
Type 14  39.01  17.85  110.09  0.22  107.91  327.79 
Type  15  32.02 15.16  138.52 0.94  81.48  327.06 
Type 16  38.43  23.55  103.78  0.37  114.22  327.63 
Type  17  36.35 17.83  125.44 0.34  92.56  327.60 
Type 18  29.04  15.20  145.81  0.90  72.19  327.10 
Type  19  40.23 21.49  109.59 0.18 108.41  327.82 
Type 20  12.77  07.58  168.50  1.66  49.50  326.34 
Type  21  14.45 08.37  166.88 1.97  51.12  326.03 
Type 22  16.77  13.43  160.88  1.64  57.12  326.36 
Type  23  27.21 12.43  145.87 1.19  72.13  326.81 
Type 24  21.42  12.74  154.30  1.13  63.70  326.87 
Type  25  11.33 07.49  170.46 2.28  47.54  325.72 






































Figure 8.14   Performance of PAM for various choices of prodromes (Dataset 2)   -137-
The overall model outputs for Dataset 2 suggest that the PAM system is most 
reliable for patient types 20 to 25, who were being observed for four/five different 
choices of prodromes. PAM is less reliable for patient types 11 to 19, who had only 
opted for three prodromes. Recall that Dataset 2 relates to patients with less severe 
forms of BD, in which depressive and manic data overlap considerably with the 
normal range of data. In comparison with Dataset 1, there will indisputably be less 
variability in Dataset 2 between normal and abnormal data. Thus, we would expect 
that it would be more difficult to detect the onset of acute episodes with such patients.  
We would not only expect fewer true and false alerts (TPs and FPs), but also greater 
delays in detecting the onset of depressive and manic episodes (ODEs and OMEs). 
This can indeed be seen from the model results (see Figures 8.15, 8.16, 8.17 and 8.18) 



















































































































Figure 8.17   Comparison of ODEs between Dataset 1 and Dataset 2 
 
 

































Figure 8.18   Comparison of OMEs between Dataset 1 and Dataset 2 
However, even for individuals who chose three or more prodromes, there 
seems to be some poor outcomes in some cases, compared with the outputs of 
Dataset 1.  The comparisons are shown in Tables 8.4 and 8.5 below: 
 
Patient type 










Type  14  39.01 17.85 50.50  0.07 
Type 16  38.43  23.55  47.61  0.11 
Type  17  36.35 17.83 57.54  0.12 
Type 19  40.23  21.49  50.27  0.05 














Type  14  33.35 07.15 62.85  0.20 
Type 16  32.84  20.85  57.28  0.25 
Type  17  27.31 04.28 72.04  0.32 
Type 19  33.03  07.06  64.48  0.30 
Table 8.5   Poor outcomes for three prodromal choices (Dataset 1)   -140-
The system performance in terms of TPs, ODEs and OMEs is particularly 
inadequate for the patient types listed in Table 8.4. Similarly, the overall results for 
patients with two personalised prodromal choices are also very poor. Nevertheless, 
the average results for patient type 1 (TP: 58.82%, FP: 0.21%, ODE: 34.15 days and 
OME: 22.23 days) are possibly acceptable  (see Table 8.3). 
 
8.2.3  Varying the decision rules 
To investigate how the choice of decision rules affected the results, the model was 
run for 1,000 iterations with Dataset 1 for an 18-month period for every patient, but 
this time an alert was sent if the threshold was exceeded for two successive days 
(Decision rules 2). So far, the PAM system’s overall performance for patients with 
only two prodromal choices has been unsatisfactory. Therefore, we were particularly 
interested to see if the change in decision rules improved the overall system’s 
performance for these patient types. Figure 8.19 and Table 8.6 below, and Appendix 






































Figure 8.19   Performance of PAM for all patient types (Decision rules 2) 
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Patient 
type  ODE  OME  TP  FP  FN  TN 
Type  1  25.04 12.93  104.48 0.02 113.52  327.98 
Type 2  36.64  15.92  70.15  0.10  147.85  327.90 
Type  3  39.89 17.37 67.35  0.03 150.65  327.97 
Type 4  27.40  17.83  88.01  0.62  129.99  327.38 
Type  5  33.10 09.35 87.45  0.01 128.55  327.99 
Type 6  33.65  05.96  98.65  0.14  119.35  327.86 
Type  7  21.74 12.41  109.47 0.04 108.54  327.97 
Type 8  40.73  10.46  75.88  0.06  142.13  327.94 
Type  9  38.31 17.07 74.57  0.02 143.43  327.98 
Type 10  37.79  14.57  81.15  0.24  136.85  327.76 
Type  11  14.03 04.85  140.18 0.26  77.82  327.74 
Type 12  16.59  04.16  140.17  0.39  77.83  327.61 
Type  13  08.93 05.58  152.28 1.07  65.72  326.93 
Type 14  30.56  05.60  110.98  0.41  107.02  327.59 
Type  15  17.86 08.04  125.00 1.37  93.00  326.63 
Type 16  26.88  18.06  88.29  0.60  129.71  327.40 
Type  17  21.50 03.22  128.24 0.45  89.76  327.55 
Type 18  13.27  05.24  138.99  0.20  79.02  327.81 
Type  19  28.58 05.66  115.73 0.86 102.22  327.14 
Type 20  06.76  02.29  163.89  1.45  54.11  326.55 
Type  21  06.43 03.26  161.50 2.05  56.50  325.95 
Type 22  06.98  02.75  161.85  3.00  56.15  325.00 
Type  23  13.12 03.80  142.36 3.10  75.64  324.90 
Type 24  09.11  02.61  155.12  1.76  62.88  326.24 
Type  25  05.18 02.08  170.64 4.93  47.36  323.07 
Table 8.6   Performance of PAM for all patient types (Decision rules 2) 
 
Unfortunately, the change in decision rules did not improve the system’s 
performance for individuals with two prodromal symptoms. However, for patients 
with three or more prodromal choices, the system was again found to be reliable 
enough in terms of the TPs found with Dataset 1 for both Decision rules 1 and 
Decision rules 2 (see Figure 8.20). Overall, the TPs found with Decision rules 2 were 
consistently low (see Figure 8.20). However, one would to some extent expect this 
given the nature of the decision rules. For example, the system would send an alert 
for a pattern such as 1, 0, 1, 0, 1 using Decision rule 1, but not with Decision rule 2 
since prodromal symptoms in the pattern do not appear for two successive days. 
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TP (decision rules 2)
 
Figure 8.20   Comparison of TPs between the two different Decision rules (Dataset 1) 
 
The outputs found here also suggest that there is no need to test the system 
with stricter criteria, for example continuance of prodromal symptoms for three or 
more successive days, since this would only further reduce the TP rates. On the other 
hand, the FP rate would be unacceptably high if only a single day’s symptoms were 
used. Thus, Decision rules 1 are clearly more effective in every respect. 
 
8.2.4  Other sources of variation in PAM-detected output 
Problems caused by sparse or missing data are very likely in the real PAM system, 
due not only to local technical problems with the sensors themselves (or the patient’s 
deliberate or accidental actions, as described earlier) but also due to issues relating to 
consistent quality of service from the communications infrastructure. Therefore, the 
real-world collected data is likely at times to be sparse and incomplete, and the 
effectiveness of PAM in these circumstances was also tested through simulation 
modelling.   -143-
We have thus far allowed the actual estimations of observed behaviours to 
deviate by a relatively small amount, according to the numbers shown in the 
Technical variation 1 column of Table 8.7, to deal with the potential technological 
uncertainties. We now assume a greater range of variability in the PAM-observed 
estimates for these behaviours, than the baseline Technical variation 1 (as earlier 
shown in Table 7.4 in Page 111) due to more serious technical malfunctions.  
 
Observed behavioural activity 
(unit) 
Technical variation 1 
(±) 
Technical variation 2 
(±) 
Daily activity (PAL)  0.2  0.2 + 0.1 
Earliest time of leaving home (time of day)  0.5  0.5 + 0.1 
Latest time of getting back home (time of day)  0.5  0.5 + 0.1 
TV remote keypresses (number)  10  10 + 5 
Time spent in bed (hours)  0.5  0.5 + 0.2 
Light level between 11pm to 7am (lux)  2  2 + 1 
Noise level between 11pm to 7am (decibels)  2  2 + 1 
Time spent talking on the phone (minutes)  5  5 + 3 
Number of daily phone calls (number)  1  1 + 0 
Time being outside between 5pm and 1am (hours)  0.5  0.5 + 0.1 
Cupboard doors usage (ditto)  2  2 + 1 
Fridge doors usage (ditto)  2  2 + 1 
Microwave door usage (ditto)  2  2 + 0.5 
Usual time of cooking (time of day)  0.5  0.5 + 0.1 
Table 8.7   Further technical variations 
 
The model was run for 1,000 iterations with Dataset 1 and Decision rules 1, 
but with the new technical variations. Table 8.8 and Figure 8.21 below show the 





   -144-
Patient 
type  ODE  OME  TP  FP  FN  TN 
Type  1  37.13 21.57  143.41 1.01  74.59  326.99 
Type 2  36.80  15.02  106.13  0.46  111.88  327.54 
Type  3  41.35 16.66 96.94  0.15 121.06  327.85 
Type 4  19.44  15.34  125.25  7.43  92.76  320.57 
Type  5  36.55 11.30  119.50 0.31  98.50  327.69 
Type 6  32.17  06.30  97.73  0.23  120.27  327.77 
Type  7  17.30 10.68  104.35 0.29 113.65  327.71 
Type 8  42.28  12.84  98.73  0.07  119.27  327.93 
Type  9  39.67 17.99  101.72 0.15 116.28  327.85 
Type 10  39.32  15.36  106.38  1.00  111.62  327.00 
Type  11  12.80 05.11  171.93 2.19  46.07  325.81 
Type 12  13.59  04.24  171.34  2.21  46.66  325.79 
Type  13  06.27  04.26 182.37 12.11  35.61 315.89 
Type 14  28.62  05.95  142.75  1.62  75.25  326.38 
Type  15  11.09  05.92 162.61 13.23  55.39 314.77 
Type 16  20.42  14.95  125.18  7.03  92.82  320.97 
Type  17  24.03 04.26  159.85 1.37  58.15  326.63 
Type 18  12.28  05.47  169.10  1.80  48.90  326.20 
Type  19  29.99 06.08  142.00 3.01  76.00  324.99 
Type 20  06.27  02.83  190.05  5.67  27.95  322.31 
Type  21  04.40 02.69  194.08 20.8  23.92  307.20 
Type 22  04.49  02.45  193.60  25.63  24.40  304.27 
Type  23  07.60  03.10 179.06 27.10  38.94 302.90 
Type 24  08.07  02.88  184.22  08.08  33.78  319.92 
Type  25  03.83  02.08 198.55 25.21  19.45 302.79 








































Figure 8.21   Performance of PAM for various choices of prodromes (Technical variation 2)   -145-
The outputs again tend to be better for patients with 3 or more prodromes than 
for those with 2 prodromes. Comparing the TPs (Figure 8.22), FPs (Figure 8.23), 
ODEs (Figure 8.24) and OMEs (Figure 8.25) for the two sets of technical variation, in 
many cases the change in technical variation did not appear to make any real 
significant difference. However, there are some notable differences. For example, the 
FP results for patient types 4, 13, 15, 16, 21, 22, 23 and 25, are strikingly different 
(see Figure 8.23). These patients all have two specific prodromes (‘activity level’ and 
‘appetite’) in common. These two prodromes are based on eight observable 
behaviours, and thus the overall results differ more widely than for prodromes based 
on a smaller number of observable behaviours. Likewise, there are some differences 
in the TP results for patient types 7, 21 and 23 (see Figure 8.22 below), and in the 
ODE and OME results for patient types 4, 7, 15, 16 and 23 (see Figures 8.24 and 






















































Table 8.9   Patient types with specific prodromes   -146-
  It can be seen from Table 8.9 that prodromes such as ‘activity level’ and 
‘appetite’ (each with four observed behaviours) and ‘sleep’ (with three observed 
behaviours) are rather more informative than prodromes such as ‘talkativeness’ and 
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Figure 8.25   Comparison of OMEs between the two sets of technical variation (Dataset 1) 
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8.3  Minimum sets of sensors for personalised choices 
The aim of the trials conducted so far was to evaluate the performance of PAM under 
various sensor configurations, corresponding to an individual patient’s willingness to 
be monitored for different combinations of prodromes. Conversely, it is also of 
interest to investigate what sensors would be required in order to provide information 
of a given quality to the patient. In other words, the model results can be used 
“backwards”: the required performance criteria are now defined in advance, and the 
model used to determine which sensor configurations meet these criteria. Following 
discussions with the rest of the PAM team, it was decided to set the following target 
performance criteria for PAM: a minimum TP rate of 70%, a maximum FP rate of 
3%, a maximum ODE of 3 weeks and a maximum OME of 2 weeks. 
Using the simulation results already obtained, the following three Tables 
(8.10, 8.11 and 8.12) were constructed.  Each Table shows the smallest set of sensors 
acceptable to patients in each category, in descending order of TP values, which meet 
these target criteria for different combinations of Dataset and Decision rules. 
 
Patient type  Prodromal 
choice 
















Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone 
sensor; Camera;  
Cupboard door sensors 






Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone sensor 






Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Camera; 
Cupboard door sensors 






Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone 
sensor; Camera;  
Cupboard door sensors 
 






GPS; Pressure mat; Light 
sensor; Microphone; 
Phone sensor; Camera; 
Cupboard door sensors 





Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Camera; 
Cupboard door sensors 






Accelerometer; GPS; TV 
usage sensor; Phone 
sensor; Camera;  
Cupboard door sensors 





Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone 





Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone sensor 





Pressure mat; Light 
sensor; Microphone; 
Phone sensor; Camera; 
Cupboard door sensors 





Accelerometer; GPS; TV 
usage sensor; Camera; 
Cupboard door sensors 
21.08 09.71 70.40  0.56 
Table 8.10   Acceptable choices in descending order of TPs (Dataset 1; Decision rules 1) 
 
Figure 8.26 below shows the acceptable choices of prodromes (for Dataset 1 
and Decision rules 1) listed in the above table along with their associated number of 
sensors. The minimum number of sensors required is found to be 5 (out of a total 9 
available) for patient type 15. However, with 7 sensors, the PAM system is capable of 
offering up to 4 personalised choices of prodromes (patient types 11, 20, 23 and 24). 
Clearly, patient type 21 would be better advised to choose the same set of prodromes 
as patient type 25, because both these types require exactly the same number of 
sensors but Type 21 is only monitored on 4 prodromes whereas Type 25 is monitored 
on 5.  Similarly, it would be better for patient types 11 and 13 to choose the same 
prodromes as patient types 20 and 22, respectively.   -150-
The two trend-lines in Figure 8.26 show that the choices of prodromes which 
are derived from more sensors are generally more robust. However, this is not always 
true, for example compare patient type 20 (with a TP of 85.22% from 7 sensors) with 
patient type 21 (with a TP of 83.65% from 9 sensors). This apparently 
counterintuitive result occurs because ‘activity level’ and ‘social energy’ share 
common sensors, and both of these prodromes belong to patient type 20. 
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Figure 8.26   Acceptable choices of prodromes and their sensors requirement 
 
Out of all the 11 acceptable choices of prodromes (see Table 8.10 above), 
‘activity level’ appeared 9 times, ‘sleep’ 9 times, ‘talkativeness’ 8 times, ‘social 
energy’ 6 times and ‘appetite’ 8 times. This indicates that ‘social energy’ is clearly 
less informative compared with other prodromes. This is not surprising since the two 
observed behaviours that mapped ‘social energy’ were monitored only via one sensor 
(i.e. GPS), and moreover, one of these two observed behaviours is associated with 
‘activity level’. Moreover, it is tricky, in reality, to monitor specific behaviours that 
may be mapped to ‘social energy’, because a person can be socially energetic in their 
own home as well as outside it. Clearly, there is no simple way to monitor this 
prodrome, and thus to be able to detect this prodrome efficiently, the number of   -151-
required sensors would be quite high, which will of course increase the cost.  The 
only reason for deciding to monitor ‘social energy’ was that the GPS was required for 
‘activity level’, and therefore this sensor could also be used, at no extra cost, for 
‘social energy’. 
Table 8.11 represents the acceptable choices of prodromes in descending order 
of TPs (for Dataset 1 and Decision rules 2), while Table 8.12 represents the 
acceptable choices of prodromes in descending order of TPs (for Dataset 2 and 
Decision rules 1).  The patient types listed in these two tables are subsets of patient 
types listed in Table 8.10 above.  
 




















Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone 
sensor; Camera;  
Cupboard door sensors 






Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone sensor 






Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Camera; 
Cupboard door sensors 






Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone 
sensor; Camera;  
Cupboard door sensors 






GPS; Pressure mat; Light 
sensor; Microphone; 
Phone sensor; Camera; 
Cupboard door sensors 





Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Camera; 
Cupboard door sensors 
08.93  05.58  69.85  0.33 
Table 8.11   Acceptable choices in descending order of TPs (Dataset 1; Decision rules 2)   -152-
 
 




















Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone 
sensor; Camera;  
Cupboard door sensors 






Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone sensor 






Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Phone 
sensor; Camera;  
Cupboard door sensors 






Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Camera; 
Cupboard door sensors 





Accelerometer; GPS; TV 
usage sensor; Pressure 
mat; Light sensor; 
Microphone; Camera; 
Cupboard door sensors 






GPS; Pressure mat; Light 
sensor; Microphone; 
Phone sensor; Camera; 
Cupboard door sensors 
21.42  12.74  70.78  0.34 
Table 8.12   Acceptable choices in descending order of TPs (Dataset 2; Decision rules 1) 
 
More challenging performance criteria, for example a minimum TP rate of 
75%, a maximum FP rate of 1%, 2 weeks for ODE and one week for OME, are still 
achievable although not in quite so many cases. 
   -153-
 
 
9.  Discussion and conclusion 
This chapter discusses the achievements of this research, the model results and their 
implications, and discusses its limitations and future research ideas. We end with 
some final thoughts and conclusions. As mentioned earlier, we clearly distinguish 
between the objectives, achievements, scientific contributions and limitations of the 
PAM project as a whole, and those of the specific research described in this thesis. 
 
9.1  Achievements of this thesis 
We recall the original research questions, which underpinned the specific modelling 
work described in this thesis, presented in Section 1.8. 
•  Can a “natural history” model be developed for BD, using clinical data from 
the medical literature? 
•  What type of modelling approach is best suited for such a model? 
•  Is adequate clinical data available, and if not, can expert opinion be used 
instead? 
•  Can simulation be combined with this natural history model to capture the 
inherent variability and uncertainty in the real-world system? 
•  Can this model then be used to compare and evaluate different sets of indicator 
responses, from different configurations of sensors, in order to describe an 
individual’s ‘activity signature’? 
•  Can the model assist the design of PAM by minimising the number of sensors 
required, for a given individual? 
These questions are addressed one by one, and represent the scientific 
contribution of the research carried out in this thesis.   -154-
•  Can a “natural history” model be developed for BD, using clinical data from 
the medical literature? 
This was possibly the greatest challenge in this research. BD manifests itself in 
various forms, and it is extremely difficult to develop a “natural history” model due to 
the illness’s characteristics. There are no easily identifiable or measurable diagnostic 
criteria: diagnosis is a very individual and subjective process, based mainly on self-
reports by patients on their moods or behaviour, combined with the observation, 
experience and judgment of the psychiatrist. No universally accepted staging models 
for bipolar disorder are to be been found in the medical literature, such as are 
common for physical diseases such as cancer. There are only a few examples of OR 
models for mental illness in general, compared with physical disease. No examples 
were found in the OR literature for modelling bipolar disorder, although Markov 
modelling has been applied to unipolar major depression, e.g. Patten and Lee (2005).   
We developed a multi-state Markov disease state transition model based on 
transition parameters derived from the clinical literature, and this provided an 
“archetypal” clinical trajectory for bipolar disorder. In this model, the cycle length is 
18 months. The patient starts in the normal state, and undergoes a lengthy period of 
depression followed later by a shorter period of mania. Through the use of Monte 
Carlo simulation, individual variability was incorporated this model by adding 
random “noise” to the current state. 
 
•  What type of modelling approach is best suited for such a model? 
The choice of a Markov state transition model in combination with Monte Carlo 
simulation was made following the review of the literature and consideration of the 
objectives and purpose of our model. A Markov state transition model was simple yet 
sufficiently realistic for our purposes. This approach was the most commonly used in 
the literature for mental illness modelling. Combining the Markov model within a 
Monte Carlo experimental framework enabled us to capture stochastic and dynamic 
behaviour. We did consider discrete-event simulation, but discarded this for practical   -155-
reasons. A DES model would have required a great deal of detailed patient data, 
which were not available. We were able to perform multiple replications and 
sensitivity analyses in a much shorter time than would have been possible using a 
DES model. The other option we considered was a decision tree, but this would not 
have been feasible due to the unmanageable number of potential branches in the tree. 
 
•  Is adequate clinical data available, and if not, can expert opinion be used 
instead? 
Some data regarding the natural history of BD were available from the clinical 
literature, and were used in the model (see Section 7.5). For some state transition 
probabilities and a general discussion about the disease model structure, we also took 
advice from the expert members of the PAM Steering Group. For the technical 
variables concerning the reliability of the PAM sensors, we consulted with the 
engineers in the PAM research team.  However, for values of some of the behavioural 
parameters, for example the average number of phone calls a person might make each 
day or the normal time they leave home in the morning or cook their evening meal, 
we had to resort to common sense. While there was evidence in the literature about 
the importance of these behaviours, we had no secondary or primary data on which to 
populate the model.  
 
•  Can simulation be combined with this natural history model to capture the 
inherent variability and uncertainty in the real-world system? 
The model was implemented in Microsoft Excel, coded in VBA, and using the @Risk 
simulation software add-in (Palisade, 2008). The Monte Carlo experimentation 
revealed that the stochastic Markov model is able to capture dynamic behaviour and 
detect a patient’s true health state over time.  Although it was important to be able to 
assess the model’s reliability in practice, the process of model verification is never 
easy. The computer simulation model was verified by incorporating a comprehensive 
understanding of the real-world system. The results it produced were realistic and   -156-
plausible. In Section 8.2 of Chapter 8, we have shown that the model created is 
actually a very good representation of reality.  
 
•  Can this model then be used to compare and evaluate different sets of 
indicator responses, from different configurations of sensors, in order to 
describe an individual’s ‘activity signature’? 
The answer to this question is yes, although we went a slightly different route than 
originally planned due to delays with the NHS ethics, and used illustrative rather than 
real-life data from the patient trial. However, the value of the thesis from a 
mathematical OR viewpoint has not been affected. The simulation model was used to 
perform a very large number of hypothetical trials, using a) two different (realistic) 
clinical patterns of bipolar disorder; b) two different decision rules about when to 
send the patient an alert about a potential change on their behaviour; c) 25 different 
combinations of up to five behavioural prodromes for which patients were willing to 
be monitored (this was a proxy for the actual personalised selection of sensors and 
locations in the home, of which there would be unfeasibly many); d) two different 
levels of technical reliability of the PAM system itself.  
The PAM system was tested with two types of clinical data: Dataset 1 and 
Dataset 2.  Patients in the first group have more extreme mood swings and associated 
abnormal behaviour than in the second. These datasets are presented in Appendices 
A.3 and A.4. The results showed that the PAM system can offer a wider set of 
personalised prodromal choices to patients who fall into Dataset 1 than into Dataset 
2. In order to determine whether or not to send alerts to patients, two different groups 
of decision rules were tested, Decision rules 1 and Decision rules 2. The former 
required prodromal thresholds to be exceeded (i.e. abnormal behaviour observed) on 
3 out of 5 successive days.  The latter required prodromal thresholds to be exceeded 
on two successive days.  Decision rules 1 were found to be more effective in 
enhancing the performance of the system, and were used in all further 
experimentation.    -157-
Output from the model included the four most common healthcare technology 
evaluators, i.e. true positive alerts (TP), false positive alerts (FP), true negatives (TN) 
and false negatives (FN). In addition the model computed the average number of days 
that the PAM system took to detect the onset of a depressive episode (ODE) and the 
onset of a manic episode (OME). The ideal would be a very low FP, a very high TP, 
and very low ODE and OME. Although the PAM system did send some false alerts, 
these were minimal in all cases. On the other hand, the TP rate did not exceed 90% 
for any of the personalised prodromal choices examined. This shows that the model is 
not biased towards keeping the FP values low. 
The PAM system was able to detect both aspects of BD, but was more 
efficient in detecting the onset of manic relapse than depressive relapse. This is in 
accordance with clinical reality (see Section 8.2.1). Nevertheless, PAM was still able 
to detect the onset of depressive relapse early enough for various personalised 
prodromal choices.  
 
•  Can the model assist the design of PAM by minimising the number of sensors 
required, for a given individual? 
The overall performance of the system was found to be inadequate for almost all the 
personalised choices of two prodromes only. This is not surprising, because the 
clinical literature suggests it is difficult to confirm a relapse signature with the 
appearance of only two prodromal symptoms. However, the outputs presented in 
Table 8.10 of Chapter 8 (see Page 145) confirms that the PAM system is efficient 
enough to provide its intended services to individuals who opt to be monitored for 
four or five personalised prodromal choices. 
The performance of the system was also found to be efficient for various 
personalised choices of three prodromes. However, the system was found to be less 
effective for some combinations of personalised prodromal choices, for example 
‘sleep’, ‘talkativeness’ and ‘social energy’, or ‘talkativeness’, ‘social energy’ and 
‘appetite’. To be able to effectively offer choices such as these, the system may need   -158-
to increase the number of their associated observable behaviours. This will not only 
improve the performance of these particular choices, but will also improve the 
performance of other choices. 
 
9.2  Achievements of the PAM project 
We begin by recalling the original research questions, which underpinned the PAM 
project as a whole. 
•  Is it possible to obtain, in an automatic, ambient and unobtrusive manner, 
‘activity signatures’ from mental health patients that provide information 
about the trajectory of their health status? 
•  If this is so, can this information be used to assist their healthcare? 
The first of these two research questions has been answered affirmatively.   
The discreet sensor system built by the Nottingham group was indeed capable of 
deriving data which could be analysed and transmitted onwards using IT systems 
developed by the Stirling group, from which different activity patterns could clearly 
be identified through the use of feature extraction algorithms developed by the ISVR 
group. The PAM system was tested on healthy volunteers (the team members 
themselves) and also on a bipolar patient. The second question, however, still remains 
partly open: in order to test the practical clinical benefit, a large-scale randomised 
controlled trial will be required. However, the contribution of OR modelling and the 
findings from the simulation modelling reported in this thesis suggest strongly that 
clinically useful information can indeed be obtained through PAM. 
 
9.3 Limitations 
We were unable to recruit four bipolar patients for our original small field study, due 
to delays in receiving NHS ethical approval (in March 2010) and the inevitable 
bureaucratic processes required by NHS ethics in order to find suitable patients to 
take part in our study. Although we did recruit one participant, we did not receive her 
data in time for inclusion in any of the doctoral research which was part of PAM.   -159-
Thus, the OR model (and indeed, the algorithms and experimental hypotheses in the 
other three PhD theses arising from the PAM project) could not be tested on real 
patient data. Although most of the data used in our simulation model was obtained 
from the medical literature, this must nevertheless be seen as a limitation of the study. 
However, it is probably less of a limitation for the simulation modelling than it was 
for the engineering and computer science students.  
Bipolar disorder is a multi-dimensional and extremely complex illness, and 
clearly even a multi-state Markov model based on a single parameter λ is a huge 
oversimplification. For example, BD is now clearly understood by psychiatrists to 
have mixed episodes as well as the simple one-dimensional spectrum from depression 
to mania. Moreover, clinical evidence suggests there are as many different patterns of 
BD as there are humans suffering from it, and to assume that this can be modelled by 
a single “archetypal” disease trajectory (albeit with some random variation in timing, 
duration and intensity of episodes) is arguably our most limiting assumption. We did 
attempt to mitigate this by modelling the two different clinical datasets: Dataset 1 and 
Dataset 2. However, we believe that our disease state transition model is nevertheless 
fit for the intended purpose of this research, in the sense of providing an adequate 
description of the natural history of BD within which to test the PAM system.  
Many other model assumptions, such as the choice of triangular distributions 
for the activity patterns, could have been made more realistic had empirical data been 
available and other distributions fitted. One obvious drawback of the triangular 
distribution is that it does not allow the sampling of extreme values. However, this 
was not felt to be a severely limiting assumption for the behavioural variables. The 
derivation of equation 7.1, and the mapping from λ to the generated behaviour using 
the parameters N, M and D, was again chosen somewhat arbitrarily and clearly other 
functions could have been used. Once again, we were restricted by the absence of 
empirical data and the total absence in the literature of any kind of similar research.  
As a first effort therefore, equation 7.1 and the subsequent addition of random noise 
to the generated values was considered adequate for its intended purpose. The   -160-
mapping from λ to a behaviour value matched both clinical experience and common 
sense.  
 
9.4 Further  research 
Once again, some potential future work relates to the PAM project as a whole, and 
other work relates to further development or application of the simulation model 
described in this thesis. Clearly, the next stage in the development of PAM would be 
a larger scale clinical trial over a longer period (18 months to 2 years) involving a 
much larger set of patients. Patients could be randomised so that some use PAM and 
others use traditional manual diary-based methods. This would require the 
development of more robust sensors, software and IT communications network. For 
the small trial performed in this project, the devices were “home-made” and the 
network very much an experimental effort, rather than a production-type system. In 
addition, the level of user support would need to be fairly high initially, as inevitably 
there would be some technical issues. We had to make several home visits to our trial 
participant. 
One key issue was not really explored in the PAM project due to lack of time, 
but which such a clinical trial could evaluate, was the acceptability of PAM from the 
perspectives of both patients and caregivers. The PAM team members tested the 
system on healthy volunteers (i.e. themselves), and showed that the system works 
technically and generates detectable repeated daily activity patterns from different 
sensors. It seemed from our discussions with self-help bipolar groups that in general, 
acceptability was unlikely to be a problem. However, we did not have the opportunity 
to assess for ourselves in practice whether bipolar sufferers would actually accept 
remote monitoring using PAM. This research question underpinned the practical trial 
with real participants, and unfortunately we were only able in the end to recruit one 
participant. Therefore, this remains a topic for further research. It is possible that this 
could be partially addressed by a patient survey, but we believe that people really 
need to experience monitoring for themselves before making a reliable judgment.  
The team members who tested PAM on themselves found that the process of being   -161-
monitored was in some ways quite different to what they had expected. Some aspects 
of monitoring were genuinely ignorable, but the researchers remained conscious of 
some sensors throughout the trial.  
The simulation model showed the feasibility of inferring the mental state of 
bipolar patients from their behavioural activity patterns. The PAM technology could 
potentially be applied to the management of other chronic mental diseases in which 
the early onset of acute episodes is characterised by changes in behaviour, for 
example schizophrenia. 
A common use of operational research and statistical modelling has been to 
support economic evaluation of medical interventions. For example, NICE (the 
National Institute of Health and Clinical Excellence) requires that a cost-effectiveness 
analysis is performed before any new treatment (device or drug) can be prescribed on 
the NHS. Modelling plays a key role in this (see Section 5.1). Thus, it would be very 
interesting to explore the potential use of the existing simulation model for an 
economic analysis. This could include cost analysis, cost effectiveness analysis, cost 
utility analysis and/or cost benefit analysis. It would be necessary to determine the 
operating costs of PAM once it had become established in production mode, as well 
as the intangible costs to the patient of being monitored: for example, the time spent 
charging portable devices or the potential “embarrassment factor” of having to 
explain the system to visitors. 
It would also be necessary to estimate the financial benefits (e.g. the costs of 
averted hospital admissions or medications) and the intangible benefits such as 
increased psychological wellbeing and sense of control over one’s condition. Of 




We have shown that bipolar disorder is a major and severely disabling chronic 
condition which can be alleviated by self-management. Through monitoring daily   -162-
activities, patients and caregivers develop a greater awareness of the context in which 
acute episodes occur, and can take pre-emptive action. Manual self-monitoring 
systems have been shown to be unreliable and in particular, ineffective at picking up 
the early signs of depression. The PAM system, consisting of a network of wearable 
and environmental sensors, is able to analyse activity patterns and detect small 
changes in behaviour which may indicate the onset of an acute episode.  
Operational Research modelling was crucial to test the robustness of the PAM 
process. A dynamic disease state transition model was developed which represented 
the progression of bipolar disorder. This was then embedded in an Excel-based 
modelling framework which represented significant activity patterns for BD patients, 
and modelled the detection of these patterns using the PAM system. Technological 
considerations, risk and uncertainty inherent in monitoring patients using PAM were 
incorporated into this model through the use of Monte Carlo simulation using the 
add-in @Risk. The model showed that an automated ambient self-monitoring system 
like PAM can be adjusted and personalised, and can be offered as a direct motivator 
for behavioural change in bipolar patients. 
In this novel approach, technology and modelling were combined to describe 
the dynamic behaviour of bipolar patients. We believe that this approach will be of 
great interest to the OR healthcare modelling community. The model tested the 
capability of the PAM system to produce reliable results in a real-life situation from a 
limited set of sensors. The model was used to specify the minimum best set of sensors 
for adequate monitoring. The overall performance of PAM was found to be good 
enough to support the need for further trialling. 
The PAM system has been found to be capable to capture mood variability in 
an automatic, ambient and unobtrusive manner. Through PAM, it is possible to 
provide useful information about a patient’s mental health status. The modelling 
component of the PAM project showed that it is possible to send timely alerts of an 
imminent bipolar episode through integrating behavioural signatures into a patient’s 
healthcare plan. The system could therefore provide healthcare professionals with   -163-
additional clinical information to benefit bipolar patients. Hopefully, in future 
healthcare communities, patients and their families will find PAM reliable, simple to 
use and an effective method to improve the quality of care while also reducing costs. 
It is also possible that the same technology may be applicable to other patient groups 
with very little changes required.  
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if and only if 
Activity level 
Sleep 
Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
[If  A+B+C+D >= 2 
AND 
If  E+F+G >= 2] 
OR 
[If  A+E = 2 
AND 
If  B+C+D+F+G >= 2] 
OR 
[If  A = 1 
AND 
If  E+F+G >= 2] 
OR 
[If  E = 1 
AND 
If  A+B+C+D >= 2] 
OR 
[If A+D+E = 3] 
OR 
[If  A+B+C+D+E+F+G >= 5] 
Activity level 
Talkativeness 
Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
[If  A+B+C+D >= 2 
AND 
If  H+I >= 1] 
OR 
[If  A+H = 2 
AND 
If  B+C+D+I >= 2] 
OR 
[If  A+I = 2 
AND 
If  B+C+D+H >= 2] 
OR 
[If  A = 1 
AND 
If  H+I >= 1] 
OR 




Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
[If  A+B+C+D >= 2 
AND 
If  J = 1] 
OR 
[If  A+C+J = 3] 
OR 
[If  A+J = 2 
AND 
                                                 
1 Social energy comes from spending time in a stimulating environment with other people. Source: 
   http://www.scotthyoung.com/blog/2007/04/10/social-energy/ (accessed on 20.01.2010)   -190-
If  B+C+D >= 2] 
OR 
[If  C+J = 2 
AND 
If  A+B+D >= 2] 
OR 




Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 
Usual time of cooking (N) 
[If  A+B+C+D >= 2 
AND 
If  K+L+M+N >= 2] 
OR 
[If  A+N = 2 
AND 
If  B+C+D+K+L+M >= 2] 
OR 
[If  A = 1 
AND 
If  K+L+M+N >= 2] 
OR 
[If  N = 1 
AND 
If  A+B+C+D >= 2] 
OR 
[If A+M+N = 3] 
OR 
[If B+C+D+M+N = 5] 
OR 
[If A+B+C+D+K+L+M+N >= 6] 
Sleep 
Talkativeness 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
[If  E+F+G >= 2 
AND 
If  H+I >= 1] 
OR 
[If  E+H = 2 
AND 
If  F+G+I >= 1] 
OR 
[If  E+I = 2 
AND 
If  F+G+H >= 1] 
OR 
[If  E = 1 
AND 
If  H+I >= 1] 
OR 
[If  E+F+G+H+I >= 4] 
Sleep 
Social energy 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
[If  E+F+G >= 2 
AND 
If  J+C >= 1] 
OR 
[If  E+J = 2 
AND 
If  F+G+C# >= 1] 
OR 
[If  E+C = 2 
AND 
If  F+G+J >= 1] 
OR 
                                                 
2 Appetite is the desire to eat and drink. A decreased appetite refers to when someone has a reduced desire to 
  eat or drink despite the body’s basic energy needs. Source: Webster’s Dictionary.   -191-
[If  E = 1 
AND 
If  J+C >= 1] 
OR 




Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 
Usual time of cooking (N) 
[If  E+F+G >= 2 
AND 
If  K+L+M+N >= 2] 
OR 
[If  E+N = 2 
AND 
If  F+G+K+L+M >= 2] 
OR 
[If  E = 1 
AND 
If  K+L+M+N >= 2] 
OR 
[If  N = 1 
AND 
If  E+F+G >= 2] 
OR 
[If  E+M+N = 3] 
OR 
[If  F+G+M+N = 4] 
OR 
[If  E+F+G+K+L+M+N >= 5] 
Talkativeness 
Social energy 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
[If  H+I >= 1 
AND 
If  J+C >= 1] 
OR 
[If  H = 1 
AND 
If  J+B >= 1] 
OR 
[If  H+J = 2 
AND 
If  I+C >= 1] 
OR 
[If  H+C = 2 
AND 
If  I+J >= 1] 
OR 
[If  H+I+J+C >= 3] 
Talkativeness 
Appetite 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 
Usual time of cooking (N) 
[If  H+I >= 1 
AND 
If  K+L+M+N >= 2] 
OR 
[If  H+N = 2 
AND 
If  I+K+L+M >= 2] 
OR 
[If  I+N = 2 
AND 
If  H+K+L+M >= 2] 
OR 
[If  N = 1 
AND 
If  H+I >= 1] 
OR 
[If  H+I+N = 3] 
OR   -192-
[If  H+M+N = 3] 
OR 
[If  I+M+N = 3] 
OR 
[If  H+I+K+L+M+N >= 5] 
Social energy 
Appetite 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 
Usual time of cooking (N) 
[If  J+C >= 1 
AND 
If  K+L+M+N >= 2] 
OR 
[If  J+N = 2 
AND 
If  C+K+L+M >= 2] 
OR 
[If  C+N = 2 
AND 
If  J+K+L+M >= 2] 
OR 
[If  J+M+N = 3] 
OR 
[If  C+M+N = 3] 
OR 




Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time spent talking on the phone (H) 














Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time being outside between 5pm and 1am (J) 














Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 














Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Time being outside between 5pm and 1am (J) 














Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 














Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 














Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Time being outside between 5pm and 1am (J) 














Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 














Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 















Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time spent talking on the phone (H) 
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Time being outside between 5pm and 1am (J) 















Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 

























Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 
























Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 
























Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 

























Daily activity (A) 
Earliest time of leaving home (B) 
Latest time of getting back home (C) 
TV remote keypresses (D) 
Time spent in bed (E) 
Light level between 11pm to 7am (F) 
Noise level between 11pm to 7am (G) 
Time spent talking on the phone (H) 
Number of daily phone calls (I) 
Time being outside between 5pm and 1am (J) 
Latest time of getting back home (C) 
Cupboard doors usage (K) 
Fridge doors usage (L) 
Microwave door usage (M) 
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Appendix A3   Dataset 1 












3  RiskTriang(1.7,1.9,2.0) RiskTriang(1.9,2.2,2.5) RiskTriang(1.0,1.4,1.7) if AA > 2.0  OR 
AA < 1.7, then 1 
Earliest time of 
leaving home (time) 
RiskTriang(7,8,9)  RiskTriang(5,6,7)  RiskTriang(8,9,11)  if AA < 7 OR 
AA > 9, then 1 
Latest time of getting 
back home (time) 
RiskTriang(18,19,21) RiskTriang(20,23,24) RiskTriang(16,17,19) if AA > 21 OR 
AA < 18, then 1 
TV remote 
keypresses (number) 
RiskTriang(20,40,60)  RiskTriang(40,75,100)  RiskTriang(0,15,25)  if AA > 60 OR 
AA < 20, then 1 
Time spent in bed 
(hour) 
4 
RiskTriang(6,7,9) RiskTriang(2,4,6) RiskTriang(8,12,14)  if AA < 6 OR 
AA > 9, then 1 
Light level between 
11pm to 7am (lux) 
5, 6 
RiskTriang(5,10,20)  RiskTriang(20,40,70)  RiskTriang(1,4,10)  if AA > 20 OR 
AA < 5, then 1 
Noise level between 
11pm to 7am (dB) 
7 
RiskTriang(15,20,25) RiskTriang(25,30,40) RiskTriang(5,10,20)  if AA > 25 OR 
AA < 15, then 1 
Time spent talking 
on the phone (minute) 
RiskTriang(10,25,50)  RiskTriang(40,70,120)  RiskTriang(0,10,20)  if AA > 50 OR 
AA < 10, then 1 
Number of daily 
phone calls (number) 
RiskTriang(2,5,7) RiskTriang(7,10,16)  RiskTriang(0,1,3) if AA > 7 OR 
AA < 2, then 1 
Time being outside 
btwn 5pm & 1am (hour) 
RiskTriang(1,2,4)  RiskTriang(3,5,8)  RiskTriang(0,0.5,1)  if AA > 3 OR 
AA < 1, then 1 
Cupboard doors usage 
(number)  RiskTriang(8,10,14) RiskTriang(12,18,22)  RiskTriang(2,4,10)  if AA > 14 OR 
AA < 8, then 1 
Fridge doors usage 
(number)  RiskTriang(6,8,10)  RiskTriang(10,14,18)  RiskTriang(2,4,6)  if AA > 10 OR 
AA < 6, then 1 
Microwave door usage 
(number)  RiskTriang(4,6,8) RiskTriang(6,10,14)  RiskTriang(0,2,4) if AA > 8 OR 
AA < 4, then 1 
Usual time of cooking 
(time)  RiskTriang(18,19,21)  RiskTriang(20,22,24)  RiskTriang(16,18,19)  if AA > 20 OR 
AA < 18, then 1 
                                                 
3 Sedentary lifestyle (1.40-1.69 PAL), moderately active lifestyle (1.70-1.99 PAL), vigorously active 
lifestyle (2.00-2.40 PAL) and extremely active lifestyle (>2.40 PAL). Source: www.fao.org/docrep/007/y 
5686e/y5686e07.htm  (accessed on 15.01.2010). 
4  A general guideline for adults is 7 to 9 hours of sleep each night. Source: the National Institutes of Health. 
5  Pollard B, et al (2008). Breast mass detection under increased ambient lighting. Proceedings of the 9th 
international workshop on Digital Mammography. 
6  Campbell S and Dawson D (1990). Enhancement of nighttime alertness and performance with bright 
ambient light. Physiology and Behavior 48(2): 317-20. 
7 Bedroom - sleep disturbance and annoyance if >30 dB. Source: www.engineeringtoolbox.com/decibel-
dba-levels-d_728.html (accessed on 16.01.2010).   -198-
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Appendix A4   Dataset 2 











Daily activity (PAL)  RiskTriang(1.7,1.9,2.0)  RiskTriang(1.9,2.2,2.5) RiskTriang(1.0,1.4,1.8) if AA > 2.0  OR 
AA < 1.7, then 1 
Earliest time of 
leaving home (time) 
RiskTriang(7,8,9)  RiskTriang(5,6,8)  RiskTriang(8,9,11)  if AA < 7 OR 
AA > 9, then 1 
Latest time of getting 
back home (time) 
RiskTriang(18,19,21) RiskTriang(20,23,24) RiskTriang(16,17,19) if AA > 21 OR 
AA < 18, then 1 
TV remote 
keypresses (number) 
RiskTriang(20,40,60)  RiskTriang(40,75,100)  RiskTriang(0,15,30)  if AA > 60 OR 
AA < 20, then 1 
Time spent in bed 
(hour) 
RiskTriang(5,7,9) RiskTriang(2,4,6) RiskTriang(8,12,14)  if AA < 5 OR 
AA > 9, then 1 
Light level between 
11pm to 7am (lux) 
RiskTriang(5,10,20)  RiskTriang(15,40,70)  RiskTriang(1,4,10)  if AA > 20 OR 
AA < 5, then 1 
Noise level between 
11pm to 7am (dB) 
RiskTriang(15,20,25) RiskTriang(20,30,40) RiskTriang(5,10,20)  if AA > 25 OR 
AA < 15, then 1 
Time spent talking 
on the phone (minute) 
RiskTriang(10,25,50)  RiskTriang(35,70,100)  RiskTriang(0,10,20)  if AA > 50 OR 
AA < 10, then 1 
Number of daily 
phone calls (number) 
RiskTriang(2,5,7) RiskTriang(5,10,16)  RiskTriang(0,1,4) if AA > 7 OR 
AA < 2, then 1 
Time being outside 
btwn 5pm & 1am (hour) 
RiskTriang(1,2,4)  RiskTriang(3,5,8)  RiskTriang(0,1,2)  if AA > 4 OR 
AA < 1, then 1 
Cupboard doors usage 
(number)  RiskTriang(8,10,14) RiskTriang(10,16,22)  RiskTriang(2,4,10)  if AA > 14 OR 
AA < 8, then 1 
Fridge doors usage 
(number)  RiskTriang(6,8,10)  RiskTriang(8,14,18)  RiskTriang(2,4,8)  if AA > 10 OR 
AA < 6, then 1 
Microwave door usage 
(number)  RiskTriang(4,6,8) RiskTriang(6,10,14)  RiskTriang(0,2,6) if AA > 8 OR 
AA < 4, then 1 
Usual time of cooking 
(time)  RiskTriang(18,19,20)  RiskTriang(19,22,24)  RiskTriang(16,18,19)  if AA > 20 OR 
AA < 18, then 1 
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Appendix A5   Model outputs 
 





ODE  OME  TP  FP  FN  TN 
Min  2  2 119 0  52  325 
Max  46 27  166 3  99  328 
Mean  30.72 15.58  143.03 0.88  74.97  327.12 
Patient 1 
SD  13.45  8.14 7.37 0.83 7.37 0.83 
Min  0  1  80  0  93  324 
Max  57  27  125  4  138  328 
Mean  40.26  18.67  102.87  0.18  118.01  327.82 
Patient 2 
SD  6.59  7.75  7.92  0.53  7.92  0.53 
Min  7  1 73 0 96  325 
Max  55 27  122 3 145  328 
Mean  41.63 19.86 97.34  0.10 120.66  327.91 
Patient 3 
SD  3.09 7.26 7.42 0.24 7.42 0.24 
Min  0  0  95  0  59  320 
Max  45  26  159  8  123  328 
Mean  33.23  21.14  124.08  0.86  93.93  327.14 
Patient 4 
SD  11.81  6.63  8.65  1.17  8.65  1.17 
Min  2  2 90 0 71  325 
Max  53 26  147 3 128  328 
Mean  37.92 11.18  116.96 0.25 101.04  327.75 
Patient 5 
SD  9.66 7.35 8.39 0.58 8.39 0.58 
Min  3  1  97  0  65  325 
Max  48  25  153  3  121  328 
Mean  38.40  7.53  125.90  0.32  92.10  327.68 
Patient 6 
SD  8.60  5.57  8.50  0.68  8.50  0.68 
Min  2  0 121 0  53  325 
Max  45 26  165 3  97  328 
Mean  26.29 14.96  144.25 0.84  73.75  327.16 
Patient 7 
SD  14.05  8.13 7.43 0.85 7.43 0.85 
Min  5  1  74  0  97  324 
Max  55  25  131  4  144  328 
Mean  42.61  13.31  97.64  0.05  120.36  327.95 
Patient 8 
SD  2.58  7.94  6.55  0.28  6.55  0.28 
Min  4  1 81 0 92  324 
Max  62 26  126 4 137  328 
Mean  41.06 19.83  101.97 0.11 116.03  327.89 
Patient 9 
SD  5.50 7.21 6.73 0.43 6.73 0.43 
Min  4  0  89  0  86  321 
Max  51  26  132  7  129  328 
Mean  40.62  17.86  107.89  0.22  110.11  327.78 
Patient 10 
SD  4.65  7.99  6.66  0.63  6.66  0.63 
Min  0  0 145 0  34  323 
Max  43 25  184 5  73  328 
Mean  18.82  6.33 165.66 1.47  52.34  326.53 
Patient 11 
SD  13.03  4.78 6.57 0.91 6.57 0.91 
Min  0  0  148  0  32  322 
Max  43  24  186  6  70  328 
Mean  20.83  4.81  166.60  1.47  51.40  326.53 
Patient 12 
SD  13.49  3.39  6.67  0.97  6.67  0.97   -202-
Min  0  0 153 0  25  316 
Max  41 25  193  12 65  328 
Mean  10.99 7.26  171.10 2.3  46.90  325.70 
Patient 13 
SD  9.03 5.63 7.03 1.41 7.03 1.41 
Min  0  0  115  0  57  322 
Max  45  25  161  6  103  328 
Mean  33.35  7.15  137.02  0.67  80.98  327.33 
Patient 14 
SD  10.91  5.49  8.65  0.99  8.65  0.99 
Min  0  0 127 0  40  319 
Max  43 25  178 9  91  328 
Mean  21.88  9.71 153.48 1.83  64.52  326.17 
Patient 15 
SD  14.12  6.99 7.36 1.64 7.36 1.64 
Min  0  0  98  0  67  322 
Max  46  26  151  6  120  328 
Mean  32.84  20.85  124.88  0.81  93.12  327.19 
Patient 16 
SD  12.50  6.96  8.89  1.11  8.89  1.11 
Min  0  0 133 0  39  322 
Max  43 25  179 6  85  328 
Mean  27.31  4.28 157.05 1.05  60.95  326.95 
Patient 17 
SD  13.86  2.90 7.30 1.08 7.30 1.08 
Min  1  0  139  0  30  323 
Max  43  25  188  5  79  328 
Mean  16.73  6.54  165.20  1.39  52.80  326.62 
Patient 18 
SD  12.00  4.85  7.02  0.90  7.02  0.90 
Min  0  0 113 0  41  319 
Max  3  25  177 9 105  328 
Mean  33.03  7.06 140.56 1.00  77.44  327.00 
Patient 19 
SD  12.50  5.21 8.58 1.24 8.58 1.24 
Min  0  0  162  0  13  313 
Max  40  13  206  15  56  328 
Mean  8.10  3.12  185.77  2.79  32.23  325.21 
Patient 20 
SD  6.73  1.80  6.65  1.59  6.65  1.59 
Min  0  0 164 0  16  313 
Max  40 17  202  15 54  328 
Mean  8.37  4.01 182.36 3.45  35.64  324.55 
Patient 21 
SD  7.12 2.65 7.09 2.02 7.09 2.02 
Min  0  0  165  0  14  313 
Max  41  21  204  15  53  328 
Mean  8.17  3.54  183.47  4.26  34.53  323.74 
Patient 22 
SD  6.82  2.40  6.81  2.54  6.81  2.54 
Min  0  0 147 0  26  305 
Max  41 25  192  23 71  328 
Mean  15.97  4.70 168.37 3.90  49.63  324.10 
Patient 23 
SD  12.33  3.65 6.85 2.68 6.85 2.68 
Min  0  0  160  0  11  316 
Max  41  16  207  12  58  328 
Mean  11.14  3.43  179.93  3.02  38.07  324.98 
Patient 24 
SD  9.33  2.16  6.53  1.97  6.53  1.97 
Min  0  0 179 0  2 258 
Max  24  8 216  70 39  328 
Mean  5.90  2.64 190.71 6.94  27.29  321.06 
Patient 25 
SD  3.34 1.50 6.71 9.26 6.71 9.26 
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ODE  OME  TP  FP  FN  TN 
Min  2  2 101 0  65  326 
Max  46 28  153 2 117  328 
Mean  34.15 22.23  128.23 0.68  89.77  327.32 
Patient 1 
SD  11.82  5.66 8.40 0.79 8.40 0.79 
Min  1  0  52  0  105  326 
Max  58  28  113  2  166  328 
Mean  42.04  21.17  87.22  0.09  130.78  327.91 
Patient 2 
SD  5.71  6.67  8.40  0.34  8.40  0.34 
Min  5 3  24  0  136  326 
Max  72 31 82  2 194  328 
Mean  46.13 25.37 49.71  0.01 168.29  327.99 
Patient 3 
SD  5.88 1.70 8.70 0.14 8.70 0.14 
Min  1  0  79  0  74  321 
Max  48  27  144  7  139  328 
Mean  38.45  23.46  104.23  0.40  113.77  327.60 
Patient 4 
SD  8.33  4.60  8.91  0.75  8.91  0.75 
Min  3  2 70 0 98  326 
Max  55 30  120 2 148  328 
Mean  40.98 20.74 96.53  0.13 121.47  327.87 
Patient 5 
SD  6.98 6.75 8.20 0.40 8.20 0.40 
Min  4  4  53  0  113  326 
Max  52  32  105  2  165  328 
Mean  42  24.69  79  0.06  138.99  327.94 
Patient 6 
SD  3.43  2.42  8.33  0.29  8.33  0.29 
Min  2  2 87 0 74  325 
Max  47 27  144 3 131  328 
Mean  36.67 23.65  119.60 0.49  98.40  327.51 
Patient 7 
SD  10.10  4.03 8.92 0.75 8.92 0.75 
Min  39  4  32  0  130  326 
Max  130  31  88  2  186  328 
Mean  45.66  24.82  2.17  0.01  155.83  327.99 
Patient 8 
SD  5.71  1.93  8.44  0.03  8.44  0.03 
Min  2 2  60  0  112  325 
Max  68 29  111 3 162  328 
Mean  43.31 23.66 81.76  0.04 138.09  327.96 
Patient 9 
SD  3.58 4.04 8.21 0.23 8.21 0.23 
Min  11  8  44  0  121  326 
Max  54  30  97  2  174  328 
Mean  42.82  25.06  67.29  0.01  150.71  327.98 
Patient 10 
SD  2.55  1.22  8.48  0.15  8.48  0.15 
Min  1  1 131 0  46  323 
Max  43 26  172 5  87  328 
Mean  25.13 12.24  153.25 1.15  64.75  326.85 
Patient 11 
SD  13.97  7.76 6.43 0.91 6.43 0.91 
Min  2  2  123  0  56  325 
Max  43  27  162  3  95  328 
Mean  31.12  19.21  142.72  0.90  75.28  327.10 
Patient 12 
SD  12.58  7.63  6.69  0.84  6.69  0.84 
Min  1  1 136 0  43  321 
Max  42 26  175 7  82  328 
Mean  20.73 15.76  156.32 1.45  61.68  326.55 
Patient 13 
SD  13.50  7.97 5.73 0.84 5.73 0.95 
Min  3  1  86  0  84  324 
Max  50  26  134  4  132  328 
Mean  39.01  17.85  110.09  0.22  107.91  327.79 
Patient 14 
SD  8.07  7.77  7.67  0.57  7.67  0.57   -204-
Min  0  0 112 0  56  322 
Max  6  25  162 8 106  328 
Mean  32.02 15.16  138.52 0.94  81.48  327.06 
Patient 15 
SD  12.69  8.16 8.17 1.15 8.16 1.15 
Min  1  1  73  0  84  323 
Max  47  27  134  5  145  328 
Mean  38.43  23.55  103.78  0.37  114.22  327.63 
Patient 16 
SD  8.26  4.32  9.58  0.74  9.58  0.74 
Min  2  2 100 0  6 325 
Max  46 26  156 3 118  328 
Mean  36.35 17.83  125.44 0.40  92.56  327.60 
Patient 17 
SD  10.21  7.72 8.00 0.69 8.00 0.69 
Min  2  1  122  0  48  325 
Max  43  26  170  3  96  328 
Mean  29.04  15.20  145.81  0.90  72.19  327.10 
Patient 18 
SD  13.75  8.16  7.14  0.87  7.14  0.87 
Min  2  1 89 0 87  325 
Max  47 26  131 3 129  328 
Mean  40.23 21.49  109.59 0.18 100.41  327.82 
Patient 19 
SD  5.28 6.09 6.60 0.52 6.60 0.52 
Min  0  0  148  0  27  323 
Max  42  25  191  5  70  328 
Mean  12.77  7.58  168.50  1.66  49.50  326.34 
Patient 20 
SD  10.05  5.62  6.47  0.86  6.47  0.86 
Min  0  0 148 0  27  320 
Max  42 25  191  10 70  328 
Mean  14.45  8.37 166.88 1.97  51.12  326.03 
Patient 21 
SD  11.13  6.15 6.69 1.18 6.69 1.18 
Min  0  0  145  0  37  321 
Max  41  25  181  7  73  328 
Mean  16.77  13.43  160.88  1.64  57.12  326.36 
Patient 22 
SD  12.01  7.89  5.52  0.87  5.52  0.87 
Min  0  0 121 0  47  322 
Max  43 25  171 6  97  328 
Mean  27.21 12.43  145.87 1.19  72.13  326.01 
Patient 23 
SD  11.11  7.89 7.64 1.20 7.64 1.20 
Min  1  0  135  0  46  324 
Max  42  25  176  4  87  328 
Mean  21.42  12.74  154.30  1.13  63.70  326.87 
Patient 24 
SD  13.95  7.75  6.37  0.88  6.37  0.88 
Min  0  0 153 0  22  317 
Max  41 25  196  11 65  328 
Mean  11.33  7.49 170.46 2.28  47.54  325.72 
Patient 25 
SD  9.41 5.82 6.82 1.35 6.82 1.35 
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Min  0  0 82 0 90  327 
Max  44 26  128 1 136  328 
Mean  25.04 12.93  104.48 0.02 113.53  327.98 
Patient 1 
SD  14.44  8.46 7.60 0.13 7.60 0.13 
Min  0  0  47  0  126  326 
Max  51  27  92  2  171  328 
Mean  36.64  15.92  70.15  0.10  147.85  327.90 
Patient 2 
SD  10.28  8.43  6.90  0.32  6.9  0.32 
Min  0 0  49  0  129  327 
Max  51 26 89  1 169  328 
Mean  39.89 17.37 67.35  0.03 150.65  327.97 
Patient 3 
SD  6.03 7.92 6.44 0.17 6.44 0.17 
Min  0  0  62  0  98  324 
Max  44  26  120  4  156  328 
Mean  27.40  17.83  88.01  0.62  150.65  327.38 
Patient 4 
SD  14.19  7.87  7.14  0.81  6.44  0.81 
Min  1 0  69  0  109  327 
Max  52 25  109 1 149  328 
Mean  33.10 9.35 87.45 0.01  128.55  327.99 
Patient 5 
SD  13.01  7.44 6.36 0.01 6.36 0.01 
Min  0  0  80  0  96  325 
Max  49  24  122  3  138  328 
Mean  33.65  5.96  98.65  0.14  119.35  327.86 
Patient 6 
SD  11.96  5.52  6.60  0.38  6.60  0.38 
Min  0  0 86 0 85  326 
Max  44 26  133 2 132  328 
Mean  21.74 12.41  109.47 0.04 108.54  327.86 
Patient 7 
SD  14.42 8.3  7.21 0.19 7.21 0.38 
Min  1  0  57  0  123  326 
Max  56  26  95  2  161  328 
Mean  40.73  10.46  75.88  0.06  142.13  327.94 
Patient 8 
SD  5.56  7.81  5.81  0.25  5.81  0.25 
Min  1 0  55  0  122  327 
Max  54 26 96  1 163  328 
Mean  38.31 17.07 74.57  0.02 143.43  327.98 
Patient 9 
SD  8.58 8.17 6.28 0.12 6.28 0.12 
Min  0  0  62  0  116  324 
Max  49  26  102  4  156  328 
Mean  37.79  14.57  81.15  0.24  136.85  327.76 
Patient 10 
SD  8.47  8.75  6.43  0.53  6.43  0.53 
Min  0  0 116 0  59  325 
Max  42 24  154 3 102  328 
Mean  14.03  4.85 140.18 0.26  77.82  327.74 
Patient 11 
SD  11.72  4.62 6.34 0.53 6.34 0.53 
Min  0  0  121  0  58  325 
Max  42  21  160  3  97  328 
Mean  16.59  4.16  140.17  0.39  77.83  327.61 
Patient 12 
SD  12.80  3.64  6.49  0.61  6.49  0.61 
Min  0  0 124 0  48  323 
Max  40 24  170 5  94  328 
Mean  8.93  5.58 152.28 1.07  65.72  326.93 
Patient 13 
SD  8.28 5.23 6.12 1.09 6.12 1.04 
Min  0  0  93  0  89  323 
Max  46  24  129  5  125  328 
Mean  30.56  6.00  110.98  0.41  107.02  327.59 
Patient 14 
SD  13.39  5.43  6.08  0.68  6.08  0.68   -206-
Min  0  0 104 0  71  321 
Max  42 24  147 7 114  328 
Mean  17.86  8.04 125.00 1.37  93  326.63 
Patient 15 
SD  13.57  6.87 6.49 1.17 6.49 1.17 
Min  0  0  67  0  103  324 
Max  46  26  115  4  151  328 
Mean  26.88  18.06  88.29  0.60  129.71  327.40 
Patient 16 
SD  14.41  8.13  7.10  0.78  7.10  0.78 
Min  0  0 110 0  72  324 
Max  43 24  146 4 108  328 
Mean  21.50  3.22 128.24 0.45  89.76  327.55 
Patient 17 
SD  14.33  3.20 6.40 0.68 6.40 0.68 
Min  0  0  116  0  61  325 
Max  41  24  157  3  102  328 
Mean  13.27  5.24  138.99  0.20  79.02  327.81 
Patient 18 
SD  11.42  4.66  6.54  0.46  6.54  0.46 
Min  0  0 92 0 83  322 
Max  45 24  135 6 126  328 
Mean  28.58  5.66 115.73 0.86 102.27  327.14 
Patient 19 
SD  13.87  5.23 6.00 0.98 6.00 0.98 
Min  0  0  148  0  30  321 
Max  40  12  188  7  70  328 
Mean  6.76  2.29  163.89  1.45  54.11  326.55 
Patient 20 
SD  6.04  2.01  6.08  1.30  6.08  1.30 
Min  0  0 143 0  39  321 
Max  40 22  179 7  75  328 
Mean  6.43  3.26 161.50 2.05  56.50  325.95 
Patient 21 
SD  6.41 3.04 6.06 1.49 6.06 1.49 
Min  0  0  141  0  38  317 
Max  40  15  180  11  77  328 
Mean  6.98  2.75  161.85  3.00  56.15  325.00 
Patient 22 
SD  6.94  2.45  5.86  1.90  5.86  1.90 
Min  0  0 120 0  58  316 
Max  42 24  160  12 98  328 
Mean  13.12  3.80 142.36 3.10  75.64  324.90 
Patient 23 
SD  11.40  3.62 6.22 1.94 6.22 1.94 
Min  0  0  136  0  42  319 
Max  40  17  176  9  82  328 
Mean  9.11  2.61  155.12  1.76  62.88  326.24 
Patient 24 
SD  8.61  2.33  6.23  1.49  6.23  1.49 
Min  0  0 152 0  31  314 
Max  28 18  187  14 66  328 
Mean  5.18  2.08 170.64 4.93  47.36  323.07 
Patient 25 
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Min  2  2 119 0  53  325 
Max  43 27  165 3  99  328 
Mean  37.13 21.57  143.41 1.01  74.59  326.99 
Patient 1 
SD  9.08 6.21 6.28 0.83 6.28 0.83 
Min  0  0  81  0  86  323 
Max  51  27  132  5  137  328 
Mean  36.80  15.02  106.13  0.46  111.88  327.54 
Patient 2 
SD  10.08  8.30  8.42  0.89  8.42  0.89 
Min  3  0 70 0 91  325 
Max  57 27  127 3 148  328 
Mean  41.35 16.66 96.94  0.15 121.06  327.85 
Patient 3 
SD  4.84 8.23 8.24 0.50 8.24 0.50 
Min  0  0  97  0  66  297 
Max  43  27  152  31  121  328 
Mean  19.44  15.34  125.25  7.43  92.76  320.57 
Patient 4 
SD  14.06  8.73  9.45  4.83  9.15  4.83 
Min  2  1 92 0 70  324 
Max  52 25  148 4 126  328 
Mean  36.55 11.30  119.50 0.31  98.50  327.69 
Patient 5 
SD  10.54  7.43 8.94 0.64 8.94 0.64 
Min  0  0  77  0  103  325 
Max  50  24  115  3  141  328 
Mean  32.17  6.30  97.73  0.23  120.27  327.77 
Patient 6 
SD  12.94  5.57  6.77  0.48  6.77  0.48 
Min  0  0 81 0 90  325 
Max  45 24  128 3 137  328 
Mean  17.30 10.68  104.35 0.29 113.65  327.71 
Patient 7 
SD  12.91  7.90 7.53 0.55 7.53 0.55 
Min  6  0  78  0  95  322 
Max  57  26  123  6  140  328 
Mean  42.28  12.84  98.73  0.07  119.27  327.93 
Patient 8 
SD  3.32  7.96  6.82  0.4  6.82  0.40 
Min  1  0 75 0 90  322 
Max  58 26  128 6 143  328 
Mean  39.67 17.99  101.72 0.15 116.28  327.85 
Patient 9 
SD  8.38 8.01 7.97 0.50 7.97 0.50 
Min  0  0  85  0  90  318 
Max  51  26  128  10  133  328 
Mean  39.32  15.36  106.38  1.00  111.62  327 
Patient 10 
SD  7.68  8.39  7.25  1.55  7.25  1.55 
Min  0  0 148 0  26  318 
Max  42 23  192  10 70  328 
Mean  12.80  5.11 171.93 2.19  4.07 325.82 
Patient 11 
SD  10.28  3.83 7.28 1.54 7.28 1.54 
Min  0  0  146  0  27  315 
Max  42  24  191  13  72  328 
Mean  13.59  4.24  171.34  2.21  46.66  325.79 
Patient 12 
SD  10.63  2.99  7.12  1.78  7.12  1.78 
Min  0  0 159 1  12  282 
Max  39 24  206  46 59  327 
Mean  6.27  4.26 182.37  12.11 35.61  315.89 
Patient 13 
SD  5.87 3.72 7.70 6.17 7.70 6.17 
Min  0  0  111  0  46  318 
Max  45  25  172  10  107  328 
Mean  28.62  5.95  142.75  1.62  75.25  326.38 
Patient 14 
SD  13.94  4.69  8.83  1.76  8.83  1.76   -208-
Min  0  0 134 1  28  289 
Max  45 25  190  39 84  327 
Mean  11.09  5.92 162.61  13.23 55.39  314.77 
Patient 15 
SD  10.30  5.10 8.79 6.60 8.79 6.76 
Min  0  0  88  0  64  300 
Max  48  29  154  28  130  328 
Mean  20.42  14.95  125.18  7.03  92.82  320.97 
Patient 16 
SD  14.41  8.70  10.01  4.76  10.01  4.76 
Min  0  0 131 0  36  319 
Max  43 22  182 9  87  328 
Mean  24.03  4.26 159.85 1.37  58.15  326.63 
Patient 17 
SD  14.18  2.94 7.39 1.37 7.39 1.37 
Min  0  0  147  0  20  320 
Max  42  25  198  8  71  328 
Mean  12.28  5.47  169.10  1.8  48.90  326.20 
Patient 18 
SD  9.90  4.17  7.79  1.43  7.79  1.43 
Min  0  0 118 0  52  311 
Max  45  25 166 17 100  328 
Mean  29.99  6.08 142 3.01  76  324.99 
Patient 19 
SD  13.66  4.92 8.74 2.68 8.74 2.68 
Min  0  0  168  0  7  306 
Max  39  17  211  22  50  328 
Mean  6.27  2.83  190.05  5.69  27.95  322.31 
Patient 20 
SD  5.35  1.78  6.70  3.23  6.70  3.23 
Min  0  0 172 3  4 280 
Max  32 21  214  48 46  325 
Mean  4.40  2.69 194.08  20.80 23.92  307.20 
Patient 21 
SD  3.99 2.22 6.92 8.18 6.92 8.18 
Min  0  0  166  6  4  266 
Max  32  13  214  62  52  322 
Mean  4.49  2.45  193.60  25.63  24.40  302.37 
Patient 22 
SD  4.23  2.09  7.05  8.33  7.05  8.33 
Min  0  0 156 5  16  269 
Max  41 22  202  59 62  323 
Mean  7.60  3.10 179.06  27.10 38.94  300.90 
Patient 23 
SD  7.74 2.81 7.73 9.38 7.73 9.38 
Min  0  0  164  0  12  296 
Max  41  13  206  32  54  328 
Mean  8.07  2.88  184.22  8.08  33.78  319.92 
Patient 24 
SD  7.36  1.93  6.88  4.33  6.88  4.33 
Min  0  0 177 5  2 269 
Max  25 11  216  59 41  323 
Mean  3.83  2.08 198.55  25.21 19.45  302.79 
Patient 25 









   -209-
 
 
Appendix A6   VBA Pseudo-code 
 
A6.1   Forming questions for “OK” command 
Private Sub cmdOK_Click() 
   Unload Me 
End Sub 
 
Private Sub UserForm_Initialize() 
    ResetForm 
End Sub 
 
Public Function Ask(Optional ByVal Prompt As String, Optional ByVal Caption As String, _ 
Optional ByRef Cancel As Boolean) As String 
 
    ResetForm 
    Me.Caption = Caption 
    lblPrompt.Caption = Prompt 
    txtResponse.SetFocus 
    Me.Show vbModal 
     
    Cancel = mblnCancel 
    If mblnCancel Then 
        Ask = "" 
    Else 
        Ask = txtResponse.Text 
    End If 
End Function 
 
Private Sub ResetForm() 
    cmdOK.Caption = "OK" 
    cmdCancel.Caption = "Cancel" 
    Me.Caption = "Personalised Ambient Monitoring" 
    lblPrompt.Caption = "Prompt:" 
    mblnCancel = False 
    With txtResponse 
        .Text = "" 
        .WordWrap = True 
        .MultiLine = True 
    End With 
End Sub 
 
Private Sub UserForm_QueryClose(Cancel As Integer, CloseMode As Integer) 
   If (CloseMode = vbFormControlMenu) Then 
        mblnCancel = True 
    End If 
End Sub   -210-
 
A6.2   Forming questions for “Cancel” command 
Private mblnCancel As Boolean 
 
Private Sub cmdCancel_Click() 
    mblnCancel = True 
    Unload Me 
End Sub 
 
Private Sub cmdOK_Click() 
   Unload Me 
End Sub 
 
Private Sub UserForm_Initialize() 
    ResetForm 
End Sub 
 
Public Function Ask(Optional ByVal Prompt As String, Optional ByVal Caption As String, _ 
Optional ByRef Cancel As Boolean) As String 
 
    ResetForm 
    Me.Caption = Caption 
    lblPrompt.Caption = Prompt 
    txtResponse.SetFocus 
    Me.Show vbModal 
     
    Cancel = mblnCancel 
    If mblnCancel Then 
        Ask = "" 
    Else 
        Ask = txtResponse.Text 
    End If 
End Function 
 
Private Sub ResetForm() 
    cmdOK.Caption = "OK" 
    cmdCancel.Caption = "Cancel" 
    Me.Caption = "Personalised Ambient Monitoring" 
    lblPrompt.Caption = "Prompt:" 
    mblnCancel = False 
    With txtResponse 
        .Text = "" 
        .WordWrap = True 
        .MultiLine = True 
    End With 
End Sub 
 
Private Sub UserForm_QueryClose(Cancel As Integer, CloseMode As Integer) 
   If (CloseMode = vbFormControlMenu) Then 
        'End 
        mblnCancel = True 
    End If 
End Sub   -211-
A6.3   Prodromal data storing 
Sub Activity() 
    Dim strInput_minNormal As String 
    Dim strInput_modeNormal As String 
    Dim strInput_maxNormal As String 
    Dim strInput_minManic As String 
    Dim strInput_modeManic As String 
    Dim strInput_maxManic As String 
    Dim strInput_minDepressed As String 
    Dim strInput_modeDepressed As String 
    Dim strInput_maxDepressed As String 
    Dim strInput_thresholdMax As String 
    Dim strInput_thresholdMin As String 
    Dim blnCancel As Boolean 
    Dim blnIsNumeric As Boolean 
     
    ' MINIMUM ACTIVITY LEVEL WHEN NORMAL 
    Do 
        strInput_minNormal = frmQuestion.Ask("Minimum activity level when normal", "Min Normal", blnCancel) 
         
        blnIsNumeric = IsNumeric(strInput_minNormal) 
        Data.Cells(3, 3).Value = strInput_minNormal 
         
        If Not blnCancel And Not blnIsNumeric Then 
            MsgBox "You must provide a number", , "Min Normal" 
        End If 
         
        If blnCancel Then 
            MsgBox "A default value # will be stored", , "Min Normal" 
            Data.Cells(3, 3).Value = # 
            Exit Do 
        End If 
    Loop Until blnIsNumeric Or blnCancel 
     
    ' MAXIMUM ACTIVITY LEVEL WHEN NORMAL 
    Do 
        strInput_maxNormal = frmQuestion.Ask("Maximum activity level when normal", "Max Normal", blnCancel) 
         
        blnIsNumeric = IsNumeric(strInput_maxNormal) 
        Data.Cells(5, 3).Value = strInput_maxNormal 
         
        If Not blnCancel And Not blnIsNumeric Then 
            MsgBox "You must provide a number", , "Max Normal" 
        End If 
         
        If blnCancel Then 
            MsgBox "A default value # will be stored", , "Max Normal" 
            Data.Cells(5, 3).Value = # 
            Exit Do 
        End If 
    Loop Until blnIsNumeric Or blnCancel 
     
   -212-
    ' MODE OF ACTIVITY LEVEL WHEN NORMAL 
    Do 
        strInput_modeNormal = frmQuestion.Ask("Mode activity level when normal", "Mode Normal", blnCancel) 
         
        blnIsNumeric = IsNumeric(strInput_modeNormal) 
        Data.Cells(4, 3).Value = strInput_modeNormal 
         
        If Not blnCancel And Not blnIsNumeric Then 
            MsgBox "You must provide a number", , "Mode Normal" 
        End If 
         
        If blnCancel Then 
            MsgBox "A default value # will be stored", , "Mode Normal" 
            Data.Cells(4, 3).Value = # 
            Exit Do 
        End If 
    Loop Until blnIsNumeric Or blnCancel 
     
    ' MINIMUM ACTIVITY LEVEL WHEN MANIC 
    Do 
        strInput_minManic = frmQuestion.Ask("Minimum activity level when manic", "Min Manic", blnCancel) 
         
        blnIsNumeric = IsNumeric(strInput_minManic) 
        Data.Cells(9, 3).Value = strInput_minManic 
         
        If Not blnCancel And Not blnIsNumeric Then 
            MsgBox "You must provide a number", , "Min Manic" 
        End If 
         
        If blnCancel Then 
            MsgBox "A default value # will be stored", , "Min Manic" 
            Data.Cells(9, 3).Value = # 
            Exit Do 
        End If 
    Loop Until blnIsNumeric Or blnCancel 
     
    ' MAXIMUM ACTIVITY LEVEL WHEN MANIC 
    Do 
        strInput_maxManic = frmQuestion.Ask("Maximum activity level when manic", "Max Manic", blnCancel) 
         
        blnIsNumeric = IsNumeric(strInput_maxManic) 
        Data.Cells(11, 3).Value = strInput_maxManic 
         
        If Not blnCancel And Not blnIsNumeric Then 
            MsgBox "You must provide a number", , "Max Manic" 
        End If 
         
        If blnCancel Then 
            MsgBox "A default value # will be stored", , "Max Manic" 
            Data.Cells(11, 3).Value = # 
            Exit Do 
        End If 
    Loop Until blnIsNumeric Or blnCancel 
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    ' MODE ACTIVITY LEVEL WHEN MANIC 
    Do 
        strInput_maxManic = frmQuestion.Ask("Mode activity level when manic", "Mode Manic", blnCancel) 
         
        blnIsNumeric = IsNumeric(strInput_modeManic) 
        Data.Cells(10, 3).Value = strInput_modeManic 
         
        If Not blnCancel And Not blnIsNumeric Then 
            MsgBox "You must provide a number", , "Mode Manic" 
        End If 
         
        If blnCancel Then 
            MsgBox "A default value (2.2) will be stored", , "Mode Manic" 
            Data.Cells(10, 3).Value = 2.2 
            Exit Do 
        End If 
    Loop Until blnIsNumeric Or blnCancel 
     
    ' MINIMUM ACTIVITY LEVEL WHEN DEPRESSED 
    Do 
        strInput_minDepressed = frmQuestion.Ask("Min. activity level when depressed", "Min Dep.", blnCancel) 
         
        blnIsNumeric = IsNumeric(strInput_minDepressed) 
        Data.Cells(15, 3).Value = strInput_minDepressed 
         
        If Not blnCancel And Not blnIsNumeric Then 
            MsgBox "You must provide a number", , "Min Depressed" 
        End If 
         
        If blnCancel Then 
            MsgBox "A default value # will be stored", , "Min Depressed" 
            Data.Cells(15, 3).Value = # 
            Exit Do 
        End If 
    Loop Until blnIsNumeric Or blnCancel 
     
    ' MAXIMUM ACTIVITY LEVEL WHEN DEPRESSED 
    Do 
        strInput_maxDepressed = frmQuestion.Ask("Max. activity level when depressed", "Max Dep.", blnCancel) 
         
        blnIsNumeric = IsNumeric(strInput_maxDepressed) 
        Data.Cells(17, 3).Value = strInput_maxDepressed 
         
        If Not blnCancel And Not blnIsNumeric Then 
            MsgBox "You must provide a number", , "Max Depressed" 
        End If 
         
        If blnCancel Then 
            MsgBox "A default value # will be stored", , "Max Depressed" 
            Data.Cells(17, 3).Value = # 
            Exit Do 
        End If 
    Loop Until blnIsNumeric Or blnCancel 
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    ' MODE ACTIVITY LEVEL WHEN DEPRESSED 
    Do 
        strInput_maxManic = frmQuestion.Ask("Mode activity level when depressed", "Mode Dep.", blnCancel) 
         
        blnIsNumeric = IsNumeric(strInput_modeDepressed) 
        Data.Cells(16, 3).Value = strInput_modeDepressed 
         
        If Not blnCancel And Not blnIsNumeric Then 
            MsgBox "You must provide a number", , "Mode Depressed" 
        End If 
         
        If blnCancel Then 
            MsgBox "A default value # will be stored", , "Mode Depressed" 
            Data.Cells(16, 3).Value = # 
            Exit Do 
        End If 
    Loop Until blnIsNumeric Or blnCancel 
     
End Sub   -215-
 
A6.4   Logic to work out the onset of bipolar episodes 
Public Sub Decision_Rules() 
    Dim i As Long 
    Dim j As Integer 
     
    Dim Count_ODE As Integer 
    Dim Count_OME As Integer 
     
    Count_ODE = 0 
    Count_OME = 0 
     
    'PAM SCORING SYSTEM COLUMN # 
    j = 31 
     
    'WORKING OUT THE FIRST DAY OF AN ONSET OF DEPRESSIVE EPISODE 
    For i = 167 To 296 
        If Not Actual.Cells(i, j + 1) = 0 Then 
            Exit For 
        End If 
         
        If Actual.Cells(i, j + 1) = 0 Then 
            Count_ODE = Count_ODE + 1 
        End If 
    Next i 
    Results.Cells(3, 2).Value = "=RiskOutput() + " & Count_ODE 
     
    'WORKING OUT THE FIRST DAY OF AN ONSET OF MANIC EPISODE 
    For i = 461 To 548 
        If Not Actual.Cells(i, j + 1) = 0 Then 
            Exit For 
        End If 
         
        If Actual.Cells(i, j + 1) = 0 Then 
            Count_OME = Count_OME + 1 
        End If 
    Next i 
    Results.Cells(3, 3).Value = "=RiskOutput() + " & Count_OME 
End Sub   -216-  -217-
 
 








What is PAM?    
PAM - Personalised Ambient Monitoring - is a three year research project funded by the 
UK Engineering and Physical Sciences Resea r c h  C o u n c i l .   P A M  a i m s  t o  p r o v i d e  n e w  
technology to help people with bipolar disorder to take control of their health care and 
lead more independent lives. Using a system of discreet and unobtrusive sensors, the aim 
is to help you identify the very early signs of an acute manic or depressive episode and 
thus hopefully avoid it. It is well known that early detection may be able to avoid both 
full-blown episodes and hospital admissions.  For more detailed information, see the 
project website: www.pam-research.org 
 
Who is doing this research?  
This project builds on existing research in this area at the Universities of Southampton, 
Nottingham and Stirling. The PAM team consists of four senior academics: a biomedical 
signal processing engineer, Dr Christopher James, and a management scientist, 
Professor Sally Brailsford (both University of Southampton), a biomedical engineer, 
Professor John Crowe (University of Nottingham) and a computer scientist, Professor 
Evan Magill (University of Stirling).  Each of these four academics has a PhD student 
funded as part of the project, making a multi-disciplinary team of eight in total. PAM also 
has a Steering Group which includes a service user, plus a clinical psychiatrist (Dr Paul 
Courtney of Hampshire Partnership Trust) and the Chief Executive of the mental health 
charity Solent MIND, Mr Richard Barritt. 
 
How does PAM work? 
PAM uses a system of unobtrusive small wearable and environmental sensors to monitor 
your personal daily behaviour patterns. PAM analyses the data from these to determine   -218-
your normal “activity signature”, i.e. a picture (like a fingerprint) of your normal activity. 
PAM is not “Big Brother” – the type of data it collects is very basic and cannot identify 
individuals directly. Having established your normal baseline activity signature, the aim 
of PAM is to identify small changes, for example minor unexplained disruptions in your 
sleep or meal patterns, which you may not be aware of yourself but which may potentially 
herald the early signs of an acute episode. PAM will alert you to the change and then you 
can decide what to do: maybe nothing, or maybe contact your doctor, for example. 
 
The project team wants to test the PAM system in a six-month trial involving volunteers 
with BD. The P in PAM stands for “Personalised”, since the level of monitoring that each 
person will be comfortable with will be different. The system will allow you to adjust the 
monitoring to suit your individual preferences.  You can switch individual sensors on or 
off, as you like, or even switch the whole system off.  
 
How many participants are being recruited? 
We are only planning to recruit four participants.  This is not a clinical trial, but a 
feasibility study, to see if the PAM kit works and is acceptable to users. 
 
What will happen if I agree to take part?  
There are two stages to agreeing to participating in PAM.  Initially,  you would only be 
agreeing to a home visit by two members of the research team (a senior investigator and 
one of the PhD students).   The aim of the home visit is to demonstrate the sensors and 
the rest of the PAM kit, and to answer all your questions about participation.  There is 
absolutely no commitment to continue any further with the trial if at this point you 
decide PAM is not for you.   
 
From the date you receive this information pack, you will be given two weeks to think it 
over, to obtain the letter from your GP and to return the consent form to us. If we do not 
hear back from you within two weeks of the postmark on this letter, we will make one 
further attempt to contact you, by email or telephone.  If we cannot get hold of you, or if 
you tell us you have decided not to proceed, we will regard you as withdrawn from the 
study and we will delete all correspondence with you.  
 
On receipt of the signed consent form and GP letter, the researchers will contact you by 
email or telephone and make an appointment for a home visit.  At this first home visit, 
which could last between one and two hours, the research team will give a full verbal 
explanation of the nature of the involvement in PAM, and will demonstrate all the 
available sensors.  They will answer any questions, and also explain that you can 
telephone number/email a member of the research team if you have further questions 
after this visit.  
 
There will be a second potential exit point here if you now decide not to proceed. You will 
be given one week to think it over. After one week, the researchers will contact you again   -219-
by email or telephone, check if you wish to proceed, and if so make an appointment for a 
second home visit. 
 
At the second home visit, which will be made by two or three members of the research 
team (one of the investigators and one or two of the PhD students), the main consent 
form will be signed (this is to PAM being installed). This will be followed by selection of 
the acceptable set of PAM sensors to be used, and then installation of the PAM kit and 
user training.  This visit could take up to six hours.  We will also conduct an entry 
interview at this time, to record your feelings about participating before it starts.  
 
The daily routine for the next six months will involve charging and checking devices, 
putting on the wearable device in the morning and removing it in the evening, brief mood 
status checks (using the special mobile phone), and initiating uploading of data. This will 
take a maximum of 15 minutes per day.  Reporting of faults in the system should they 
occur, plus any queries about the system or concerns about the sensors (for example, if 
you decide that you are no longer happy to use a particular sensor), may take slightly 
longer. You will be given a telephone number and email address which you should 
contact, and a response within 24 hours is guaranteed. There will also be a global “Off” 
switch which you can use at any stage, which will turn off all sensors.  You will also have 
the right to withdraw at any stage during the study and have all your data removed and 
deleted.  
 
At the end of the six months, or earlier if you decide to withdraw or has an acute bipolar 
episode, the PAM kit will be removed. This will be done at an agreed time and your house 
will be left in good order.  There will be an exit interview at this point, when you will have 
an opportunity to comment on the experience.  
 
Exactly what sensors can I choose? 
PAM collects data from three types of source. Firstly, from sensors situated in the home 
that collect information on light levels, sound levels, movement information, and aspects 
of television usage. Secondly, from sensors that are worn by the individual that detect 
sound and light levels, movement, and position. Finally, using a mobile phone the system 
collects information from individuals on activities and mood.  
We have minimised the level of identifiable information these sensors produce. The 
camera system does not record actual visual images but merely detects the presence or 
absence of moving objects, by comparing successive black and white images taken at 10-
second intervals. The Passive Infra-Red (PIR) sensor works in a similar way, in exactly 
the same way that a domestic security light detects movement.   Finally, the microphones 
do not record actual sounds or speech but merely record sound levels. 
 
You can select any or all of the following list of sensors, and you will be shown how to 
turn them off at any point if you choose. All of these will be demonstrated and explained 
to you in plain language during the initial home visit.   -220-
 
•  Wearable device with microphone (records sound features only not actual voice); also 
includes GPS, light sensor and accelerometer. This is comparable in size and weight 
to an iPod or mobile phone. Any of the sensors on it can be disabled.   
•  PIR (passive infra-red) devices: only record presence/absence of movement, like a 
household intruder detector 
•  Cameras (do not store images but merely presence/absence of moving objects)  
•  Ambient microphone (records sound features only not actual voice) 
•  Ambient light sensors: detect levels of daylight/artificial light 
•  Pressure mats (for detecting movements through doorways, thresholds, bedside mats 
etc): these will only be placed in locations where you give consent 
•  TV remote monitor (counts number of button presses only) 
•  R e a d  s w i t c h e s  ( u s e d  o n  c u p b o a r d  o r  f r i d g e  d o o r s ,  e t c ,  t o  d e t e c t  w h e n  a  d o o r  i s  
opened or closed) 
•  Bluetooth encounters (a device on the PAM mobile phone to detect proximity to 
other devices using bluetooth protocol, e.g. mobile phones) 
 
You will also be given a special mobile phone. You may continue to use your own mobile 
as well if you wish, but you could also choose to use the PAM phone as your sole mobile 
(at your own expense).  The actual PAM services do not involve any cost to you, you 
would just pay for calls and other services e.g. internet.  The PAM mobile is needed for 
storing and processing data from the wearable, and uploading it to the PC; and for brief 
mood and activity status requests. If you wish to use the PAM phone as your sole mobile, 
the research team will set this up for you and will ensure that it is working properly. 
 
You will also be provided with a dedicated PC. This will require internet access. The PC 
will be provided and installed free of charge by the PAM team. It is needed for temporary 
local data storage and manipulation and onward transmission (in an encrypted format) 
to one of the participating universities for analysis.  
 
Can I be personally identified as a result of taking part? 
Absolutely not. You will be completely anonymous in any publications or reports 
produced in this study.  If we need to refer to you individually, you will be assigned a 
letter, e.g. “Patient A”.  If we wish to use a direct quotation from your interview, we will 
always ask your permission first and show you a draft of the text for your approval before 
we go ahead.   Obviously the research team will know which data is yours. However there 
will be nothing transmitted or stored which would identify you personally to anyone 
outside the research team.  Within six months after the end of the study, all identifiers 
(names, address, contact details) will be deleted.  As experienced researchers, we are 
accustomed to dealing with confidential data and all our universities have facilities for 
secure storage of such data.  All transmitted data will be encrypted, and the data will be 
kept on a secure password-protected server in a locked room.    
 
Will I be able to find out the results of the trial? 
At the end of the study, we plan to hold one final meeting with each participant, in a 
place which is mutually convenient (possibly your home, or one of the participating   -221-
universities) where we will report the findings of the study. At this stage you will have a 
final opportunity to reflect and comment on your experience. 
 
What is the benefit to me in participating? 
There is no direct benefit to you personally, but you would have the satisfaction of 
knowing that you had potentially helped to develop an intervention which could have a 
big impact on the quality of life of bipolar patients in the future.  We also hope you would 
find the experience interesting.  
 
What are the risks to me in participating? 
There are no physical risks involved in using any of the PAM equipment.  The clinician 
on our Steering Group has assured us that there is no medical reason why PAM should 
have an adverse effect on your mental health, but we would still like to be assured that 
your GP knows you are participating and is happy for you to do so.  Your GP can contact 
one of the research team for more information if they like.  
 
We do appreciate that different people will respond in different ways to being monitored, 
and therefore if you do find that you don’t get on with PAM once you have started, we 
stress that you will be free to withdraw at any time, without needing to give any reason 
and without your legal rights being affected. 
 
What happens if I should become ill during the study? 
If you becomes so unwell during the study that you are unable to use the PAM 
equipment, you will be withdrawn from the study. PAM is not intended for use with 
patients who are actually suffering from acute manic or depressive episodes: it is 
intended to give people early warning of an impending episode. However clearly the data 
obtained prior to this episode would potentially be extremely valuable and so we would 
not wish to lose it.  The possibility of this will be discussed with you in confidence at the 
outset and will form part of the consent form. 
 
How can I find out more? 
You could visit the PAM website www.pam-research.org. You could also contact one of 
the academic investigators, whose names, emails and telephone numbers are given 
below.  
 
I want to participate.  What should I do next? 
You should sign and return the Stage 1 consent form enclosed with this Information 
Sheet using one of the stamped addressed envelopes provided. You should send (or give) 
the second copy of this information sheet to your GP and ask him/her to sign the GP 
consent form and either return it direct to us, or send it to you so that you can then 
forward it to us with your own Stage 1 consent form.   Your GP can of course contact one 
of the research team for further information.  
   -222-
Is there an independent person I can contact if I am unhappy about the 
research team? 
If you are unhappy about any aspect of the research and do not wish to raise it with the 
research team, you can contact the project sponsor, Dr Martina Prude, Head of Research 




Researcher contact details 
 
Professor Sally Brailsford  023 8059 3567   s.c.brailsford@soton.ac.uk 
Dr Christopher James    023 8059 3043   c.james@soton.ac.uk 
Professor John Crowe    0115 951 5590    john.crowe@nottingham.ac.uk 
Professor Evan Magill    01786 46 7425   ehm@cs.stir.ac.uk 
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Appendix A8   Computer model 
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Figure A9.4   Time spent talking on the phone during various mood states 






































Figure A9.6   Time away from home between 5pm and 1am during various mood states 

































































































Figure A9.10   Usual time of cooking during various mood states   -230-  -231-
 
 
Appendix A10   Use of Excel Functions 
 
 
Figure A10   Screenshot of Excel functions 
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Appendix A11   Patient types and their 
sensors requirement 
 




PAM-observed                            
behaviour 
Sensor   
requirement 
1  Activity level 
Sleep 
Daily activity 
Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Accelerometer 
GPS 




2  Activity level 
Talkativeness 
Daily activity 
Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent talking on the phone 
Number of daily phone calls 
Accelerometer 
GPS 
TV usage sensor 
Phone sensor 
3  Activity level 
Social energy 
Daily activity 
Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time being outside between 5pm and 1am 
Latest time of getting back home 
Accelerometer 
GPS 
TV usage sensor 
4  Activity level 
Appetite 
Daily activity 
Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 
Usual time of cooking 
Accelerometer 
GPS 




5  Sleep 
Talkativeness 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time spent talking on the phone 





6  Sleep 
Social energy 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time being outside between 5pm and 1am 









Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 







8  Talkativeness 
Social energy 
Time spent talking on the phone 
Number of daily phone calls 
Time being outside between 5pm and 1am 
Latest time of getting back home 
Phone sensor 
GPS   -234-
9  Talkativeness 
Appetite 
Time spent talking on the phone 
Number of daily phone calls 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 





10  Social energy 
Appetite 
Time being outside between 5pm and 1am 
Latest time of getting back home 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 














Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time spent talking on the phone 















Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time being outside between 5pm and 1am 













Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 
















Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent talking on the phone 
Number of daily phone calls 
Time being outside between 5pm and 1am 











Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent talking on the phone 
Number of daily phone calls 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 














Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time being outside between 5pm and 1am 
Latest time of getting back home 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 
Usual time of cooking 
Accelerometer 
GPS 








Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time spent talking on the phone 
Number of daily phone calls 
Time being outside between 5pm and 1am 











Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time spent talking on the phone 
Number of daily phone calls 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 













Time spent talking on the phone 
Number of daily phone calls 
Time being outside between 5pm and 1am 
Latest time of getting back home 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 
















Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time spent talking on the phone 
Number of daily phone calls 
Time being outside between 5pm and 1am 















Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time spent talking on the phone 
Number of daily phone calls 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 



















Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time being outside between 5pm and 1am 
Latest time of getting back home 
Cupboard doors usage 
Fridge & microwave doors usage 

















Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent talking on the phone 
Number of daily phone calls 
Time being outside between 5pm and 1am 
Latest time of getting back home 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 
Usual time of cooking 
Accelerometer 
GPS 










Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time spent talking on the phone 
Number of daily phone calls 
Time being outside between 5pm and 1am 
Latest time of getting back home 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 















Earliest time of leaving home 
Latest time of getting back home 
TV remote keypresses 
Time spent in bed 
Light level between 11pm to 7am 
Noise level between 11pm to 7am 
Time spent talking on the phone 
Number of daily phone calls 
Time being outside between 5pm and 1am 
Latest time of getting back home 
Cupboard doors usage 
Fridge doors usage 
Microwave door usage 
Usual time of cooking 
Accelerometer 
GPS 
TV usage sensor 
Pressure mat 
Light sensor 
Microphone 
Phone sensor 
Camera 
Cupboard door 
sensors 
 
 